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ABSTRACT 
Introduction 
Medicines are used with the intention of benefitting from their effect. The 
effects of medicines can also be undesirable and potentially lead to harm. A 
drug-related problem (DRP) is a term used to describe problem(s) that exist 
in the use of medicines. There remains a distinct paucity of data on the 
epidemiology of DRPs in children with kidney disease. 
Aim 
To investigate the epidemiology of DRPs in children with kidney disease in 
clinical practice at tertiary Paediatric Nephrology units.  
Methods 
Study 1: Prospective observational study on the characteristics of DRPs in 
hospitalised children with kidney disease.  
Study 2: Randomised control trial on clinical pharmacist (CP) interventions 
in resolving DRPs on the renal outpatient clinic.  
Results 
Study 1: A total of 127 patients were recruited and a total of 203 DRPs 
were identified. The incidence of DRP was 51.2% (95% CI 43.2-60.6%) of 
patients reviewed by the CPs. The number of medicines prescribed per child 
was the only significant risk factor for the occurrence of DRPs (OR 1.06, 
95% CI 1.02-1.10, p=0.002). The majority of DRPs were minor in clinical 
significance (68%, n=138/203). The predominant DRPs were sub-optimal 
drug effect. These DRPs were associated with drug selections and dosage 
errors. 
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Study 2: A total of 100 patients were recruited (Control n=53, Intervention 
n=47). The trial showed no effect of intervention in the resolution of active 
DRPs (p=0.96) between the Control and Intervention arms.  
Conclusion  
DRPs are common in children with kidney disease and necessitate a 
comprehensive approach to their identification and resolution. Their 
characteristics in both settings are different even though the majority of 
them shared a similar level of clinical significance. Further research is 
required to evaluate the effectiveness of pharmacists’ intervention in 
resolving  DRPs at the outpatient clinics.    
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OVERVIEW OF THE THESIS CHAPTERS  
 
CHAPTER 1  Introduction  
This thesis starts with an introduction to chronic kidney disease (CKD) in 
childhood, followed by the concept of pharmaceutical care (PC) and drug-
related problems (DRPs).  
 
CHAPTER 2  Systematic literature review: Drug-related 
problems in children with chronic kidney disease 
Chapter 2 presents a review of current literature on DRPs in children with 
CKD and the justification for research on this topic. The research aim, 
research questions and strategies are presented at the end of this chapter.  
 
CHAPTER 3   Methodological approach 
Based on the predetermined research questions, this chapter discusses the 
selections of study designs and the research tools used in the two main 
studies which are reported in Chapter 5 and 6. 
 
CHAPTER 4  Feasibility studies 
Two feasibility studies that were conducted prior to each of the main studies 
are presented in this chapter. Feasibility Study (I) works on developing an 
operational definition for Pharmaceutical Care Network (PCNE) classification 
system for DRPs and to test the feasibility of an observational study at the 
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selected hospitals. Feasibility Study (II) is to test the conduct of a 
randomised control trial at the renal outpatient clinic. The challenges in the 
proposed method for the studies in this research are also described.  
 
CHAPTER 5  Prospective observational study on the 
characteristic of DRPs in hospitalised children with kidney disease 
Chapter 5 presents the work of the first study (Study 1) of this research. 
Children hospitalised with kidney disease are hypothesised to have higher 
incidence of DRPs than those without kidney impairment who are 
hospitalised at the general medical wards; and the characteristics of DRPs in 
this population are also assumed to be similar to those in their adult 
counterparts. To the best of our knowledge, there has been no study carried 
out to identify the epidemiology of DRPs in this group of patients. Findings 
reported in this study therefore add new knowledge. 
 
CHAPTER 6  The effect of clinical pharmacist-led interventions 
in resolving DRPs at the renal outpatient clinic: A randomised 
control trial  
Chapter 6 reports a randomised control trial (RCT) of clinical pharmacists-
led interventions to identify and resolve DRPs in children attending the renal 
outpatient clinic (Study 2). Findings reported in this trial give new insight in 
understanding the characteristics and the management of DRPs in this 
population of interest at the outpatient setting.  
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CHAPTER 7 Overall discussions 
Finally, Chapter 7 summarises and discusses the epidemiology of DRPs in 
children with kidney disease and provides practice implications of the 
research findings. The strengths as well as the limitations of the overall 
research are also discussed and future research topics are identified. 
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1.1 Introduction 
Chronic kidney disease (CKD) is one of the most common chronic illnesses 
in childhood, and the patient requires lifelong healthcare as well as potential 
future solid organ transplantation (Kim et al., 2013; Warady and Chadha, 
2007). Pharmacotherapy management of patients with kidney disease is 
specialised and complex, thus putting this group of children at risk of 
developing problems associated with drug therapy, or so-called drug-related 
problem (DRP). Pharmaceutical Care (PC) has been advocated as a strategy 
to manage DRPs. This chapter begins with an introduction to CKD in 
childhood, followed by the concept of PC and DRP.  
 
1.2 Chronic kidney disease in childhood 
The current definition and classification of CKD in children is based on the 
National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative 
(NKF/KDOQI) clinical practice guidelines (CPG) which is also adopted by the 
United Kingdom (UK) National Institute of Health and Clinical Excellence 
(NICE) CPG (Hogg et al., 2003). The criteria for the definition of CKD 
according to the NKF/KDOQI are described in Table 1.1.  
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Table 1.1 Criteria for the definition of CKD according to the NKF/KDOQI 
guideline (Hogg et al., 2003) 
 
There are five stages of CKD that correspond to the glomerular filtration 
rate (GFR). Among patients with CKD, the stage of disease should be 
assigned based on the level of GFR, as shown in Table 1.2.  
CKD Stage 5 or end-stage kidney failure (ESKF) is defined as either GFR 
less than 15 ml/min/1.73m2 or need for initiation of renal replacement 
therapy (RRT). The two types of RRT are dialysis (which includes 
haemodialysis (HD) and peritoneal dialysis (PD)) and kidney 
transplantation. 
 
 
A patient has CKD if either of the following criteria are present: 
 
1) Kidney damage for  3months, as defined by structural or functional 
abnormalities of the kidney with or without decreased GFR, manifested by 
one or more of the following features: 
 Abnormalities in the composition of the blood or urine 
 Abnormalities in imaging tests 
 Abnormalities on kidney biopsy 
 
2) GFR < than 60 ml/min/1.73m2 for  3months with or without the other 
signs of kidney damage as described above.  
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Table 1.2 The staging of CKD according to the NKF/KDOQI guideline 
CKD Staging GFR (ml/min/1.73m2) Description Action Plan 
1 >90 Kidney damage with normal or 
increased GFR 
Treat primary and comorbid conditions. 
Slow CKD progression, cardiovascular 
disease risk reduction 
2 60-89 Kidney damage with mild reduction 
of GFR 
Estimate rate of CKD progression 
 
3A 59-45 Moderate reduction of GFR Evaluate and treat complications 
3B 44-30 
4 15-29 Severe reduction of GFR Prepare for kidney replacement therapy 
 
5 <15 
 
Kidney failure Renal replacement therapy 
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1.2.1 Prevalence and incidence  
The sources of the epidemiology data on CKD during childhood concentrate 
on the severe and late stages of renal impairment (Warady and Chadha, 
2009). The exact number of children with moderate to severe pre-dialysis 
CKD (Stages 1 to 4) is unknown (Harambat et al., 2011). In the UK, the 
number of children being treated in specialist paediatric nephrology units is 
probably 7 to 10 times more than the prevalent dialysis population (Kim et 
al., 2013).  
In 2012, a total of 861 children and adolescents under the age of 18 with 
ESKF were receiving treatment at paediatric centres in the UK, of which 
78.9% (n=679) were receiving RRT (Pruthi et al., 2012b). In children aged 
less than 16 years, the incidence and prevalence of ESKF were 9.0 and 56.7 
per million age-related population (pmarp) and these figures have risen 
steadily over the last 15 years (Pruthi et al., 2012b). Similar trends were 
also reported from population-based studies in other European countries 
with prevalence of 29 to 74 and incidence of 7 to 12 cases pmarp in children 
less than 18 years of age (Ardissino et al., 2003; Deleau et al., 1994; 
Esbjorner et al., 1997). 
 
1.2.2 Causes of kidney disease in childhood 
Causes of CKD in children are different from those in adults. In the adult 
population, CKD is secondary to uncontrolled hypertension and diabetes 
mellitus (Levey et al., 2003). In the paediatric population, almost half of all 
CKD cases are due to congenital kidney disorders such as obstructive 
uropathy and aplasia, hypoplasia and dysplasia (Warady and Chadha, 
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2007). An analysis of demographic characteristics of children with CKD 
Stage 3 to Stage 5 in South East England over a five-year period showed 
that the most common cause of ESKF in children were renal dysplasia 
(44%), followed by glomerular disease (17%) and obstructive uropathy 
(15%) (Kim et al., 2013). A fairly similar distribution of primary kidney 
disease has been reported over the years in the UK Renal Registry (UKRR) 
annual reports (Lewis et al., 2009; Lewis et al. 2010; Sinha et al., 2011b; 
Pruthi et al., 2012b).  
Drug nephrotoxicity accounts for only a small fraction of the cause of ESKF 
in the UK cohort, which is 0.5% and 1.6% in the 2009 and 2010 annual 
reports respectively (Lewis et al. 2010; Pruthi et al., 2012a). This is 
probably the result of safe prescribing in paediatrics (Sinha and Cranswick, 
2007) and that only serious drug events are usually reported (Brown et al., 
2008b). Therefore, the actual occurrence of drug problems during treatment 
of paediatric nephrology patients is yet to be evaluated. 
 
1.2.3 Mortality and morbidity 
The mortality rates in paediatric patients requiring RRT is lower than in their 
adult counterparts (Warady and Chadha, 2009). However, compared to the 
general paediatric population, the mortality rate for children receiving 
dialysis therapy is between 30 and 150 times higher (McDonald and Craig, 
2004). As an example, the expected remaining lifetime for a child 0 to 14 
years of age and on dialysis is only 20 years (USRDS, 2004 cited in Warady 
and Chandha, 2007 page 2000). Kidney transplantation offers better 
survival compared to dialysis (Pruthi et al., 2012b; Harambat et al., 2011). 
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The average life expectancy in young adults who started RRT during 
childhood was reported as 63 years for those with successful kidney 
transplantation compared with 38 years for those who remain on dialysis 
(Kramer et al., 2009). The main causes of mortality in children on RRT are 
cardiovascular disease and infection (Harambat et al., 2011; Warady and 
Chadha, 2009, Pruthi et al., 2012b). 
The nature of CKD progression and its complications requires the use of 
multiple drug therapy. Furthermore, most medicines used in children are 
used unlicensed and off-label with limited data on safe and effective doses; 
and this can lead to an increase in risk of adverse drug events (Impicciatore 
et al., 2001) and other problems in the use of medicines. In pharmacy 
practice, the management and resolution of DRP is the core activity of PC 
(Hepler and Strand, 1990). The following section introduces the concept of 
PC and DRP. 
 
1.2.4 Factors associated with the occurrence of DRPs  
The risk factors for the occurrence of DRPs in children with kidney disease 
are unknown. A study on DRPs in the general paediatric population 
concluded that children with an average of five or more prescriptions and 
children who were transferred from another hospital or ward were more 
likely to experience DRPs (Rashed et al., 2012b).  
In patients with kidney disease, it is generally accepted that those who are 
on dialysis or post kidney transplant are at higher risk of DRP because more 
drugs are required to control disease progression and complications 
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(Cardone et al., 2010; Kaplan et al., 1994b). Furthermore, dialysis removes 
medicines from blood circulation and complicates drug therapy in these 
patients (Verbeeck and Musuamba, 2009). 
DRPs were expected to be higher in young children including those with 
kidney disease. Age as a predictor for DRPs has shown conflicting results in 
previous research. Some studies have reported that adverse drug events 
are more prominent in young children (Kaushal et al., 2001; Zakharov et 
al., 2012) while others have shown the opposite (Rashed et al., 2012a; 
Avery et al., 2013). In the UK, the age group of 0-4 years was reported to 
be most vulnerable for medication incidents. Administration of incorrect 
dose was reported as the highest medication incident in neonates and 
children (NPSA, 2009). In the adult renal population, DRPs were found to 
increase with age. A possible explanation for this is the effect of aging on 
kidney function (Rowe et al., 1976) and increasing age in the adult 
population coincides with more comorbidities (Nascimento et al., 2009). 
Declining kidney function reduces the excretion of drugs and toxic 
metabolites. In contrast, paediatric kidneys have dynamic changes in 
physiology and improve with age (Atiyeh et al. 1996; Coulthard 1985; 
Heilbron et al. 1991).  
The effect of gender in the occurrence of DRPs was also inconclusive. In the 
adult population, female gender was reported as a factor related to DRPs in 
dialysis treatment, specifically non-adherence to medications (Kammerer et 
al., 2007). Some studies in adults suggest that females are more prone to 
develop ADR but this is not consistent in all studies (Bates et al., 1999; Blix 
et al., 2004; Fattinger et al., 2000).   
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1.3 Pharmaceutical Care and Drug-related problems  
Pharmaceutical care (PC) is a philosophy that shifted pharmacy practice 
from its traditional role of being product-focused to being patient-outcome-
focused. In 1990, Helper and Strand published a landmark article on 
pharmacy practice and defined PC as:  
 
“The responsible provision of drug therapy for the purpose of achieving 
definite outcomes intended to improve a patient’s quality of life” 
 
Drug therapy is administered for the purpose of achieving definite outcomes 
that improve a patient's quality of life. However, whenever drugs are given, 
the potential for outcomes that diminish the patient's quality of life is 
always present and may lead to drug-related morbidity and mortality 
(Hepler and Strand, 1990). An example of this is when an antibiotic with a 
narrow therapeutic index is prescribed for the treatment of septicaemia. 
Considering other medical conditions are taken care of, inappropriate drug 
level monitoring may either result in sub-optimal dose or drug toxicity. Sub-
optimal dose is an example of treatment failure to cure septicaemia and 
nephrotoxicity is an adverse drug event as a consequence of drug toxicity. 
Sub-optimal treatment and drug toxicity are examples of DRPs.  
 
1.3.1 Drug-related problem: Definitions  
The landmark article by Helper and Strand (1990) defined DRP as: 
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“An event or circumstance involving drug treatment that actually or 
potentially interferes with the patient's experiencing an optimum outcome 
of medical care”                            
 
Within this definition, the word ‘problem’ denotes a definite drug-related 
event that is open to detection, treatment or prevention. An event qualifies 
as a DRP when two conditions exist: (1) a patient must be experiencing or 
must be likely to experience symptoms and (2) these symptoms must have 
an identifiable or suspected relationship with drug therapy (Strand et al., 
1990).  
Other than DRP, terms that have been used to describe problems related to 
the use or outcome of medicines are drug therapy problem, medicine- or 
medication-related problem, pharmacotherapy failure, drug treatment 
failure, negative clinical outcome related to medicine and treatment-related 
failure (AbuRuz et al., 2006; Granada Consensus Committee, 2007; van Mil 
et al., 2004). These terms evaluate drug problems according to the 
Donabedian theory and hence contributed to many terms and classification 
systems for DRPs (Fernandez et al., 2004). Donabedian theory is 
a conceptual model that provides a framework for examining health services 
and evaluating quality of care (McDonald et al., 2007). According to the 
model, information about quality of care can be drawn from three 
categories: structure, process and outcomes. ‘Structure’ describes the 
context in which care is delivered, including hospital buildings, staff, 
financing, and equipment. ‘Process’ denotes the transactions between 
patients and providers throughout the delivery of healthcare. Finally, 
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‘outcomes’ refers to the effects of healthcare on the health status of 
patients and populations.  
An example of how drug problems fit into the Donabedian theory as either 
the process or outcome of a treatment can be explained in the case of a 
patient who is taking a correct dose of ACEi and experiences a dry cough, 
the problem and cause of the dry cough are debatable depending on the 
perspective of the discussion. From the pharmacotherapy process point of 
view, the selection of ACEi is inappropriate for the patient and has created a 
problem, i.e. ACEi-induced dry cough. On the other hand, ACEi-induced dry 
cough is the outcome from inappropriate selection of medicine.  
 
1.3.2 Drug-related problem: Classification systems 
In order to give evidence on the benefits of managing DRPs, not only the 
types of problems have to be identified but their contributory factors and 
resolution should be documented. This situation lead to the development of 
classification systems for DRPs. The classification systems were developed 
based on the definition of DRP adapted by the individual researcher 
(AbuRuz et al., 2006; van Mil et al., 2004). From 1990 to 2003, 14 
classification systems were introduced but only eight stated the definitions 
for DRPs (van Mil et al., 2004). Two classification systems were introduced 
after year 2003 (AbruRuz et al., 2006; Gordon et al., 2005). Some of the 
existing classifications were revised to newer versions (Granada Consensus, 
2007; PCNE, 2010). Appendix 1 presents an overview of the definitions and 
classification systems for DRP classifications published from 1990 to 2010. 
The examples of DRP classification systems that have been used in research 
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are briefly explained in the following sub-sections. The classifications are 
represented by the name of the relevant researchers or organisation and 
arranged by year of publication. 
 
1.3.2.1 Strand classification (1990) 
Strand et al. in 1990 published a landmark article on the first classifications 
of DRP (Strand et al., 1990). The Strand classification is a simple scheme 
containing eight types of DRPs and has been the foundation of PC and the 
newer DRP classifications (Table 1.3).  
 
1.3.2.2 Cipolle classification (1998) 
The Cipolle classification refers to DRPs as ‘drug-therapy problems (DTP)’ 
(cited in van Mil, 2004 pg 861). This classification introduced a selection of 
causes for the identified problems. It is more comprehensive than the 
Strand classification but its use is limited to only problems that have 
happened or manifested (Table 1.4). 
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Table 1.3 Classifications of drug-related problems (Strand et al., 1990) 
Drug-related problem* 
 
Details 
 
 
DRP1: Untreated indication 
 
The patient is not receiving drug 
therapy for medical condition(s) that 
requires treatment. 
 
DRP 2: Improper drug selection The patient has a medical condition 
for which the wrong drug is being 
taken. 
 
DRP 3: Sub-therapeutic dosage The patient has a medical condition 
for which too little of the correct 
drug is being taken. 
 
DRP 4: Over dosage The patient has a medical condition 
for which too much of the correct 
drug is being used. 
 
DRP 5: Adverse drug reaction  The patient has a medical condition 
resulting from an adverse drug 
reaction. 
 
DRP 6: Drug interactions 
 
The patient has a medical condition 
resulting from Drug-Drug, Drug-Food 
or Drug-Laboratory interactions. 
 
DRP 7: Failure to receive medication 
 
The patient has a medical condition 
that is the result of not receiving the 
prescribed drug. 
 
DRP 8: Medication used without 
indication 
 
The patient has a medical condition 
that is the result of taking a drug for 
which there is no valid medical 
indication. 
 
Definition of DRP: an undesirable patient experience that involves drug 
therapy and that actually or potentially interferes with the desired patient 
outcome. 
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Table 1.4 Classifications of drug-therapy problem (Cipolle et al., 1998) 
Drug therapy problem (DTP)      Causes 
Indication  
1: The patient has a medical condition that requires the 
initiation of new or additional drug therapy  
 The patient has a new medical condition requiring 
initiation of new drug therapy. 
 The patient has a chronic disorder requiring 
continuation of drug therapy. 
 The patient has a medical condition that requires 
combination pharmacotherapy to attain 
synergism/potentiation of effects. 
 The patient runs the risk of developing a new medical 
condition preventable by the use of prophylactic drug 
therapy and/or premedication.  
 
2: The patient is taking drug therapy that is unnecessary 
given his or her present condition 
 The patient is taking a medication for which there is 
no valid indication at this time. 
 The patient accidently or intentionally ingested a 
toxic amount of a drug or chemical resulting in the 
present illness or condition. 
 The patient’s medical problem(s) are associated with 
drug abuse, alcohol use, or smoking. 
 The patient’s medical condition is better treated with 
non-drug therapy. 
 The patient is taking multiple drugs for a condition 
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Drug therapy problem (DTP)      Causes 
for which only single-drug therapy is indicated.  
 The patient is taking drug therapy to treat an 
avoidable adverse reaction associated with another 
medication.  
 
Effectiveness  
3: The patient has a medical condition for which the 
wrong drug is being taken. 
 The patient has a medical problem for which this 
drug is not effective. 
 The patient is allergic to this medication. 
 The patient is receiving a drug that is not the most 
cost-effective for the indication being treated. 
 The patient has risk factors that contraindicate the 
use of this drug.  
 The patient is receiving a drug that is effective but 
not least costly. 
 The patient is receiving a drug that is effective but 
not the safest.  
 The patient has an infection involving organisms that 
are resistant to this drug.  
 The patient has become refractory to the present 
drug therapy.  
 The patient is receiving an unnecessary combination 
product when a single drug would be appropriate.   
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Drug therapy problem (DTP)      Causes 
4: The patient has a medical condition for which too little 
of the correct drug is being taken 
 The dosage used is too low to produce the desired 
response for this patient.  
 The patient serum drug concentration is too far 
below the desired therapeutic range.  
 Timing of prophylaxis (pre-surgical antibiotic given 
too early) was inadequate for this patient.  
 Drug, dose, route or formulation conversions were 
inadequate for this patient.  
 Dose and interval flexibility (insulin sliding scales, “as 
needed” analgesics) were inadequate for this patient. 
 Drug therapy was altered prior to adequate 
therapeutic trial for this patient.  
 
Safety  
5: The patient has a medical condition resulting from an 
adverse drug reaction  
 The drug was administered too rapidly for this 
patient. 
 The patient is having an allergic reaction to this 
medication. 
 The patient has identified risk factors that make this 
drug too dangerous to be used.  
 The patient has experienced an idiosyncratic reaction 
to this drug. 
 The bioavailability of the drug is altered due to an 
interaction with another drug or food the patient is 
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Drug therapy problem (DTP)      Causes 
taking. 
 The effect of the drug has been altered due to 
enzyme inhibition/induction from another drug the 
patient is taking. 
 The effect of the drug has been altered due to 
displacement from binding sites by another drug the 
patient is taking.  
 The patient’s laboratory test result has been altered 
due to interference from a drug the patient is taking. 
 
6: The patient has a medical condition for which too much 
of the correct dose is being taken 
 Dosage too high for this patient. 
 The patient’s serum drug concentration is above the 
desired therapeutic range.  
 The patient’s drug dose was escalated too rapidly.  
 The patient has accumulated drug from chronic 
administration.  
 Drug, dose, route, formulation conversion were 
inappropriate for this patient. 
 Dose and interval flexibility (insulin sliding scales, “as 
needed” analgesics) were inadequate for this patient. 
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Drug therapy problem (DTP)      Causes 
Compliance  
DRP 7: The patient has a medical condition resulting from 
not taking the drug appropriately 
 The patient did not receive the appropriate drug 
regimen because a medication error prescribing, 
dispensing, administration or monitoring was made.  
 The patient did not comply (adhere) with the 
recommended directions for use of the medications. 
 The patient did not take the drug as directed owing 
to the high cost of the product.  
 The patient did not take the drug(s) as directed 
because of a lack of understanding of the directions. 
 The patient did not take the drug(s) as directed 
because it would not be consistent with the patient’s 
health beliefs.  
 
Definition of DTP: Any undesirable event experienced by the patient that involves or is suspected to involve drug-
therapy and that actually or potentially interferes with a desired patient outcome 
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1.3.2.3 Granada classification (1998, 2002, 2007)  
The Granada classification was developed by a group of Spanish experts in 
1998 and was further revised in 2002 and 2007 (Granada Consensus, 
2007). In the First Granada Consensus, the term DRPs was changed to 
‘drug therapy problems’ that affect health outcomes. In 2002, the second 
consensus clarified the misinterpretations about the context of health 
outcome from the previous consensus (Granada Consensus, 2002). The 
third Granada Consensus is similar to the second but established drug 
therapy problems as negative health outcome (Table 1.5). In this 
consensus, negative health outcome is defined as pharmacotherapy that for 
different reasons either do not achieves therapy objectives, or produce 
undesirable effects. The Granada Consensus did not solve the difficulty in 
distinguishing the cause of the problem from the actual problem (Amariles, 
2006).   
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Table 1.5 Categories of drug-therapy problems of the third Granada 
Consensus 
Domains Sub-domains 
Necessity DTP 1: The patient suffers from a health problem as a 
consequence of not receiving the medication he needs. 
 
DTP 2: The patient suffers from a health problem as a 
consequence of receiving a medicine that he does not 
need. 
 
Effectiveness DTP 3: The patient suffers from a health problem as a 
consequence of a non-quantitative effectiveness of the 
medication. 
 
DTP 4: The patient suffers from a health problem as a 
consequence of a non-quantitative ineffectiveness of 
the medication.  
 
Safety DTP 5: The patient suffers from a health problem as a 
consequence of a non-quantitative safety problem of a 
medicine. 
 
DTP 6: The patient suffers from a health problem as a 
consequence of a quantitative safety problem of a 
medicine. 
Definition of DTP:  
Negative health outcomes resulting from pharmacotherapy that for 
different reasons either do not achieve therapy objectives, or produce 
undesirable effects.  
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1.3.2.4 Gordon classification (2005) 
A group of researchers in the UK published a paper on the development and 
validation of a screening tool to identify patients’ experience in taking 
medications at community pharmacies and surgeries (Gordon et al., 2005). 
As this study originated from the UK, the term ‘medication-related problem 
(MRP)’ was used instead of ‘drug’. This work looked at drug problems from 
the patient’s point of view rather than that of the healthcare providers. In 
this classification, MRP was defined as ‘any problem experienced by a 
patient that may impact on their ability to manage or take their medicines 
effectively’. Problems that were not solved at the community level could be 
a trigger factor for poor treatment outcome in the long run. This 
classification is a potential tool that can be adapted for the DRP study in the 
outpatient clinic settings.  
 
1.3.2.5 AbuRuz classification (2006) 
AbuRuz and colleagues in 2006 proposed the term and classification for  
‘treatment-related problem’ as an alternative to the term DRP. Treatment-
related problem was defined as an event or circumstance involving patient 
treatment that actually or potentially interferes with an optimum outcome 
for a specific patient (AbuRuz et al., 2006). AbuRuz pointed out that the 
term DRP limits the scope of pharmaceutical care. Two examples were 
given: (1) untreated disease and (2) a diabetic or a hypertensive patient 
without prescription or proper education about the illness or treatment – 
both were suggested as an indication of a problem in the treatment rather 
than with the drug. This opinion is debatable depending on the perspective 
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of the discussion. For instance, in the aforementioned examples, one could 
argue that not providing a drug that has a definite indication to treat a 
disease indicates a problem in the use of the drugs (process of drug use). A 
diabetic or hypertensive patient without prescription or who has a lack of 
knowledge about the illness and treatment would result in the drug not 
being used as intended and thus result in poorly controlled blood pressure 
and blood glucose levels (outcome of drug use). This tool also has the 
drawback of only identifying manifested problems. However, it has the 
advantage of being validated for the identification of DRP at the inpatient 
settings (AbuRuz et al., 2011).  
 
1.3.2.6 Pharmaceutical Care Network Europe (PCNE) 
classification (1999-2010) 
The PCNE classification system defines DRP as an event or circumstance 
involving drug therapy that actually or potentially interferes with the desired 
health outcomes (PCNE, 2010). The first version of the PCNE classification 
for DRP was developed in 1999. The most recent version is version 6.2, 
introduced in 2010. At present, this is the only classification that has 
options to record the types of problems, the causes, the interventions to 
solve the problems and the outcome of the intervention.  
 
1.3.2.7 DRP classification systems in the present research  
The evolutionary development of DRP classifications demonstrates the need 
for practical application of theoretical concepts. Being pragmatic about the 
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selection of existing DRP classifications that best suit individual practice or 
research objectives could be an alternative to the introduction of more new 
concepts. The work in this thesis adapted two DRP classification systems – 
the PCNE and the Gordon classifications.  
The present research adapted the PCNE classification system for DRP 
because it was the most appropriate option available at the time of the 
study’s initiation. The PCNE classification system has been successfully 
adapted in a similar international multicentre study investigating DRPs in 
general paediatric patients involving the paediatric population in the UK 
(Rashed et al., 2012b). It also  has an open hierarchical structure for each 
category, which consists of: type of problems, causes of the problems, 
recommendations taken to solve the problems, and resolutions. The open 
hierarchical structure enables addition of new elements to this classification 
system, which is an advantage for this study. The hierarchical structure also 
applies a coding system to facilitate data recording.  
The Gordon classification system was developed using information from 
patient interviews at the pharmacies and surgeries as well as during home 
visits. Even though it has not been used in studying DRPs in paediatrics, the 
Gordon classification could be adapted for the second study of this research 
(Study 2), which was conducted at the outpatient setting.  
 
1.3.3 ‘Drug-related problem’ as a term in medication safety 
There is no consensus in current literature on whether DRP should be 
regarded as similar to adverse drug event (ADE), adverse drug reaction 
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(ADR) or medication error (ME) which are synonymous with harm. The 
scientific community agrees that there is a lack of homogeneity in the 
terminologies not only in the context of DRP but also in the context of 
medication safety in general (Pintor-Marmol et al., 2012; Yu et al., 2005). 
Even though DRP was introduced as an element that could contribute to 
drug-related morbidity and mortality (Hepler and Strand, 1990) it has never 
been endorsed as an official term in medication safety. For instance, 
medication safety-related terms identified from an electronic search of 
websites of organisations associated with medication safety did include ADE, 
ADR and ME (Yu et al., 2005) but not DRP or its equivalent. In another 
review on classification of terminology in drug safety the main focus of 
discussion was only on ADRs (Aronson and Ferner, 2005).  
The European Council Expert Group on Safe Medication Practices suggested 
avoiding the use of ‘medication-‘ or ‘drug-related problems’ in describing 
medication safety (Airaksinen et al., 2006). According to this expert group, 
the working definition of DRP is designed for pharmaceutical care and not 
seen as applicable to medication safety. Based on the discussion above, it is 
reasonable to refer to DRP as a broader term to describe potential or 
manifested problems arising from the use of drugs in a patient’s treatment 
whereby ADR and ME are incorporated as potential causative factors in the 
treatment process. The concept of DRP promotes medication safety and the 
rational use of medicines. 
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1.3.4 Linking DRP to ADR, ADE and ME 
In the scope of this thesis, DRP is perceived to be connected to medication 
safety in several perspectives. In the examples of DRP classifications 
previously described, the elements of medication safety can either be a type 
or the contributory factors of DRPs. As an example, ADR was listed as a 
type of DRP in the Strand classifications (refer to DRP 5 in Table 1.3). In the 
Cipolle classification, ‘allergy reaction’ was listed as the cause of DRP (refer 
to Table 1.4). In the PCNE classification, prescribing error (PE) was listed as 
a cause for DRP (refer to Chapter 3, Figure 3.5). Thus, it is important to 
distinguish between the ADEs, ADRs,  MEs and DRPs before embarking in 
the present research.  
An ADE is an unintended noxious event occurring during drug therapy. It is 
an injury or harm suspected to be drug-related (Leape et al., 1991; MHRA, 
2006).  
An ADR is an unwanted or harmful reaction which occurs after 
administration of a drug or drugs and is suspected or known to be due to 
the drug(s). The reaction may be a known side effect of the drug or it may 
be new and previously unrecognised (MHRA, 2006).   
Medication error is a failure in any step of the treatment process that leads 
to, or has the potential to lead to, harm to the patient (Morimoto et al. 
2004). Medication errors include errors in the process of prescribing, 
transcribing, dispensing and administration. Prescribing error (PE) is an 
important aspect of ME and it a common cause of ADE in paediatrics 
(Ghaleb et al., 2006; Kaushal et al., 2001). 
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The link between DRP to ADR and ME can be explained in these two cases: 
(Case 1) If a patient on a correct dose of angiotensin-converting enzyme 
inhibitor (ACEi) experiences a dry cough, this case qualifies as a DRP 
because the patient experiences a dry cough, a symptom which is directly 
related to drug therapy, which in this case is an ACEi. If the ACEi is 
prescribed for a patient who has a known history of ACEi-induced dry 
cough, then the cause is ‘medication error’; whereas, if it was prescribed for 
a patient who does not have a known history of ACEi-induced dry cough, 
then it is a non-allergic ‘adverse drug reaction’ (ADR).  
Another example (Case 2) is a patient on a phosphate binding agent who 
experiences itchiness due to hyperphosphataemia. This case also qualifies 
as a DRP because the patient experiences symptoms of 
hyperphosphataemia, which may be related to sub-optimal treatment due 
to a number of reasons, such as sub-therapeutic dose requiring additional 
phosphate binders or, alternatively, patient's non-adherence. Table 1.6 
summarises the differences between ADE, ADR, ME and DRP.
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Table 1.6 The differences between drug-related problem (DRP), adverse drug reaction (ADR), adverse drug event (ADE), and 
medication error (ME) (Ibrahim et al., 2013) 
 Drug-related Problem 
(DRP) 
Adverse Drug 
Reaction 
(ADR) 
Adverse Drug Event 
(ADE) 
Medication Error 
(ME) 
Definition An event or 
circumstance involving 
drug treatment that 
actually or potentially 
interferes with the 
patient's experiencing 
an optimum outcome of 
medical care 
An unwanted or harmful 
reaction which occurs 
after administration of a 
drug or drugs and is 
suspected or known to 
be due to the drug(s) 
An unintended noxious 
event suspected to be 
drug-related 
A failure in the treatment 
process that leads to, or 
has the potential to lead 
to, harm to the patient 
*Dose of the drug 
during the incident 
↔  ↑  ↓ ↔ ↔  ↑  ↓ ↔  ↑  ↓ 
Potential cause of the 
harm  
 
Inappropriate drug or 
dosage regimen, drug 
form, dose, treatment 
duration, 
administration, supply 
and procurement and 
Type A (predictable): 
Exaggerated reaction 
towards the desired 
pharmacology effect of 
the drug. The reaction 
is dose dependent and 
Suspected to be related 
to the effect of the drug 
Mishaps or accidents 
during any stage of drug 
handling - prescribing, 
transcribing, dispensing 
and administering 
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 Drug-related Problem 
(DRP) 
Adverse Drug 
Reaction 
(ADR) 
Adverse Drug Event 
(ADE) 
Medication Error 
(ME) 
patients’ behaviour 
towards drug therapy 
reversible with dosage 
adjustment. 
Type B (idiosyncratic): 
Unknown cause and 
could possibly be 
related to immunology 
response towards the 
drug (e.g. allergic 
reaction) 
Improvement measures Pharmaceutical care 
practice 
ADR detection and 
reporting system 
Medication safety 
awareness and 
prevention 
Medication safety 
awareness and 
prevention 
Example Case 1 
Patient A experienced a 
dry cough that is 
suspected to be due to 
an angiotensin 
converting enzyme 
inhibitor (ACEi). The 
YES, because the 
patient is experiencing 
a symptom which is 
related to the drug 
YES, because the 
symptom could be an 
idiosyncratic response 
to ACEi 
YES, because the 
symptom is suspected 
to be induced by ACEi 
YES, if ACEi is prescribed 
for a patient who has a 
known history of ACEi-
induced dry cough. 
NO, if ACEi was 
prescribed for a patient 
who has no history of 
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 Drug-related Problem 
(DRP) 
Adverse Drug 
Reaction 
(ADR) 
Adverse Drug Event 
(ADE) 
Medication Error 
(ME) 
drug was stopped and 
changed to an 
alternative therapy.  
ACEi-induced dry cough. 
Example Case 2 
Patient B experienced 
itchiness, identified as a 
symptom of 
hyperphosphataemia 
despite being on a 
phosphate binding 
agent  
YES, because the 
symptom is related to 
suboptimal treatment 
with phosphate binding 
agent 
NO, because the 
symptom is not a 
pharmacological effect 
of phosphate binding 
agent 
NO, because the 
symptom is not 
suspected to be caused 
by phosphate binding 
agent 
YES 
If there is a prescribing 
error contributing to 
suboptimal treatment 
dose. 
 
NO 
If there are no incidents 
of mishaps or accidents 
(e.g. patient’s non-
adhering to treatment) 
* ↔ Normal dose;  ↑ Overdose/Toxic ; ↓ Under dose 
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1.4 Summary  
Previous studies in the adult populations have shown that DRPs are 
common in patients with kidney disease and their management has been 
shown to improve disease-oriented and patient-oriented outcomes (Kaplan 
et al., 1994a; Pai et al., 2009; Cardone et al., 2010). The next chapter 
addresses the gap in the knowledge regarding DRPs in children with CKD.  
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CHAPTER 2                                                                                
Systematic Review: Drug-Related 
Problems In Children With Chronic 
Kidney Disease 
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 2.1 Introduction 
The focus of this chapter is the review of published studies on DRPs in 
children with CKD. 
 
2.2 Methods 
 
2.2.1 Search terms and strategy 
Search terms were derived from three main keywords: ‘drug-related 
problem’, ‘paediatric’ and ‘chronic kidney disease’. A list of search terms 
associated with each keyword was generated from the MeSH database in 
PubMed and Alm Tree mapping in Embase. Relevant terms were also 
handpicked from literature (van Mil et al., 2004; AbuRuz et al., 2006). 
Keywords not listed as Medical subject headings (MeSH) term were 
searched for as phrases using the free text search mode. The following 
electronic databases were searched for all periods until 31st May 2011: 
BIOSIS Preview (Web of Knowledge), Embase (Ovid), International 
Pharmaceutical Abstract (Ovid) and Medline (Ovid). The list of search terms 
and the search strategy are shown in Appendix 2. 
 
2.2.2 Eligibility criteria of selected articles 
The criteria for relevant studies were: (1) involving participants aged 18 
years and below who were diagnosed with CKD at all stages; (2) studies 
reported in the English language; and (3) studies reporting on the types of 
DRP, possible causes of the problem and outcomes of interventions (or 
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actions taken) to solve the identified problem in children with kidney 
disease. The above inclusion criteria were based on literature in the adult 
CKD population. Articles related to medications that referred to specific 
therapeutic medications or routes of administration were excluded.  
 
2.2.3 Data extraction 
All articles were merged into the EndNote X3® program (Thomas Reuters, 
New York, US). Three reviewers (NI, YG and SP) were involved. In the initial 
screening, duplicates were removed and all identified abstracts were 
manually read for their applicability of the predetermined criteria. To 
standardise the assessment for relevant articles in the screening phase, all 
reviewers followed a standard assessment protocol (Figure 2.1). The full-
text manuscripts of the potentially relevant articles were obtained by 
electronic or paper copy for assessment. Otherwise, the corresponding 
authors were contacted.  
Information extracted from the full-text manuscripts was recorded in a 
proforma and this included the following data: year and country of study, 
subject characteristics (age, clinical characteristic, sample size), study 
design, epidemiology data of DRP (type, possible causes and classification 
scheme) and outcomes of intervention or suggestions for the DRP. 
Throughout this process, any disagreement was solved by consensus among 
the research team.  
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Does the title or abstract signify drug-related problem  
(or other associated term)? 
Do the study 
participants 
indicate chronic 
kidney disease 
at any stage?  
Do the study 
participants 
indicate 
paediatric 
population?  
Exclude 
Is this a study 
reporting 
problems of 
specific 
therapeutic 
medications or 
routes of 
administration? 
Consensus 
among 
reviewers 
Include for full-text 
retrieval  
Relevant
No Unsure Yes 
Yes 
No 
Figure 2.1 Flowchart of data extraction 
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2 Abstracts of conference proceeding  
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208 Duplicate articles  
628 Articles removed: 
 
333 Articles on studies involving adult population  
119 Articles on studies in paediatric not related to 
kidney disease  
118 Article on kidney transplant  
58 Articles on studies in animal and laboratory tests  
198 Articles removed: 
 
134 Articles on disease diagnosis and management  
49 Articles on pharmacological effect of specific 
drug(s)  
12 Article on psychology problem  
3 Articles not in English language 
4 Potentially relevant articles to retrieve full-text  
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830 Records for title and abstract screening 
 
202 Articles on studies involving paediatric with chronic 
kidney disease  
Figure 2.2 Flowchart of result analysis 
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2.2.4 Excluded literature 
Of the aforementioned four potentially relevant articles (Table 2.1), one was 
a descriptive study aimed at identifying the potential roles of clinical 
pharmacists in a paediatric nephrology and hypertension clinic through the 
provision of cognitive pharmacy services (So et al., 2010). Another study 
reported on the impact of electronic prescribing system (ePS) on the rate of 
prescribing errors (PE) at a paediatric nephrology clinic (Jani et al., 2008). 
The remaining two articles were abstracts of unpublished studies 
(Lincenberg et al. 1986; Perrier-Cornet et al., 2010). For the two abstracts, 
efforts to retrieve the full-text by contacting the corresponding author and 
checking for availability in the British Library Integrated Catalogue were 
unsuccessful. Further information from the BLIC showed that the two 
studies had not been published in full. The details of the excluded data are 
described in the following paragraphs and summarised in Table 2.1. 
 
So et al., 2011 
This is a descriptive study aimed at identifying the potential roles of the CPs 
as a provider in a paediatric nephrology and hypertension clinic. The study 
was conducted at a referral clinic for children and adolescents with CKD and 
hypertension from Central and Eastern North Carolina in the US. The study 
was conducted for eight months and involved a total of 283 patients with 
the mean age (SD) of 10.3 (5.6). The patients’ clinical characteristic was 
described as having CKD Stage 1 to 5 or high blood pressure. 
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The CP’s potential role was determined by providing a cognitive pharmacy 
service which was referred to as services provided by pharmacists related to 
the management of the effectiveness and appropriateness of patients’ 
therapeutic regimens. Within this service, for each patient, the pharmacist 
would discuss treatment recommendations and pharmaceutical care issues 
with the physicians before medical consultation. After medical consultation, 
patients would be referred back to the pharmacist if there was a change in 
drug regimen or if there was a need for further management of 
pharmaceutical care issues.  
The pharmacy-based interventions that were performed during clinic visits 
include: (1) counselling and/or verification of understanding on current drug 
therapy; (2) adherence assessment; (3) conveying patients’ 
concerns/issues regarding their drug therapy to physicians; (4) provision of 
information to patients/parents about drugs that were not prescribed by 
their nephrologists; (5) drug dosing/monitoring recommendation; (6) 
provision of drug information; (7) identification of drug discrepancies; (8) 
medication education for kidney transplant candidates; (9) counselling on 
new drugs; (10) updating drug allergies; (11) customised letters warning 
against pregnancy for females of child-bearing age on ACEi or angiotensin 
receptor blockers and (12) calling the patient’s pharmacy to obtain refill 
rate if the patient did not bring drugs to clinic or in situations where there 
was a suspicion of non-adherence. 
The study result showed the mean number of pharmacist’s intervention per 
patient was 2.3 (SD: 1.0) and the mean number of medication prescribed 
per patient was 5.7 (SD: 4.8). Counselling on medication regimens to 
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patients and family members was the most frequent pharmacy service 
provided at the clinic (85%). The most challenging part of the counselling 
was to provide an understanding of medication indication and side effects. 
Factors that contributed to this challenge were: the lack of understanding of 
medications; difficulty in interpreting medication labels; below-average 
literacy level of study population; lack of parental supervision for 
adherence; and lack of appropriate drug formulations. This study also 
reported a trend that showed patients on haemodialysis or after kidney 
transplant were on more medications compared to those in the pre-dialysis 
stage (p<0.05); this is expected because disease complications increase 
with severity. The overall rate of non-adherence was 15%. Indeed, it would 
be interesting to have more information on the different rate of non-
adherence between patients at different stages of CKD. 
This study is useful to determine the types of pharmacy services at a 
paediatric nephrology clinic, but there was a lack of information on DRPs as 
well as the clinical and non-clinical outcomes of the services towards 
patients’ treatment.  Such information would be beneficial to evaluate the 
impact of  clinical pharmacy practice (Fernandez-Llimos et al., 2004). It 
would also provide guidance in initiating medicine improvement 
programmes at facilities with restricted numbers of renal pharmacists (or 
nurses) and financial resources. 
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Perrier-Cornet et al., 2010 
This study fulfils most of the criteria of interest; however, the results were 
not published. Thus, information presented here is limited to what was 
reported in the abstract. This study aimed to describe pharmaceutical care 
issues in a nephrology paediatric care unit in France. The study was 
conducted over seven months and involved a total of 28 patients aged in 
the range of two months to 20 years. The acceptance of pharmacists’ 
interventions by prescribers and clinical significance for each intervention 
were also evaluated.  
Drug dose adjustment was the most frequently encountered DRP, 
representing 30% of the reported problem. Antihypertensive and drugs 
affecting haematopoiesis were the two groups of drugs most frequently 
associated with DRP. Out of 44 pharmacists’ interventions to solve the 
identified DRPs, 66% were accepted by prescribers. Clinical significance of 
the interventions was rated as moderate in 22 cases, of mild importance in 
15 cases and major in seven cases. Further information on the causes of 
the identified DRPs, outcomes of the intervention and the description of 
severity were not mentioned in the abstract. 
Jani et al., 2008 
Jani and colleagues conducted a pre- and post- intervention study aimed at 
determining the impact of ePS on the rate of prescribing error (PE) at a 
paediatric nephrology clinic of a tertiary paediatric hospital in the UK. The 
outcome measures were prescribing error rate, number of illegible items 
and number of patients’ visits that were error-free.  
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In the pre-intervention phase, prescribers handwrote prescriptions on a 
designated form. This form was given to patients or parents who then took 
it to the pharmacy for dispensing. Four months after the introduction of the 
ePS at the clinic setting, prescriptions were prospectively collected. A total 
of 1140 prescriptions containing 2242 items were retrospectively reviewed 
for errors by two researchers. The inter-rater reliability for error 
identification was 0.65 (95% CI 0.46-0.85).  
This study concluded that the introduction of ePS reduced the rate of 
prescribing error by approximately 94% from 77.4 to 4.8% in the pre- and 
post-intervention phases respectively (95% CI 75.3-79.4%), reduced the 
number of items with missing essential information from 73.3% (95% CI 
71.1-75.4%) to 1.4% (95% CI 0.7-2.6%) and increased error-free visits by 
69% (95% CI 64-73.4%).  
This study is useful to justify the need for an ePS but it was limited to the 
occurrence of PE rates at the renal outpatient settings.  
 
Lincenberg et al., 1986 
This abstract reported on the influence of group-based reinforcement to 
improve dietary and medication compliance in five adolescents undergoing 
continuous ambulatory peritoneal dialysis; patients were aged between 14 
and 18 years. Further information regarding the country where the study 
took place, the method and results was not reported. 
CHAPTER 2      SYSTEMATIC  REVIEW 
 
71 
 
Table 2.1 Characteristics of the excluded articles 
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So et al., 
2011  
USA 
Observational 
 
8 months 
Paediatric 
nephrology 
and 
hypertension 
clinic 
283 
patients 
10.3 
(SD:5.6) 
Patients with 
primary 
diagnosis of 
kidney 
disease or 
hypertension  
Not 
reported 
Not 
reported 
Pharmacy 
cognitive 
service at 
the 
nephrology 
clinic 
Not 
reported 
No 
information 
on 
characterist
ics of DRP 
and 
outcome of 
interventio
n 
Perrier-
Cornet et 
al., 2010   
France 
Descriptive  
 
6 months 
Nephrology 
care unit of a 
teaching 
hospital 
28  
patients 
Between 
0.2 to 20 
All patients Inappropria
te drug 
doses 
(other 
characterist
ics not 
mentioned) 
Not 
reported 
Pharmaceut
ical 
intervention 
through 
provision of 
pharmaceut
ical care by 
pharmacist 
Not 
reported 
Full-text 
not 
available 
 
Full 
characterist
ics of DRP, 
causes and 
outcome of 
interventio
n not 
reported in 
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abstract 
Jani et al., 
2008 
UK 
Pre- and Post- 
 
12 months 
Paediatric 
nephrology 
clinic of an 
acute 
tertiary care 
paediatric 
hospital 
520 
patients 
8.8 
(SD:5.6) 
All patients Prescribing 
error  
Conventi
onal 
hand 
written 
prescript
ions 
Electronic 
prescribing 
system 
94% 
reduction in 
prescribing 
errors after 
electronic 
prescribing 
was 
introduced 
Only one 
specific 
type of DRP  
Lincenberg 
et al., 
1986 
Pre- and Post-  Not reported 5  
patients 
Between 
14 to 18 
On CAPD Non-
adherence 
to 
medication 
and dietary 
restrictions 
Not 
reported 
Group-
based 
reinforceme
nt on 
adherence  
Not 
reported 
Full-text 
not 
available 
 
Only one 
specific 
type of DRP 
CAPD (continuous ambulatory peritoneal dialysis), DRP (drug-related problem), SD (standard deviation), USA (United States of America), 
UK (United Kingdom) 
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2.3 Discussion  
2.3.1 Generating search terms 
The development of the search terms and strategy was based on a trial-
and-error approach whereby the candidate search terms identified were 
entered into the bibliographic database with the corresponding syntax and 
tested regarding whether references from the development set could be 
detected. The major problem in retrieving relevant articles contributed to 
the non-standardised terms used to describe problems related to the use of 
drugs. It became even more complicated because the phrase ‘drug-related 
problems’ is not listed as a MeSH term. The word ‘drug’ without appropriate 
syntax attracted an enormous amount of articles related to the use of 
abusive substance. 
As previously explained in Chapter 1, DRP is not a unique term to describe 
problems related to the use of medicines. Revision of secondary sources by 
Fernandez-Llimos et al. (2004) on published papers using the concept of 
DRP between 1990 to 1999 reported that, from a total 457 articles, 77.6% 
were retrieved for the term ‘drug-related problem’, 11.6% for ‘drug-therapy 
problem’, 10.7% for ‘medication-related problem’ and less than 1% for 
‘medicine-related problem’. One of the reasons that contribute to the 
varieties of terminologies are the use of the term ‘medicine’ or ‘medication’ 
and ‘drug’ by publications in British and America respectively (Fernandez-
Llimos et al., 2004; Granada Consensus, 2007; van Mil et al., 2004).  
In this systematic review, the researcher generated a list of candidate 
search terms by referring to two references. One was a review on DRP 
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classification systems from 1999 until 2003 (van Mil et al., 2004) and the 
second article was a study aimed at developing and validating a tool to 
assess treatment-related problems (AbuRuz et al. 2006). These two articles 
also reported difficulties in identifying previous literature on DRP from 
electronic journal databases; each article suggested a list of search terms 
for ‘drug-related problems’.  
The terms ‘medication error’ and ‘prescribing error’ were initially 
categorised under ‘questionable search term’. The aforementioned terms 
were questionable because they refer to accidents that can potentially cause 
harm to patients during any stage of drug use. In contrast, DRP refers to 
inappropriate use of drug, which can interfere with the desired treatment 
outcome, both actual and potential. However, these terms were then 
included to increase specificity based on the fact that errors can contribute 
to the occurrence of DRPs. 
  
2.3.2 Justification for research 
The limitations of the excluded articles demonstrate the gap in knowledge in 
this area. The reasons for the need of epidemiological data on DRP in 
children with kidney disease are outlined below.   
Firstly, paediatric doses for most drugs are calculated by estimated GFR, 
BSA or body weight (Atiyeh et al., 1996; Brandt et al., 2006); determining 
the appropriate dosage regimen for an optimum therapeutic effect poses 
challenges in daily practice. The availability of data on DRPs is beneficial to 
construct proactive strategies to promote drug safety in treating children 
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with kidney diseases. Furthermore, kidney disease and dialysis alter the 
pharmacokinetic properties of drugs, which makes dosing more difficult 
(Hassan et al., 2009).  
Secondly, children with kidney impairment may be at greater risk of 
developing DRPs due to the nature of disease progression and complications 
that demand complex drug therapy. The NKF/KDOQI clinical practice 
guideline for CKD in children and adolescents recommends that a 
medication review should be performed at all visits for dosage adjustment, 
detection of potentially adverse drug effects on kidney function or 
complications of CKD, detection of drug interactions and therapeutic drug 
monitoring (Hogg et al., 2003). Even though the term ‘DRP’ was not 
imposed, they are examples of problems related to the use of medicines. A 
better understanding of the nature and characteristics of DRPs in the 
paediatric-CKD population provides information on the risk factors for the 
occurrence of DRPs.  
Currently, risk factors for the occurrence of DRPs in children with CKD are 
assumed to be similar to those of adults with CKD or general paediatric 
populations. However, this assumption may not be valid. Studies of DRPs in 
the general paediatric population indicate that the risk factors for this 
patient group are the use of off-labelled drugs, younger age and 
polypharmacy (Impicciatore et al., 2001; Kimland et al., 2007). Whereas 
risk factors identified from adult DRP studies are: higher stages of disease 
based on NKF/KDOQI clinical practice guideline; having more than three 
concurrent disease states; drug regimen changed more than four times in 
the past twelve months; more than five medications in present drug 
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regimen; on more than twelve medication doses per day; history of non-
adherence; and presence of drugs that require therapeutic drug monitoring 
(Churchwell and Mueller, 2007; Grabe et al., 2007; Kaplan et al., 1994a; 
Manley et al., 2003).  
Finally, most drug management studies in paediatric nephrology were 
conducted in the post kidney transplant group. For example, one area that 
has received much interest in post kidney transplantation is medication 
non-adherence. This may be related to the immediate malignant outcomes 
associated to both organ and patient outcomes as a direct result of non-
adherence. In comparison, effects of non-adherence in children with CKD 
may not be evident relatively immediately (Chisholm-Burns et al., 2009; El 
Nahas, 2005). The consequences of underestimating non-adherence and 
other DRPs among children (and parents) in the pre-transplant stage may 
lead to unforeseen treatment failure. It is important to note that patients 
with dialysis-dependent CKD are also likely to experience DRPs. 
 
2.4 Summary 
There is currently no epidemiological data on DRPs in children with kidney 
disease. Children with kidney disease are at risk of experiencing DRPs and 
DRPs may potentially lead to harm. It is not known whether the 
characteristics of DRPs in this group of interest resemble their adult 
counterpart and/or the general paediatric population. The occurrence of 
DRPs in clinical practice is also difficult to recognise without a structured 
approach. Therefore, further research using a standardised method and 
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operational definition is required to identify the characteristics of the DRPs 
in this specific group.  
 
2.5 Research Aims and Strategy 
Arguments in the section above strongly justify the need for further 
research in this area of knowledge. The aims of this thesis were to 
investigate the epidemiology of DRPs using standardised definitions and 
methods, and the effect of CPs’ intervention in the management of DRPs in 
paediatric nephrology patients. The research questions are: 
1) What are the nature and characteristics of DRPs in paediatric 
nephrology patients? 
2) What are the potential risk factors associated with the occurrence of 
DRPs in paediatric nephrology patients? 
3) How significant are the DRPs in the clinical settings?  
4) Is a pharmacy-based intervention effective in resolving DRPs in the 
renal outpatient clinic?   
In order to answer the research questions, two studies were conducted. The 
first study (Study 1) was a prospective observational study at the paediatric 
renal wards and the second (Study 2) was a randomised control trial that 
took place at the paediatric nephrology clinics. Table 2.2 summarises the 
objectives and strategies for the whole research.  
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Table 2.2 Research objectives and strategies 
 
The next chapter discusses the methodological approach that has guided 
the conduct of this research. 
Research Objectives     Strategy 
 
To determine the gap in current 
knowledge on DRPs in children with 
chronic kidney disease. 
 
 
Literature review on DRPs in 
children with chronic kidney 
disease (Chapter 2) 
 
To identify the characteristics, 
predictors and severity rate of DRPs 
in hospitalised children at the 
inpatient setting  
 
*Study 1: Prospective 
observational study on the 
characteristic of DRPs in 
hospitalised children with kidney 
disease (Chapter 5) 
 
 
To identify the characteristics, 
predictors and severity rate of DRPs 
at the renal outpatient clinics  
 
To evaluate the effectiveness of 
pharmacist intervention in resolving 
DRP at renal outpatient clinics   
 
 
*Study 2: The effect of CP 
interventions in resolving DRPs at 
the renal outpatient clinic: A 
randomised control trial  
(Chapter 6) 
  
 
*Feasibility studies were conducted prior to the initiation of Study 1 and 
Study 2 and are reported in Chapter 4.  
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3.1 Introduction 
This chapter gives an overview of the study sites, study designs and tools 
adapted in this research. The first three sub-sections in this chapter give an 
overview on the setting of the study sites, the justification of the selected 
study designs and the evaluation of outcomes in patient safety research. 
The next three sub-sections describe the methods and tools that have been 
adapted to detect, classify and assess the severity of DRPs in the current 
research. The final section gives an overview of ethical considerations. 
Throughout this chapter, Study 1 refers to the prospective observation 
study that was conducted at the inpatient setting and Study 2 refers to the 
RCT on the effectiveness of CP interventions at the renal outpatient clinic 
setting. 
 
3.2 Setting of the study sites 
This research was conducted at two National Health Service (NHS) 
children’s hospitals in London:  
a) The Evelina London Children’s Hospital (ELCH), Guy’s and St. 
Thomas’ Hospital NHS Foundation Trust, King’s Health Partners  
b) The Great Ormond Street Hospital for Children (GOSH), NHS Trust 
The selection of both hospitals as the study sites is justified in the sense 
that they are among the largest renal units in the UK. The ELCH is the main 
referral centre for paediatric nephrology cases in London and the South East 
of England. The GOSH serves a bigger population which includes London, 
Eastern, South East, South West and West Midland regions. The total 
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number of children with CKD is difficult to determine and is suspected to be 
at least triple than the reported number for the established kidney failure 
population (Kim et al., 2013; Harambat et al., 2011).  
Both sites are teaching hospitals that provide tertiary care to children aged 
less than 18 years. The renal units in both hospitals provide comprehensive 
inpatient and outpatient-based diagnostic and treatment services for 
children with renal disorders and are led by teams of paediatric renal 
consultants and specialists, supported by a dedicated team of medical, 
nursing and healthcare professionals including doctors, nurses, CPs and 
nutritionists. 
 
3.2.1 Inpatient setting and ward pharmacy services 
Study 1 was conducted in the renal wards at ELCH and GOSH. Both 
hospitals used paper-based multidisciplinary medical notes and electronic 
results for all laboratory tests. Paper-based drug charts were used in ELCH; 
however, an ePS was used in GOSH.  
The clinical teams in both hospitals conducted full patient review and daily 
clinical rounds. A clinical round is a multidisciplinary discussion on the 
progress and treatment plan for individual patients. The types of patients 
that are seen in both hospitals include kidney transplant patients, patients 
with CKD, peritoneal and haemodialysis patients, and patients with any type 
of disorder that affects the kidneys and urinary tract system. The inpatient 
settings of the study sites are presented in Table 3.1. 
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Table 3.1 The inpatient settings of both study sites 
 Study Sites* 
ELCH GOSH 
Setting of the renal ward   
Number of ward beds 18 16 
Availability of dialysis machines  
on the wards 
 
Yes Yes 
Medical notes 
 
 
Prescribing system 
 
 
 
Paper-based multidisciplinary notes with 
electronic laboratory results 
 
Paper-based prescriptions 
 
 
 
Paper-based multidisciplinary notes with 
electronic laboratory results 
 
Electronic prescribing system (ePS) with 
Electronic medicine administration (eMA) 
system 
 
 
Operation time Monday to Friday: 1000 to 1730 
Saturday: 0900 to 1700 
Other times and on Sunday: On-call 
pharmacist provides cover 
Monday to Friday: 0830 to 1800 
Saturday: 0900 to 1200 
Other times and on Sunday: On-call 
pharmacist provides cover 
 
*ELCH – Evelina London Children’s Hospital; GOSH – Great Ormond Street Hospital for Children, London 
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3.2.1.1 The electronic prescribing system (ePS) at GOSH 
The ePS is combined with the electronic medication administration (eMA) 
system. In order to prescribe using the ePS, the child’s allergy status, 
weight and height are mandatory information to be entered before ordering 
the medicines. The prescribers have the option to use the ‘Calculate Dose’ 
option on the prescription screen to obtain a crude calculation based on the 
patient’s weight, which will need to be rounded to a measurable dose. 
Prescriptions could be ordered as new items, renewed from previous 
admission or selected to continue at discharge from the patient’s inpatient 
medication list (Jani, 2008). The current system does not offer dose 
checking. Checking of the appropriate does is carried out by the CPs during 
routine prescription chart review.  
 
3.2.1.2 Ward pharmacy services 
The wards received a typical UK pharmacy ward service with a daily visit 
from a designated CP on weekdays and a short visit on Saturdays (Franklin 
et al., 2009; Taxis et al., 1999). At the time of each visit, the CPs initiated 
the supply of any non-stock drugs required and also checked that all 
prescriptions were clinically appropriate. Non-stock drugs are medicines that 
are not normally stored on the wards. In order to supply the medicine, the 
CP has to order it from the main pharmacy. The CP also gathered 
information on patients’ drug history, provided medication counselling to 
patients and family members especially at hospital discharge; and reviewed 
medication charts for the appropriate use of medicines. At GOSH, the 
availability of the ePS enables the CP to review patients’ medication lists 
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from the pharmacy office to identify DRPs before attending the clinical 
rounds. On the wards at both hospitals, the CPs also discussed patients’ 
drug-related issues with the clinical team on a regular basis. All these 
activities enable the CPs to identify and solve DRPs. The problems that 
could be solved at the pharmacy level with notification to the clinical team 
are for instance shortage of drug supply and compatibility of different 
pharmaceutical products. The CP also provided feedback on drug-related 
inquiries by the medical team. DRPs that required changes to the treatment 
regimen were discussed with the doctors, and followed up to assess their 
resolution. A DRP was defined as ‘resolved’ when actions were taken before 
causing any harm to patients or actions were taken to solve an ongoing 
DRP. 
The pharmacy departments are open during office hours on Monday to 
Friday and have limited hours on Saturday. Outside the opening hours and 
on Sundays, an on-call pharmacist would be on duty (Table 3.1). The lead 
CPs at both study sites were in band 8, based on the UK NHS grading, with 
more than ten years of experience in paediatric renal pharmacy practice and 
similar academic qualifications. Figure 3.1 shows the flow of ward pharmacy 
activities in the standard care at the inpatient settings.   
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Identify DRPs during clinical rounds and discussion with the 
medical team 
Evaluate the causes of the problem and provide suggestion for its 
resolution 
Provide recommendations to solve DRPs with the goal to provide 
better quality of care  
Activities of the ward pharmacists in the standard care in both 
hospitals 
Check the appropriateness of prescriptions 
Ensure that drug are adequately supplied to the right patient with 
the right dose and administered at the right time 
Review medication chart to reconcile patient’s own drugs and the 
ones being prescribed on the ward 
Drug history taking 
Discuss with the clinical team on drug-related issues for individual 
patients 
Provide drug information and drug updates to the medical team 
Figure 3.1 Ward pharmacy activities in the standard care at the inpatient 
settings 
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3.2.2 Outpatient setting 
Study 2 was conducted at the ELCH. The initial plan was to include ELCH 
and GOSH; however, due to logistical reasons and staff constraints at 
GOSH, this was not possible. Thus, this is an overview of the setting of the 
renal outpatient clinic in ELCH.  
The ELCH renal outpatient clinics used multidisciplinary electronic medical 
records (eMR), electronic records for all laboratory tests and paper-based 
prescriptions. These clinics comprise CKD clinics (for children living with 
reduced kidney function), renal transplant clinics (for children who are 
candidates for or who have had kidney transplantation) and general 
nephrology clinics (for children with previously diagnosed kidney disease or 
high blood pressure). The dialysis clinics for children who are undergoing 
peritoneal or haemodialysis treatment are based at the dialysis units in the 
wards. The renal clinics operate from Monday to Friday, and involve the 
paediatric renal consultants, registrars and specialist renal nurses.  
The typical procedure of clinic visits starts with the patients receiving clinic 
letters that contain information about their medical progress and the 
tentative date for the next clinic appointment. When the patient attended 
the appointment, their vital signs were measured and phlebotomies were 
taken prior to the doctor’s consultation. After the doctors’ consultation 
session, patients collected the newly prescribed medications from the 
hospital pharmacy if needed. Other medications were to be continued (and 
supplied) at the community level by the general practitioners and the 
community pharmacies. Unlike the inpatient setting, pharmacy services 
have not been embedded in the standard care of the outpatient setting. 
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Figure 3.2 presents the workflow of the standard care in the outpatient 
clinics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.2 The workflow of the standard care in the outpatient clinics 
Clinic registration at the clinic reception 
Vital signs and phlebotomy  
(10 minutes)a 
Doctor consultation  
(20 minutes) α 
+/- See other healthcare provider if required (e.g. 
social worker, play specialists) 
+/- Collect prescribed medicines at the hospital 
pharmacy 
Notes:  
 αApproximate waiting time 
Vital signs and phlebotomy  
(10 minutes)a 
 CHAPTER  3     METHODOLOGICAL APPROACH 
 
88 
 
3.3  Selection of study design 
Observational study design was used in Study 1 and Study 2 was conducted 
as an RCT. The justification for selecting these two study designs is 
discussed in the following sub-sections.  
 
3.3.1 Observational study design  
The aim of Study 1 was to determine the characteristics of DRPs identified 
by the CPs during their routine ward pharmacy practice. Ward pharmacy 
service is a standard inpatient care on the paediatric renal wards at both 
study sites. The CPs’ involvement in managing patients’ treatment on the 
wards is already an intervention in the standard care; thus, it would be 
unethical to have a control group who would not receive the existing 
interventions. In observational studies the subjects receive no additional 
intervention beyond the standard care. Subjects are therefore observed in 
their natural state (Peacock and Peacock, 2013). Examples of observational 
study designs are cohort-study, case-control, cross-sectional and case 
study. The prospective cohort-study design was used in the current 
research.   
 
3.3.1.1 Prospective cohort study design 
Observational studies can be conducted prospectively and retrospectively. 
The prospective approach allows the estimation of the time course of event 
and the population at risk (Kumar, 2011). Cohort-study design is suitable to 
be used when there is a lack of information on the risk factors for an event 
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of interest in a particular population disease (Peacock and Peacock, 2013; 
Hennekens and Buring, 1987), which was the case with regard to risk 
factors for the occurrence of DRPs in children with kidney. This study design 
demonstrates an appropriate temporal sequence between exposure (i.e. 
potential risk factors) and outcome (i.e. DRPs). The above criterion is an 
advantage because identifying DRPs in the clinical setting involves complex 
decision making and the temporal sequence can be difficult to be 
determined.  
In this study design, all potential subjects must be free from the event of 
interest at the initiation. The number of sample size and the length of 
follow-up should be sufficient to determine the occurrence of the event and 
potential risk factors (Peacock and Peacock, 2013). Cohort study-design is 
prone to several types of bias such as information bias and selection bias 
(Byona and Olsen, 2004; Hennekens and Buring, 1987; Kumar, 2011).  
Information bias is the misinterpretation in the estimate of association 
between risk factor and outcome that is due to misclassification of subjects 
on one or more variables, either risk factor or disease status. In the current 
study, information bias could be related to the method of classifying the 
characteristics of DRPs. This can be minimised by adapting validated tools 
to determine the characteristics and severity of DRPs. Further descriptions 
of study tools are presented in sections 3.6 and 3.7.  
The prospective approach of cohort study offers the benefit of minimising 
selection bias (Peacock and Peacock, 2013). Selection bias is the 
misinterpretation in the estimate of association between risk factor and 
outcome that results from how the subjects are selected for the study. It 
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can be minimised by selecting subjects that are representative of the target 
population. In the current study, subjects were selected from the renal 
wards to represent children with kidney diseases.  
 
3.3.2 Interventional study design 
The aim of Study 2 was to determine the effectiveness of CPs’ intervention 
in resolving DRPs at the renal outpatient setting. Unlike the inpatient 
setting, clinical pharmacy services were not a standard care at the 
outpatient setting in both study sites. This situation offered the opportunity 
to introduce and test the effectiveness of interventions by CPs at the renal 
clinics. Randomised control trial could demonstrate the beneficial effects of 
interventions and was used in the current study.  
 
3.3.2.1 Randomised control trial  
The strength of RCT is the avoidance of bias when allocating interventions 
to trial subjects (Schulz et al., 2010). In RCT, subjects are placed into one 
of two groups at random: receive the intervention (Intervention group) or 
do not receive the intervention (Control group). In the current study, 
subjects in the Intervention group receive CP’s interventions and the 
controls receive standard care. When an intervention is a programme of 
care, it is common practice for the control group to receive the standard 
care (Wong, 2004). Random allocation into either of the groups ensures 
that the individuals in the study are truly representative of the population 
from which they are drawn.  
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In order to gain the benefit of randomisation, all randomised participants 
should be retained in the group to which they were allocated and all 
participants should be included in the analysis whether or not they received 
the intervention or completed the trial. These are the conditions in the 
principle of intention-to-treat (ITT) analysis (Schulz et al., 2010). Non-
adherence to the trial protocol is a condition that limits the application of 
ITT analysis. It refers to situations when participants deviate from the trial 
protocol, such as participants did not receive the intervention or loss of 
follow-ups. The Per Protocol analysis refers to a method of analysis that 
excludes participants who deviated from protocol.  
Figure 3.3 shows the outline design for an RCT. The comparison of the 
intervention takes place in parallel and the observation for the intended 
outcome at baseline before and after intervention is compared between the 
control and intervention groups.  
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Standard care 
Outcome 
T
im
e
 
Select potential subjects 
Intervention  Control  
Introduce 
intervention 
Outcome 
Obtain informed consent 
Baseline measurement  
Define reference population  
Random allocation  
Figure 3.3 Basic outline for the design of randomised control trial 
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3.4 Evaluating outcomes in patient safety research 
In the third article from a set of four series on the epistemology of patient 
safety research, the authors explained the use of multiple endpoint 
measurements in patients’ safety research (Brown et al., 2008c). The 
authors of this paper introduced a model for causal link of intervention and 
outcome chain. This model demonstrates how interventions might work and 
also provides a conceptual map of the end points that may be measured in 
an evaluation of any patient safety intervention (Brown et al., 2008a). The 
model could be applied in developing the types of interventions to resolve 
DRPs at the renal outpatient clinic setting for the RCT. The following sub-
section explains the aforementioned causal chain linking interventions to 
outcomes and the types of endpoint that could be considered in the current 
research.   
 
3.4.1 Causal chain linking interventions to outcome 
The types of endpoints in patient safety research originate from the causal 
link between intervention and outcomes. This link is derived from the 
Donabedian theory. Donabedian theory evaluates the elements of 
‘structure’, ‘process’ and ‘outcome’ in appraising quality (McDonald et al., 
2007).  
Figure 3.4 illustrates the previously mentioned model for causal link of 
intervention and outcome chain. In the context of the causal chain of 
interventions to outcome, ‘structure’ refers to the external factors that are 
beyond the control of the managers within a particular health organisation. 
These may include national directives, licensing products and budget 
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constraints. ‘Process’ refers to the endogenous processes that are under 
local control. There are two types of processes: management (or 
organisational) processes and clinical processes.  
The management processes are related to the process in managing the 
organisation e.g. training of staff and human resources. Errors in the 
management processes are latent and lie dormant within the system for 
many years before they combine with active errors to create an accident 
opportunity (Reason, 2000). Generic interventions are aimed at 
strengthening an organisation by reducing latent errors that affect patients’ 
safety outcomes.  
The clinical processes are the matters involved in providing treatment to 
patients e.g. adoption of medication safety  and evidence based practices. 
Errors in the clinical processes are active and warrant specific interventions 
that affects clinical practice. Last in the chain are clinical outcomes and 
throughput. 
In the context of the current research, outcome refers to the occurrence 
and resolution of DRPs. This causal chain of intervention and outcome 
illustrates that interventions to prevent or solve DRPs could be conducted at 
either the management process or the clinical process. The outcome of the 
interventions can be measured at the patient level or surrogate endpoint.  
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Structure Management 
processes 
Latent errors 
Intervening 
variables 
Clinical 
processes 
Active errors 
Patient 
outcomes 
Fidelity Fidelity 
Throughput, 
e.g. number of 
patients 
treated 
Specific 
intervention 
Generic 
intervention 
Figure 3.4 General and specific interventions across the system and evaluation end points. The coloured boxes 
represent the endpoint that could be measured in an evaluation of a patient safety intervention. Surrogate end point 
are shown in italics (Figure from Brown et al., 2008a) 
 
Process Outcome 
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3.4.2 Measuring outcomes in patient safety research 
Within the aforementioned causal link model, endpoints can be measured at 
either the patient level, i.e. patient outcomes, or at any level prior to the 
final patient outcome, i.e. surrogate end points.  
 
3.4.2.1 Patient outcomes 
Patient outcomes can be either clinical or patient derived. Examples of 
clinical patient outcomes are morbidity, mortality or specific objective 
parameters to indicate improvements in disease management, e.g. blood 
pressure and low-density lipoprotein levels for hypertension and 
hypercholesterolemia respectively. Other examples are: patients’ quality of 
life and satisfaction. Two issues that arise when patient outcomes are used 
as an end point are precision and bias (Brown et al., 2008c). 
It is difficult to precisely evaluate an improvement caused by an 
intervention because outcomes may also be influenced by other factors such 
as the prescribing pattern, clinical judgement among healthcare providers 
and the disease progression (Brown et al., 2008c). The other factors that 
influenced patient outcome are also called signal to noise ratio. Signal is the 
indicator of improvement caused by the intervention and noise is the 
confounding factors that cause variance in the outcome. There is a tendency 
towards false positive statistical error in using patient outcome as the end 
point in an evaluation of a patient safety intervention.  
As an example, a patient who has a high level of serum phosphate is 
treated with a phosphate-binding agent. The reduction of the phosphate 
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level is the intended clinical outcome and optimising the dose of the 
phosphate-binding agent would be most sensible to achieve this outcome. If 
the drug was omitted by error, it is speculated that there will be a poor 
outcome by showing no improvement or worsening of the serum phosphate 
level. However, the poor outcome may also be influenced by other factors, 
for instance progressive kidney failure requiring dialysis (dialysis eliminates 
excessive serum phosphate) or alteration in patient’s diet to high phosphate 
content. Therefore, measuring the serum phosphate level as a signal to 
assess the negative implication of omission error would be an imprecise 
endpoint. 
One of the strategies to improve signal to noise ratio is by choosing an 
outcome that arises exclusively from error as the signal, but the choice of 
these outcomes is limited (Brown et al., 2008a). Another strategy is to 
select the signal of cases of poor outcomes that were caused by poor care. 
This requires the identification of poor outcomes and then examination of 
the process of care to select the instances when the poor outcome was the 
result of deficiencies in care. The limitation to the second strategy is bias in 
making judgement about preventable poor outcomes. Clinical outcome in 
pharmacy practice research is also difficult to measure in a consistent way. 
In the context of research, it is important to ensure that the same observer 
makes the measurement if possible. This is to ensure that the results will 
not be biased due to inter-observer difference even when applying a 
standard definition and protocol (Kumar, 2011). 
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3.4.2.2 Surrogate endpoints 
Surrogate end points are measured from the process level of the causal 
pathway. There are three types of surrogate end points: errors in clinical 
process, fidelity and intervening variables.  
 
3.4.2.2.1 Errors in clinical process  
Errors in the clinical process are the closest surrogate end point to patient 
outcome. They can be described as (1) failure to apply the correct standard 
of care, (2) failure to carry out a planned intervention as intended and (3) 
application of an incorrect plan.  
 
3.4.2.2.2 Fidelity  
Fidelity endpoints measure whether the system was implemented as 
intended. An example is to measure whether the installation of the ePS 
reduces prescribing errors; or the introduction of a new pharmacy service in 
the clinic reduces drug-related problems.  
 
3.4.2.2.3 Intervening variable 
Intervening variable is a surrogate end point to measure interventions 
targeted at a specific patient threat; it is aimed at strengthening the 
organisation. For example, implementing human resources policies are 
expected to impact on errors by means of effects on staff motivation and 
morale and reduced absence due to sickness. 
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3.5 Methods for the detection of DRPs 
There is currently no gold standard in the method for detecting DRP, PE or 
ADE (Cardone et al., 2010; Dean et al., 2005; Franklin et al., 2009). Many 
works have been carried out to evaluate the methods for detecting errors, 
particularly PE (Dean et al., 2005; Franklin et al., 2009; Franklin et al., 
2010; Ghaleb et al., 2010). It is not known how the concept in the 
methodological approach for PE would suit studies on DRPs or other ADEs 
(Dean et al., 2005) but it would be the closest method that is deemed 
suitable for the current research. There are four methods for PE detection 
that could be adapted for detecting DRPs, which are: (1) medical chart 
review, (2) pharmacists’ documentation, (3) analysis of incident reports and 
(4) trigger tools (Brown et al., 2008c; Franklin et al., 2009). The medical 
chart review and pharmacists’ documentation methods were applied for the 
detection of DRPs in the current research.  
  
3.5.1 Medical chart review   
Retrospective medical chart review can be conducted using the implicit or 
explicit methods. The implicit method involves experts making clinical 
judgement about the provided quality of care. Structured implicit methods 
require a set of questions prepared for the experts in order to extract a 
comprehensive review of the important phases of care. Researchers rather 
than expert clinicians can conduct the explicit chart review. It is more 
reproducible compared to the implicit method because the detection of 
events is guided by predetermined criteria. Nevertheless, documentation in 
medical charts may not be complete enough to assess the outcomes of 
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interest because information was not recorded for the purpose of research. 
The strengths and limitations of both methods are summarised in Table 3.2. 
  
3.5.2 Pharmacists’ documentation 
Errors that are detected from pharmacists’ documentation are usually in 
prospective studies. In this method, the pharmacists identify and record the 
errors during daily clinical practice on the wards. The limitation to this 
method is that little is known about the number of errors that have been 
identified and rectified by the pharmacists but not recorded. This may 
contribute to underreporting of the actual incidence of PE (Aucoin et al. 
2005; Bertsche et al., 2010).   
The types and numbers of problems identified by the pharmacists varies 
depending on the location of the data collection. This depends on the types 
of pharmacy services in operation. For example, ward pharmacists will have 
access to broader information about a patient’s treatment and clinical 
condition, would identify more ADEs compared to the pharmacists at the 
dispensary. Furthermore, a pharmacist, as a member of the clinical team, 
has the advantage of being more aware of the extra information in the 
context of patients’ treatment, which may facilitate the identification of 
ADEs (Dean et al., 2005). This may contribute to the variations in the types 
of ADEs identified by the pharmacists and researcher.
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Table 3.2 Strengths and limitations of implicit and explicit retrospective review (Adapted from Brown et al., 2008c) 
Methods of medical 
chart review 
      Strengths Limitations 
Implicit  Easy to develop and administer 
 High face validity, since experts define 
‘good’ and ‘bad’ care 
 Self-updating through use of experts 
 Reflects full scope of clinical decisions for a 
particular patient 
 Involves physicians and other experts in the 
quality of care 
 
 Require (expensive) clinical experts 
 More arbitrary than evidence based 
 Poor reproducibility of judgement 
Explicit  Evidence-based criteria reproducible 
 Easy to explain low score in terms of criteria 
– which may narrow score of improvement 
efforts 
 Can be conducted by researchers rather 
than expert clinicians (reduce costs) 
 Require training of reviewers 
 Limited scope of content and context 
 Need to be updated constantly 
 Potential for gaming 
 Need to decide how to analyse multiple 
criteria 
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3.5.1.1 Electronic medical chart review  
The emerging use of technologies in healthcare would eventually shift the 
detection of DRP and other ADEs from paper-based to electronic medical 
record (eMR) (Holroyd-Leduc et al., 2011). The eMR holds rich information 
from multidisciplinary medical records and is seen as a valuable source of 
information to facilitate medicine management (Eguale et al., 2008). 
However, no studies have been published comparing the effectiveness of 
electronic and paper-based medical charts review in detecting ADEs at the 
hospital setting. A systematic review on the impact of eMR on the structure, 
process and outcomes within primary care which included case-control 
studies involving 71 primary care practitioners in the UK reported that, 
although eMR contained more words in documentation, there were no 
differences in the terms of proportion of chart entries (Holroyd-Leduc et al., 
2011).   
A study on detecting DRPs by screening the eMR at an inpatient setting of a 
geriatric ward reported that the use of eMR in hospital pharmacy practice 
facilitated the CPs in prioritising medication reviews and optimising 
workload. This study also suggested the use of a trigger tool as a strategy 
to aid in the detection of DRPs using the eMR (Roten et al., 2010). A similar 
strategy was implemented to identify drug safety signals and ADEs from the 
eMRs of primary care clinics in New Zealand (Tomlin et al., 2012).  
 
3.5.3 Analysis of incident reporting 
A spontaneous reporting system is the easiest to establish and the cheapest 
to run but can suffer from poor-quality reports and underreporting (Pal et 
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al., 2013). A UK-based study by Franklin et al. (2009) comparing four 
methods in detecting PE reported that spontaneous reporting identified less 
than 1% of all errors. In the aforementioned study, other detection 
methods were trigger tool, pharmacists’ documentation and retrospective 
case review. Any change in the reported events does not reflect the true 
change in the underlying problem (Brown et al., 2008c). It is difficult to 
estimate rates and frequencies of events through spontaneous reporting 
because it does not have a standard denominator (Dean et al., 2009; Pal et 
al., 2013).  
 
3.5.4 Trigger tools 
A trigger tool is used to highlight information in medical records such as 
medication stop orders or abnormal laboratory results, which point to an 
adverse event that may have harmed a patient (James, 2013). A positive 
trigger then leads to more extensive investigation to identify whether or not 
harm has occurred (Resar et al., 2003). Since detailed case note review is 
only required with the detection of a positive trigger, the method is less 
resource-intensive than a detailed case note review (Brown et al., 2008c). 
Also, this method could not assess the temporal relationship of event or risk 
factors. For example, a medication chart containing prescriptions for a 
combination of antihistamine, corticosteroid and adrenaline following 
administration of an antibiotic might trigger the occurrence of acute 
anaphylaxis, an allergic reaction to the antibiotic. But it could not be 
ascertained if other drugs manifested the allergic reaction unless such 
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information was recorded in the medical notes. Plus, it could also indicate 
an anaphylactic shock following a chronic systemic infection. 
The limitations of using trigger tools are low sensitivity and low specificity, 
which lead to low positive predictive values and the risk of false positive 
outcomes. The proportion of adverse events detected by triggers describes 
sensitivity. However, it is difficult to assess sensitivity because there is no 
gold standard method of detecting these events (Brown et al., 2008c; 
Franklin et al., 2009; Franklin et al., 2010). For example, in the study by 
Franklin (2009) previously described, the trigger tool identified less than 
10% of all errors. The trigger tool also identified half of the harmful errors 
but these were likely false positive.  
In research, results from studies using the trigger tool are not likely to be 
comparable unless it is possible to standardise the denominator to construct 
the event rates and factors that affect the sensitivity and specificity of the 
tool, such as completeness of information on the database and the 
algorithm used to cross-examine the database (Brown et al., 2008c). 
  
  
3.6 Classification systems to characterise DRPs 
It was previously explained in Chapter 1 that the characterisation of DRPs 
depends on the definition and the classification systems adapted in a 
particular study. The two DRP classifications that were adapted in this 
research were the PCNE version 6.2 and the Gordon classifications (Gordon 
et al., 2005; PCNE, 2010). The PCNE classification was adapted as the main 
 CHAPTER  3     METHODOLOGICAL APPROACH 
 
105 
 
data collection proforma in Study 1 and Study 2. The Gordon classification 
was adapted and added into the proforma for Study 2. 
 
3.6.1 PCNE classification system (version 6.2) 
For the standardisation of data evaluation in this present research, the 
drugs associated with DRPs were documented according to the World Health 
Organisation Anatomical Therapeutic Chemical (ATC) classification (WHO-
ATC) system. The definition and the classification system for DRPs were 
adopted from the PCNE. The PCNE defines DRP as: 
 
“An event or circumstances involving drug therapy that actually or 
potentially interferes with desired health outcomes” 
 
The PCNE DRP classification system version 6.2 attributes four categories to 
each observation: (1) coding for the types of problem, (2) the actual or 
suspected cause of the problem, (3) the intervention required to resolve the 
problem and (4) its outcome. Figure 3.5 shows the codes of the four 
categories in the PCNE DRP classification system. An example to illustrate 
how the codes were used in evaluating the characteristics of a DRP is given 
in Figure 3.6.  
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Figure 3.5 PCNE classification scheme for DRP version 6.2 (Page 1/4) 
 
PCNE classification 3 14-1-2010 V6.2 
 
PCNE Classification scheme for Drug-Related Problems V6.2 - Page 1 
 
The basic classification 
 
 Code 
V6.2 
Primary domains 
Problems P1 Treatment effectiveness 
There is a (potential) problem with the (lack of) effect of 
the pharmacotherapy 
P2 Adverse reactions 
Patient suffers, or will possibly suffer, from an adverse 
drug event 
P3 Treatment costs 
The drug treatment is more expensive than necessary 
P4 Others 
Causes 
 
C1 Drug selection 
The cause of the DRP can be related to the selection of 
the drug  
C2 Drug form 
The cause of the DRP is related to the selection of the 
drug form 
C3 Dose selection 
The cause of the DRP can be related to the selection of 
the dosage schedule   
C4 Treatment duration 
The cause of the DRP is related to the duration of therapy 
C5 Drug use/administration process 
The cause of the DRP can be related to the way the 
patient uses the drug or gets the drug administered, in 
spite of proper instructions (on the label, package or 
leaflet) 
C6 Logistics 
The cause of the DRP can be related to the logistics of 
the prescribing and dispensing process 
C7 Patient 
The cause of the DRP can be related to the personality or 
behaviour of the patient. 
C8 Other 
Interventions 
  
I0 No intervention 
I1 At prescriber level 
I2 At patient (or carer) level 
I3 At drug level 
I4 Other 
Outcome of intervention O0 Outcome intervention unknown 
O1 Problem totally solved 
O2 Problem partially solved 
O3 Problem not solved 
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Figure 3.5 PCNE classification scheme for DRP version 6.2 (Page 2/4) 
 
 
 
 
PCNE classification 4  14-1-2010 V6.2 
 
PCNE Classification scheme for Drug-Related Problems V6.2 - Page 2 
 
The Problems 
 
Primary Domain 
 
Code 
V6.2 
Problem 
1.Treatment effectiveness 
There is a (potential) 
problem with the (lack of) 
effect of the 
pharmacotherapy 
P1.1 No effect of drug treatment/ therapy failure 
P1.2 Effect of drug treatment not optimal 
P1.3 Wrong effect of drug treatment 
P1.4 Untreated indication 
2. Adverse reactions 
Patient suffers, or will 
possibly suffer, from an 
adverse drug event 
P2.1 Adverse drug event (non-allergic) 
P2.2 Adverse drug event (allergic) 
P2.3 Toxic adverse drug-event  
3. Treatment costs 
The drug treatment is more 
expensive than necessary 
P3.1 Drug treatment more costly than necessary 
P3.2 Unnecessary drug-treatment 
4. Others  P4.1 Patient dissatisfied with therapy despite optimal clinical 
and economic treatment outcomes 
P4.2 Unclear problem/complaint. Further clarification 
necessary (please use as escape only) 
 
 Potential Problem 
 Manifest Problem 
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Figure 3.5 PCNE classification scheme for DRP version 6.2 (Page 3/4) 
PCNE classification 5  14-1-2010 V6.2 
 
PCNE Classification scheme for Drug-Related Problems V6.2 -Page 3 
 
The Causes 
N.B. One problem can have more causes 
 
Primary Domain Code 
V6.2 
Cause 
1. Drug selection 
The cause of the DRP is related to 
the selection of the drug  
C1.1 Inappropriate drug (incl. contra-indicated) 
C1.2 No indication for drug 
C1.3 Inappropriate combination of drugs, or drugs and food 
C1.4 Inappropriate duplication of therapeutic group or active 
ingredient 
C1.5 Indication for drug-treatment not noticed 
C1.6 Too many drugs prescribed for indication 
C1.7 More cost-effective drug available 
C1.8 Synergistic/preventive drug required and not given 
C1.9 New indication for drug treatment presented 
2. Drug form 
The cause of the DRP is related to 
the selection of the drug form  
C2.1 Inappropriate drug form 
3. Dose selection 
The cause of the DRP is related to 
the selection of the dosage 
schedule  
 
C3.1 Drug dose too low  
C3.2 Drug dose too high 
C3.3 Dosage regimen not frequent enough 
C3.4 Dosage regimen too frequent 
C3.5 No therapeutic drug monitoring 
C3.6 Pharmacokinetic problem requiring dose adjustment 
C3.7 Deterioration/improvement of disease state requiring 
dose adjustment 
4. Treatment duration 
The cause of the DRP is related to 
the duration of therapy  
C4.1 Duration of treatment too short 
C4.2 Duration of treatment too long 
5. Drug use process 
The cause of the DRP can be 
related to the way the patient uses 
the drug, in spite of proper dosage 
instructions (on the label) 
C5.1 Inappropriate timing of administration and/or dosing 
intervals 
C5.2 Drug underused/ under-administered (deliberately) 
C5.3 Drug overused/ over-administered (deliberately) 
C5.4 Drug not taken/administered at all  
C5.5 Wrong drug taken/administered 
C5.6 Drug abused (unregulated overuse) 
C5.7 Patient unable to use drug/form as directed 
6. Logistics 
The cause of the DRP can be 
related to the logistics of the 
prescribing and dispensing process 
C6.1 Prescribed drug not available 
C6.2 Prescribing error (necessary information missing) 
C6.3 Dispensing error (wrong drug or dose dispensed) 
7. Patient 
The cause of the DRP can be 
related to the personality or 
behaviour of the patient. 
C7.1 Patient forgets to use/take drug 
C7.2 Patient uses unnecessary drug 
C7.3 Patient takes food that interacts 
C7.4 Patient stored drug inappropriately 
8. Other C8.1 Other cause; specify 
C8.2 No obvious cause 
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Figure 3.5 PCNE classification scheme for DRP version 6.2 (Page 4/4) 
PCNE classification 6  14-1-2010 V6.2 
 
PCNE Classification scheme for Drug-Related Problems V6.2 -Page 4 
 
The Interventions 
N.B. One problem can lead to more interventions  
 
Primary Domain Code 
V6.2 
Intervention 
No intervention I0.0 No Intervention 
1. At prescriber level I1.1 Prescriber informed only 
I1.2 Prescriber asked for information 
I1.3 Intervention proposed, approved by  Prescriber 
I1.4 Intervention proposed, not approved by Prescriber 
I1.5 Intervention proposed, outcome unknown 
2. At patient/carer level I2.1 Patient (medication) counselling 
I2.2 Written information provided only 
I2.3 Patient referred to prescriber 
I2.4 Spoken to family member/caregiver 
3. At drug level I3.1 Drug  changed  to   ….  
I3.2 Dosage  changed  to   ….  
I3.3 Formulation  changed  to   ….
.
 
I3.4 Instructions  f
o
r   us e  changed  to   …..  
I3.5 Drug stopped 
I3.6 New drug started 
4. Other intervention or 
activity 
I4.1 Other intervention (specify) 
I4.2 Side effect reported to authorities 
 
 
 
The Outcome of the Interventions 
 
N.B. One problem (or the combination of interventions) can only lead to one level of solving 
the problem 
 
Primary Domain Code 
V6.2 
Outcome of intervention 
0. Not known O0.0 Outcome intervention not known 
1. Solved O1.0 Problem totally solved 
2. Partially solved O2.0 Problem partially solved 
3. Not solved O3.1 Problem not solved, lack of cooperation of patient 
O3.2 Problem not solved, lack of cooperation of prescriber 
O3.3 Problem not solved, intervention not effective 
O3.4 No need or possibility to solve problem 
 
 CHAPTER  3     METHODOLOGICAL APPROACH 
 
110 
 
The case: Patient A has acute kidney impairment. Upon discharge, kidney function shows improvement. The 
dosage regimen to take away for Co-amoxiclav is prescribed as twice a day. The correct frequency according 
to her current  kidney profile should be three times a day. The prescriber agreed with this change of dosing 
frequency.  
 
The problem: 
P1.2 Effect of drug sub-optimal (Potential) 
 
The causes: 
C3.1 Drug dose too low 
C3.3 Dosage regimen not frequent enough  
The intervention: 
I1.3 Intervention proposed, approved by prescriber 
I3.2 Dosage changed 
I4.1 Frequency changed 
The outcome: 
O1.0 Totally solved 
Figure 3.6 Example of classifying the characteristics of a DRP according to the PCNE classification system version 6.2 
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3.6.1.1 Considerations when using the PCNE classification 
system in research  
Previous studies that used the PCNE system had difficulty in the selection of 
categories from the classification. Lampert et al. (2008) investigation on 
DRPs in the medical wards reported on the types of DRPs which could not 
be classified by the PCNE system. In another study, Eichenberger and 
colleagues (2010) suggested additional items to be added into the PCNE 
classification. Both of these studies used the earlier version of the PCNE 
classification. However, similar difficulties would arise using the current 
version because of the unavailability of a standard operational definition.  
As an example, in Figure 3.6, the causes of DRP are (C3.1) drug dose too 
low and (C3.3) dosage regimen not frequent enough. It could be argued 
that these categories should be classified as prescribing error (i.e. drug and 
dosing error). In another example, of a patient who experiences dry cough 
after taking ACEi, the problem would most likely be categorised as (P1.3) 
wrong effect of drug treatment or (P2.1) adverse drug event (non-allergic)’ 
subject to the assessor’s understanding of the options available in the 
classification system.  
Such circumstances could potentially cause internal and external variability 
in making decisions to classify the DRPs because decision making in clinical 
practice is complex and involves subjective assessment, which can be 
influenced by several factors such as the type of information available, 
knowledge and experience (Dean and Barber, 1999). Variability in the 
process of data collection can be minimised by having a standard operating 
definition for the variables (Kumar, 2011). An operating definition is a clear 
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and concise detailed definition of a measurement. The need for an 
operational definition for the PCNE classification system is fundamental to 
ensure the consistency of data collected throughout the current research. 
The development of the operational definition for the PCNE classification 
system is described in Chapter 4 (sub-section 4.2.4.2.. 
 
 3.6.2 Gordon classification system  
The introduction to the Gordon classification for DRPs was given in Chapter 
1 (sub-section 1.3.2.4). In brief, the DRPs in this classification were 
identified by interviewing patients at the community pharmacies and 
surgeries using a standard screening tool. 
The screening tool comprised a set of questions in regard to the use of 
medicines. The questions were divided into five sections:  
1. Use of prescription and non-prescription medicines 
2. Patients’ demographic characteristics 
3. Hospital admissions, consultations as an outpatient or with private 
healthcare providers 
4. Self-reporting of non-compliance 
5. Details related to contacts with consultants at the pharmacies and 
surgeries 
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Nine types of MRPs were reported by Gordon and these problems are listed 
in Table 3.3 
 
Table 3.3 Classifications of medication-related problems (Gordon et al., 
2005) 
Medication-related problem 
 
MRP 1 :   
 
Adverse drug reactions and drug interactions   
 
MRP 2 : Cognitive, physical and sensory problems (e.g. difficulty in 
remembering or reading a label) 
 
MRP 3 : Drug prescribing problems (e.g. patient concern regarding the 
need for a prescription) 
 
MRP 4: Intentional non-compliance (e.g. decision by the patient to 
alter the dose of a medicine) 
 
MRP 5: Monitoring and review of medicines including interface 
between primary and secondary care (e.g. monitoring for 
continued appropriateness of therapy or following a change)       
 
MRP 6: Problems with non-prescription medicines 
 
MRP 7: Lack of information or opportunity to discuss medication-
related issues or concerns 
 
MRP 8: Problems with processes for obtaining repeat prescriptions 
through surgery or the pharmacy 
 
MRP 9: Problems with services from the surgery or the pharmacy 
(e.g. difficulty in obtaining appointment, uncertainty about 
generic products) 
 
Definition of MRP: Any problem experienced by a patient that may impact 
on their ability to manage or take their medicines effectively 
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The feasibility of the Gordon classification system and screening tool for 
DRP for Study 2 is presented in Chapter 4 (section 4.3). 
 
3.7 Method for assessing the severity of DRPs 
 
3.7.1 DRP severity rating 
As there was no established tool to measure the severity of DRPs, this 
research adopted a validated severity-scoring tool for MEs from Dean and 
Barber (1999). This scale was validated using cases of drug administration 
errors (Dean and Barber, 1999) and prescribing errors (Kollo and Dean, 
2000). The use of this scale in this research was justified based on the three 
points below: 
1. This scale has been used to rate the severity of DRPs in an 
international multicentre on DRPs in the paediatric population 
hospitalised at the general medical wards; this study involved the 
paediatric population in the UK (Rashed et al., 2012b). 
2. The indirect relationship between ADE and ME with DRP. Some ADEs 
are associated with MEs, and DRPs are a type of ADEs (Ibrahim et al., 
2013). 
3. Other scales used in previous studies were not validated (Easton et 
al., 2004; Easton et al., 1998) and were developed to assess 
preventability of ADRs in the United States (Schumock and Thornton, 
1992).  
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Four judges were selected to score the severity of the identified DRPs using 
this scale: two pharmacists (a paediatric pharmacy consultant and a 
medication safety pharmacist), one paediatric renal consultant and one 
paediatric renal specialist nurse. A list of DRP cases was sent electronically 
to the judges, who were requested to rate the severity of all cases within 
four weeks. Each judge scored the severity of each DRP case in terms of 
clinical significance with scores ranging from 0 to 10 in a visual analogue 
scale. The score 0 represents a case with no potential harm and 10 
represents a case that would result in death. A DRP is considered minor 
(unlikely to have any adverse effects) if the score is less than 3, moderate 
(likely to cause some adverse effects or interfere with therapeutic goals but 
very unlikely to result in death or lasting impairment) if the score is 
between 3 to 7, or severe (likely to cause death or lasting impairment) if 
the score is more than 7 (Table 3.4).  
In cases of no score being assigned by the judges, the researcher contacted 
the judges and requested a score. The average score for all judges was the 
final score assigned to each DRP. The visual analogue scale for the 
assessment of DRP severity is enclosed in Appendix 3.  
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Table 3.4 Score range and interpretation of clinical significance of DRPs 
(Dean and Barber, 1999 ) 
Clinical 
significance 
Score Interpretation  
Minor 0 – <3 Unlikely to have any adverse effects 
Moderate 3 – <7 Likely to cause some adverse effects or 
interfere with therapeutic goals  
Severe 7 – 10  Likely to cause death or lasting impairment 
 
 
3.7.2 The recruitment of judges  
As mentioned in the sub-section above, the Dean and Barber scale was 
developed to assess the severity of administration errors. The scale had 
also been validated to assess the severity of cases on administration errors 
in order to achieve generalisability coefficient of 0.8 or more. The value of 
the generalisability coefficient ranges from 0 to 1, with higher values 
indicating greater reliability or agreement respectively (Pallant, 2010). In 
general, an acceptable value is above 0.70 (Field, 2009); however, a value 
above 0.80 is considered to represent an acceptable reliability in clinical 
practice research (Smith et al., 1995).  
Dean and Barber (1999) suggested that (1) increasing the number of 
occasion on which the cases were scored and the differences on the 
profession of the judges (i.e. doctors, nurses and pharmacists)  had little 
impact on the generalisability coefficient and (2) a minimum of 4 judges 
were required to assess the severity of the cases in one occasion in order to 
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achieve generalisability coefficient above 0.8. The generalisability coefficient 
predicted with number of judges and the number of occasions the cases 
were assessed is shown in Table 3.5. 
 
Table 3.5 Generalisability coefficient predicted with number of judges 
and the number of occasions cases were assessed (Dean and Barber, 1999) 
Number of judges 
Number of occasions 
the judges assessed the 
severity of cases 
Generalisability 
coefficient 
1 1 0.575 
1 2 0.579 
1 10 0.581 
1 100 0.582 
2 1 0.725 
3 1 0.794 
4 1 0.834 
5 1 0.859 
10 1 0.916 
30 1 0.958 
 
In another study, using the Dean and Barber severity scale for prescribing 
error, Kollo and Dean (2000) also suggested at least 4 judges in order to 
achieve generalisability coefficient above 0.8 (i.e. 2 judges of each of 2 
professions selected from: doctors, nurses and pharmacists).  
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There is no evidence for the researcher to conclude the optimum number of 
judges required to assess the severity of DRPs using this severity scale. It is 
also challenging to determine how different DRPs would behave compared 
to medication errors (Franklin et al., 2009). The Dean and Barber scale had 
previously been used to assess the severity of DRPs identified in children 
hospitalised in general medical wards by three judges comprising of two 
doctors and a pharmacist (Rashed 2012b).  
In the current research, a total of 4 judges were selected. The final number 
of judges (i.e. four) for this research was based on the fact that (1) 
generalisability coefficient increases with the number of judges and four 
judges would be able to generate generalisability coefficient above 0.8 
(Dean and Barber, 1999; Kollo and Dean, 2000) and (2) if any 4 judges 
from the population of experienced UK pharmacists, medical staff and 
nursing staff are used, their mean scores would be generalised to any four 
judges selected from the same population (Dean and Barber, 1999).  
 
3.7.3 Minimising bias in scoring for DRP severity  
The following strategies were utilised to minimise the possibility of bias in 
scoring the DRPs’ severity among the judges: (1) allowing the judges to 
evaluate the cases independently within an agreed time period (i.e. three 
weeks), (2)  the judges were informed that scores would not be compared 
with other judges and the mean score of each DRP would be taken to 
represent the level of severity, and (3) all descriptions of DRPs were stated 
in a standard format to eliminate the ‘reverse phrases’ effect.  
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A ‘reverse phrase’ refers to statements that are not following the way all 
other statements were described (Field, 2009). The ‘reverse phrases’ effect 
would introduce response bias in scoring the severity level of DRPs, for 
example: IV Ciprofloxacin 5mg/kg twice a day was prescribed; the correct 
dose should have been 10-15mg/kg once a day. The reversed phrasing for 
the above DRP description: IV Ciprofloxacin correct dose was 10-15mg/kg 
once a day; but the prescribed dose was 5mg/kg twice a day.  
 
3.8 Ethical Considerations 
 
3.8.1 Ethical approvals 
The ethical approvals for this research were obtained from the following 
committees:  
 The London-Westminster Research Ethics Committee (Appendix 4) 
 The London-Hampstead Research Ethics Committee (Appendix 5) 
 The Research and Development (R&D) Committee of Guy’s and St. 
Thomas’ Hospitals NHS Foundation Trust (GSTT) and Great Ormond 
Street Hospital for Children (GOSH).  
 
3.8.2 Patient confidentiality  
Patients’ confidentiality should be maintained during data assessment and 
data analysis. The researcher was required to obtain an honorary contract 
with both hospitals and followed the Trusts’ policies and procedures for 
patient confidentiality and information governance. Data were anonymised 
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by assigning patients to unique patient identifiers rather than using their 
name, registration number or any other types of information that may be 
used for identity tracking. As part of protecting patients’ confidentiality and 
the integrity of the participating Trusts, as agreed by the Research Ethics 
Committee (REC), results comparing DRPs between research sites should 
only be shared with healthcare providers within the Trusts.  
 
3.8.3 Safety implication  
The CPs involved in this research have a minimum of ten years’ experience 
in renal pharmacy practice and they were also members of the renal team 
responsible for the care of study subjects. The researcher had attended 
Child Protection training and obtained honorary contracts from both Trusts. 
The researcher was also a pharmacist, trained in renal pharmacy and not a 
staff member of the participating Trusts. Therefore, in the event that the 
CPs or the clinical team had not identified a DRP with potential harm to 
patients, then the researcher would be responsible for alerting them to this.  
 
3.9 Summary  
Thus far, the fundamentals of the methodological approach have been 
discussed. The following chapter presents the feasibility studies that were 
conducted before the initiation of the prospective observation study in the 
inpatient setting and the RCT in the renal outpatient clinics.  
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CHAPTER 4                                       
Feasibility studies
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4.1  Introduction 
It was briefly mentioned in Chapter 2 and Chapter 3 that this research 
encompasses two main studies in investigating DRPs in children with kidney 
disease. Feasibility Study (1) was conducted prior to Study 1 and Feasibility 
Study (II) was conducted prior to Study 2. These feasibility studies were 
conducted to address the potential challenges in applying the proposed 
study designs and the DRP classification systems. 
 
4.2 Feasibility Study (I)  
 
4.2.1 Background 
The PCNE classification system for DRPs has been previously used by 
Rashed and colleagues in investigating the epidemiology of DRPs in 
hospitalised children but this excluded renal patients (Rashed et al., 201b). 
Feasibility Study (I) was conducted to identify challenges in the process of 
data collection for a prospective cohort study and to identify the suitability 
of the PCNE DRP classification system for research in paediatric nephrology 
patients. Ethical approval was not required because this study was 
conducted as an evaluation for pharmacy services at ELCH and GOSH. 
 
4.2.2 Objectives 
1) To test the feasibility of a prospective observational cohort study on 
the renal wards of ELCH and GOSH. 
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2) To develop a standard operational definition for the PCNE 
classification (version 6.2) in characterising DRPs in children with 
kidney disease. 
 
4.2.3 Method 
 
4.2.3.1 Sites and study period 
This study was conducted in the renal wards of the ELCH and GOSH. The 
study was conducted for two weeks, one week at each hospital. Data 
collection at GOSH was from 4th to 9th July 2011 and at ELCH from 11th to 
15th July 2011.  
 
4.2.3.2 Sample size  
Sample size calculation was not required because this was a feasibility 
study.  
 
4.2.3.3 Inclusion criteria for study patients  
All children aged 2 to 16 years who were admitted to the renal wards during 
the study period with the following criteria were included:  
1. Received at least one drug during their period of hospitalisation.  
2. Admitted to the ward for more than 24 hours. 
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4.2.3.4 Process of data collection 
The researcher was a non-participant observer during the study period. One 
CP was involved in the data collection at each hospital. At ELCH, the CP 
visited the ward and identified the DRPs from paper-based prescription 
chart review during routine ward pharmacy practice. At GOSH, the CP 
utilised the ePS and manually checked medication order entry for each 
patient. At both hospitals, the medical notes were reviewed when further 
details on DRPs were required.  
Recommendations on the resolution of the identified DRPs were discussed 
with the clinical team during clinical rounds, as previously described in 
Chapter 3 (sub-section 3.2.1). The CPs recorded all DRPs onto a proforma 
according to the PCNE classification system, as previously described in 
Chapter 3 (sub-section 3.6.1). During the observation period, the 
researcher documented patients’ profiles and this included their clinical 
progress, medication list and the event that led to the identification of the 
DRPs by the CPs. The process of data collection is illustrated in Figure 4.1. 
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Identify DRPs during ward 
rounds by reviewing the 
prescription charts 
Evaluate the causes of the 
problem through discussions 
with the clinical team 
CPs provide recommendations 
to solve DRPs 
Evaluate the outcome of the 
recommendations 
Documentation of 
patients’ relevant 
information and 
the DRPs 
according to the 
PCNE DRP 
classification 
scheme 
Data compilation and analyses 
Figure 4.1 Flowchart for the process of data collection 
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4.2.3.5 Data analysis 
At the end of the data collection period in each hospital, the researcher and 
the CP evaluated all patients’ profiles and the identified DRPs. The CPs were 
also asked to determine the types and contributory factors for the DRP in 
the case study. The DRP identified from both hospitals were selected for the 
case study. Challenges in characterising the DRP using the PCNE 
classification version 6.2 were recorded in order to develop a standard 
operational definition. Any disagreement was solved by consensus between 
the researcher and the CPs. 
 
4.2.4 Results 
The results are presented in two sections. Sub-section 4.2.4.1 is the 
findings to improve the study design and sub-section 4.2.4.2 presents the 
challenges in using the PCNE classification system for research.  
 
4.2.4.1 Considerations for study design 
4.2.4.1.1 Characteristics of the potential study patients 
The CPs reviewed a total of 31 patients but only 9 fulfilled the pre-
determined inclusion criteria (ELCH, n=3; GOSH, n=6). The main reason for 
patients being excluded was because of the predetermined age limit. All 
patients who were included in the analysis had at least one DRP during 
hospitalisation. The majority of patients were male (69%). Overall, patients 
were in the average age of 5.67 (range 2.97 - 9.05) years old and were 
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prescribed with an average of 6 (range 3 – 16) medications at the point 
DRPs were identified. 
 
4.2.4.1.2 Data collection schedule  
At the beginning, it was planned that data would be collected concurrently 
at both study sites. Due to logistical reasons and staff constraints, this was 
not possible. It was suggested that the researcher be stationed at each 
hospital for a specified period of time rather than alternating the days for 
data collection between both hospitals. Such an arrangement would be able 
to (1) facilitate the CPs’ rota for ward pharmacy service, (2) ensure 
uninterrupted observation of pharmacy practice throughout patients’ 
hospital stay and (3) minimise missing data due to unavailability of the 
medical notes on the wards after patients had been discharged from the 
hospital. This arrangement was applied for scheduling the data collection in 
the main prospective cohort study. 
  
4.2.4.2 Considerations for using the PCNE classification system 
in research  
4.2.4.2.1 Decision-making in using the PCNE DRP classification system  
The main challenge in using the PCNE classification for research was the 
unavailability of operational definitions for the constructs in the system. 
This contributed to inconsistency in classifying the characteristics of DRPs 
(i.e. the types of problem and contributory factors). As an example, the 
evaluation of the decision made by the CPs in classifying the characteristics 
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of DRPs using the case study showed discrepancies. As illustrated in Figure 
4.2. The CPs agreed that the unavailability of a standard operational 
definition gave a wide variability in the interpretation of DRPs because their 
management involves complex clinical assessment.   
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The case: Ciprofloxacin, which was supposed to be prescribed for 10 days but was ordered as 28 days.  
 
The problem: 
P2.1 Adverse drug event (non-allergic) 
(Potential) or,  
P2.3 Toxic adverse drug-event (Potential) 
 
The outcome: 
O2.0 Partially solved 
The contributory factors: 
C4.2 Treatment too long 
C6.2 Prescribing error  
The interventions: 
I1.3 Intervention proposed, approved by 
prescriber 
I3.4 Instruction for use changed 
The problems: 
P3.1 Drug treatment cost more than 
necessary (Manifested) or,  
P3.2 Unnecessary drug use (Potential) 
 
The interventions: 
I1.3 Intervention proposed, approved by 
prescriber 
I4.2 Request for new prescription  
 
The outcome: 
O1.1  Totally solved  
The contributory factors: 
C4.2 Treatment too long 
 
Pharmacist 1 Pharmacist 2 
Figure 4.2 The characteristics of DRPs assessed by the pharmacists according to the PCNE classification system 
version 6.2 
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4.2.4.2.2 Operational definitions for DRPs and the constructs of the PCNE 
DRP classification system 
The researcher and the CPs who were involved in identifying the DRPs 
developed the operational definition for the constructs in the PCNE DRP 
classification system. Based on the PCNE definition of DRP, the operational 
definitions are as follows:  
 
“An event or circumstances involving drug therapy1 that actually or 
potentially2 interferes with desired health outcomes3” 
 
In the definition stated above, the operational definition for the underlined 
phrases in the context of this research is explained in the following points:  
1. ‘An event or circumstances involving drug therapy1...’ includes any 
problems related to the use of medicines that occur in the drug-use 
or drug-treatment process. This research was not designed to 
separate DRPs from the element of ADEs, ADRs, and MEs thus, these 
elements were interpreted as either a type of DRP or its contributory 
factors.  
2. ‘…actually or potentially2…’ refers to the nature of a DRP. An Actual 
DRP, which is also referred to as a Manifested DRP, is a problem 
identified after it has reached the patient. Whereby, a Potential DRP 
is a problem that is identified before it reaches the patient.  
3. ‘…desired health outcomes3…’ refers to the intended outcome desired 
from a drug that is prescribed for the patient.  
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The summary of the modifications made to the original PCNE classification 
system are shown in Table 4.1 and the details are presented in Appendix 7. 
The modified PCNE DRP classification version 6.2 was developed into a 
proforma, i.e. the DRP-Registration Form (DRP-Rf) that was used for 
collecting data throughout the present research (Appendix 8).  
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Table 4.1 Summary of the modification to the PCNE DRP classification version 6.2   
Section  New codes in main categories  New codes in sub-categories 
Types of DRPs P4 Other P4.2   Drug administration problems 
Contributory factors for 
DRPs 
C5 Medication errors 
C6 Drug supply 
C3.8   Dose difficult to measure  
C5a    Prescribing error in decision making 
C5.10 Dilution error 
C8.1   Poor medication reconciliation 
C8.2  Unwanted side effects 
C8.3  Inappropriate drug administration site/route 
 
 
Intervention   I2.7  Dosing frequency changed to… 
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4.2.4.2.3 Modifications to the PCNE DRP classification 
The following sub-sections explain the modification done to sections: 
contributory factors and pharmacist interventions for DRPs. 
 
4.2.4.2.3.1 DRP contributory factors 
In the PCNE classification (Figure 3.5), category (C5) drug use process 
refers to causes of DRPs related to the way the patient uses the drug, in 
spite of proper dosage instructions on the label. For instance, the patient 
‘took the drug at the inappropriate time’ or the patient ‘taking or being 
administered the wrong drug’. The aforementioned examples are mishaps in 
the process of drug use – this is also recognised as medication errors. In 
order to narrow down the scope of DRPs’ contributory factors, category (C5) 
drug use process was modified to (C5) medication errors. 
In the PCNE classification , category (C6) logistics, refers to causes of DRPs 
related to the management of the prescribing and dispensing process, 
which includes sub-categories of (C6.1) prescribed drug not available, 
(C6.2) prescribing errors and (C6.3) dispensing errors. Category (C6.2) and 
(C6.3) were shifted to (C5) medication errors. Category (C6) logistics was 
modified to (C6) drug supply. 
 
4.2.5.2.3.2 Pharmacists’ interventions 
Category I1 for Intervention ‘At prescriber level’ in the PCNE classification 
was classified as pharmacist-prescriber encounters rather than a type of 
intervention. In clinical practice involving multidisciplinary healthcare 
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professionals, the process of notifying or seeking such acknowledgment is 
obtained through inter-professional discussions and good rapport within the 
clinical team. In view of this understanding, the act of a clinical pharmacist 
communicating with the prescribers (and vice versa) is appropriately seen 
as a process that precedes an intervention rather than a type of 
intervention.  
 
4.2.5 Discussions 
 
4.2.5.1 Amendments to the inclusion criteria 
The age restriction of between 2 to 16 years limited the recruitment of 
patients. The researcher initially suggested this age limit based on the age 
group included for data analysis in the UKRR Annual Reports. The UKRR 
reports exclude data for patients aged 16 to 18 for from the majority of 
analyses, which includes the prevalence and incidence rates, because of 
incomplete data in the medical records as children in this age group may 
receive their medical care either in a paediatric or in an adult nephrology 
centre (Lewis et al., 2010).  
This feasibility study found that children aged 16 to 18 years who were 
admitted to the wards at the study sites remained to be seen by the 
Paediatric Renal Team and incomplete data in their medical records were 
not an issue. This study also found that approximately 30% of the potential 
study population were less than 2 years old, an age group beyond the pre-
determined inclusion criteria for this research. As this was an epidemiology 
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study, all patients aged 18 years and younger (instead of only in the range 
between 2 to 16 years old) were included. The inclusion criterion for the 
final research was amended to include all patients aged 18 years and 
younger. 
 
4.2.5.2 Limitations of the PCNE classification system  
One of the limitations in using the PCNE classification was the unavailability 
of extra information (or guideline) to facilitate users in selecting the most 
appropriate category and sub-category for the characteristics of DRPs. This 
challenge has been reported by previous studies (Eichenberger et al., 2010, 
Lampert et al., 2008). Similar finding has been found in the current study.  
Another consideration in using the PCNE classification was the assessment 
to determine the causes of DRPs. The causes for a DRP can be multifactorial 
and interact with each. On many occasions, a DRP could not be attributed to 
a single cause. As an example of this, Lampert investigated DRPs identified 
in pharmacy practice in a Swiss hospital and found a total of 213 causes 
were reported for 207 DRPs (Lampert et al., 2008). A latter study on DRPs 
in the paediatric population found that a total of 674 causes were reported 
for 478 identified DRPs (Rashed et al., 2012b). Both of the aforementioned 
studies adapted the PCNE classification system and agreed that the causes 
of DRP were multifactorial; however the methods that had been used to 
assess the causes were not explained. Similar findings were obtained from 
the case study illustrated in Figure 4.2.  
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There is also no gold standard on the maximum number of causes that 
could be assigned to a DRP. For research purposes, the PCNE suggested a 
maximum of three causes for each DRP. The suggestion to limit the causes 
of DRPs to a maximum of three was accepted for the current research, 
however the term ‘contributory factors’ was the preferred term rather than 
‘causes’.  
In the process of developing the operational definition, several modifications 
were made to the original PCNE system. The main reason for modifying the 
original classification was to capture the variables required for data 
evaluation. Permission to adapt the PCNE classification with modifications 
was obtained from the PCNE representative by email (Ibrahim, 2012a). The 
adapted PCNE classification version 6.2 was developed as the proforma 
used in data collection for this research. This proforma was referred to as 
the DRP-Registration Form (DRP-Rf) and is enclosed in Appendix 8.  
 
4.2.6 Summary 
It was feasible to conduct the observational study design on the wards of 
both hospitals. A limitation in this study was that, although the CPs (data 
collectors) were involved in developing the operational definition for the 
modified PCNE DRP classification system, no inter-rater test was performed 
to evaluate their agreement on using the operational definition for real-life 
clinical cases.  
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4.3 Feasibility Study (II) 
 
4.3.1 Background 
Pharmacy practice research involving interventions on PC and medicines 
management is complex (Wong, 2004). It requires a strategic 
methodological approach to solve the difficulty in defining the component of 
intervention, identifying plausible endpoints and the practicality of the 
chosen study design at the clinical setting. Therefore, the aim of this 
feasibility study was to examine the difficulties in the data collection process 
for an RCT at the renal outpatient clinic before embarking on the major 
trial. Ethical approval was obtained from the London-Hampstead Research 
Ethics Committee and the Guy’s and St. Thomas’ R&D Committee, UK.  
 
4.3.2 Objective 
1. To determine the types of CPs’ interventions that are feasible to be 
carried out at the renal outpatient clinics.  
2. To identify the circumstances that may contribute to non-adherence to 
trial protocol and identify measures that may limit them.  
3. To test the feasibility of the modified PCNE classification and the Gordon 
classification for DRPs identified at the renal outpatient setting. 
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4.3.3 Methods 
 
4.3.3.1 Study design 
This was a single centre, simple randomisation, parallel group-study. The 
study design is illustrated in Figure 4.3. 
 
4.3.3.2 Site and study period 
This study was conducted from 18th February to 11th April 2013 at the ELCH 
renal outpatient clinics.  
 
4.3.3.3 Sample size 
Sample size calculation was not required because this was a feasibility 
study.  
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Figure 4.3 Outline of the study design 
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4.3.3.4 Study protocol   
 
4.3.3.4.1 Inclusion criteria 
All children under the care of the Paediatric Nephrology Department at ELCH 
aged 18 years and younger who attended the renal outpatient clinic and 
gave written informed consent were included. Children who were not on any 
medications and children who had received a doctor’s consultation on the 
day of clinic were excluded.  
 
4.3.3.4.2 Recruitment  
In this study, the term ‘participants’ refers to the children (the patients) and 
their parent(s). The list of patients who would be attending the renal clinic 
was obtained from the clinic receptionist at three week prior to the 
appointment date. All patients were screened for their eligibility. Study-
related materials were posted out to all patients who were deemed eligible 
as study participants. The child and their family therefore had an 
opportunity to review the study information before their next clinic 
appointment to decide whether or not to participate in the study.  
Approximately two weeks after posting out the study information, the 
researcher made a telephone follow-up call to the potential participants to 
confirm if the materials had been received and to discuss consent-related 
issues. The study materials would be posted again following any parents’ 
request if the initial information had not been received. The telephone calls 
were made at 1100 and 1200 and between 1500 and 1600 on weekdays. If 
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potential participants could not be contacted (unanswered, inactive 
telephone number) after three attempts on three different occasions, no 
further attempts to contact the family were made prior to their upcoming 
clinic appointment. 
Once verbal agreement to participate in the study had been obtained, the 
patient’s name was entered in the study database and arrangements made 
to schedule an appointment at the time of their next clinic visit. The 
schedule for enrolment is a shared electronic email calendar within the 
Trust accessible to the researcher and the CPs. At this point, the patient’s 
group allocation had not yet been assigned. On the day of the scheduled 
clinic appointment, the researcher approached all potential participants 
including those who had not been contactable via the phone to discuss the 
study in more detail and obtain informed consent (and assent where age 
appropriate). The participants were given the chance to ask further 
questions about the study before giving consent, whilst waiting for the clinic 
to start. They were also encouraged to discuss the study with other 
healthcare providers if they wished, and were informed that they could 
withdraw from the study at any point and this would not affect their 
treatment. Once informed consent had been obtained, the researcher 
identified the DRPs at baseline for all patients. The study information 
leaflets and consent forms are enclosed in the Appendices (Appendix 10 to 
Appendix 17). 
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4.3.3.4.3 Identifying DRPs at baseline 
The researcher identified DRPs at baseline for all patients in both arms. 
Baseline DRPs refers to active and inactive problems related to the use of 
drugs that occurred before patients were enrolled into the trial. Active DRPs 
refer problems that the researcher newly identified from eMR 
documentation and not which were unsolved at the point of enrolment. 
Inactive DRPs refer to problems that the researcher identified from the eMR 
and were already solved at the point of enrolment.  
The baseline DRPs were detected using the explicit retrospective review of 
the eMR from the past six months prior to trial enrolment. Even though the 
effectiveness of detecting DRPs using this method has not been previously 
studied, it was the most feasible method to use for this study because of 
the following reasons:  
1. The renal clinic notes were already uploaded onto the eMR when this 
study was initiated and the electronic charting of the clinic 
consultation notes was fully utilised by the renal team in managing 
patients at the outpatient clinic. 
2. The paper-based medical notes were fully utilised by the nurses for 
phlebotomy measurement. During this feasibility study, most of the 
time the CPs were not able to get hold of the paper medical notes 
and this contributed to patients not receiving the intended 
intervention. The eMR was accessible to the researcher and the CPs; 
and this was important to standardise the source of information in 
detecting DRPs. 
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3. Research has shown that information entered onto the eMR was 
similar to paper-based notes at the primary care (explained in sub- 
section 3.5.2.1). The ELCH renal consultants agreed with this, 
furthermore, the clinic notes are short and brief compared to the 
inpatient notes. The researcher tested this assumption by comparing 
the types of DRPs detected from both resources in five patients 
selected at random; and they were found to be similar.  
All DRPs were recorded onto the DRP-Rf proforma (Appendix 8). During the 
detection of baseline DRPs, the researcher was not supposed to intervene, 
however, if a problem(s) with significant potential for harm were identified, 
from the ethical point, the researcher would have to inform the doctor. The 
researcher is a qualified pharmacist trained in renal pharmacy but not 
working in the capacity of a clinical pharmacist within the Trust. 
 
4.3.3.4.4 Randomisation 
Once the baseline DRPs had been documented, the patients were then 
allocated into either the Control or the Intervention arm by simple 
randomisation.  
Two tables of unique numbers were generated using the online random 
number generator (Social Psychology Network, 2013). Each table contained 
a list of 100 unique random numbers for the Control and the Intervention 
arm respectively. These numbers were printed on individual 10cm x 20cm 
white cards, which were then folded inwards and sealed in an A4 envelope. 
The envelope was kept in a locked cabinet in the ELCH Pharmacy 
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Department. This procedure was part of the allocation concealment steps. 
Determination of whether a patient would be in the Control or the 
Intervention arm was made by taking out one card at random for each 
patient. If the number on the card belonged to the table of the Intervention 
group, the researcher would notify the CP on duty and the CP would attend 
the clinic to perform the intervention.  
 
4.3.3.4.5 Control group  
Participants in the Control arm received the standard care from the study 
site. Standard care refers to the usual care all patients would have received 
when attending their routine renal clinic appointment, as previously 
described in the outpatient setting of the outpatient care in sub-section 
3.2.2. 
 
4.3.3.4.6 Intervention group  
Patients who were enrolled into the Intervention arm received the CP 
interventions whilst waiting to see the doctor for their renal clinic 
appointment. Other than seeing the CP, the participants were not expected 
to do anything extra during their usual clinical review appointment. 
 
4.3.3.4.7 CPs’ interventions  
Patients in the Intervention group received the CP interventions during their 
clinic visit. Two CPs were responsible for conducting the interventions on a 
weekly schedule basis.  The interventions that were agreed and deemed 
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feasible by the CPs comprised two components: (1) conducted semi-
structured interviews with the patients to screen for DRPs and (2) provided 
recommendations to the doctors on the resolution of any identified DRPs 
from the interview sessions. 
4.3.3.4.7.1 Semi-structured interview  
The CPs conducted the semi-structured interview with the patients using 
the Gordon DRP screening tool for DRP (Gordon et al., 2005). This 
screening tool is enclosed in Appendix 19. The interview was conducted in a 
20-minute session before subjects were seen by their doctor. During that 
session, the CP reviewed patient’s medications which were on a list 
obtained from the most recent clinic note in the eMR and determined 
whether there were any problems in taking them as prescribed. Throughout 
the interview session, participants were involved as a full partner and, 
therefore, any suggestions to solve the identified problems were 
communicated with the parent (and child when age appropriate).  
 
4.3.3.4.7.2 Provide recommendations to solve  DRPs 
At the end of the session with the participant, the CP summarised the DRPs 
and provided recommendations to solve the problems by issuing a 
Pharmacist Note (PN) to the doctor. The PN was delivered together with the 
patient’s medical notes prior to the clinical consultation (Appendix 20). 
 
4.3.3.4.8 Blinding 
Due to the nature of the intervention, blinding was not possible.  
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4.3.3.4.9 Outcome measures 
The primary outcome is to measure the effect of CP interventions in 
resolving active DRPs identified at baseline by the researcher. This outcome 
was defined as the number of active DRPs that were solved after the clinic 
sessions divided by total number of active DRPs identified at baseline by the 
researcher multiplied by 100. The formula is shown below: 
 
                                            ( ) = 
 
                                              
                                                    
       
 
The resolution of active DRPs was identified by evaluating the doctor’s 
clinical notes on actions taken toward the identified problems. The concept 
of surrogate endpoint in patient safety research has been explained in sub-
section 3.4.2.2. The researcher gathered information on the changes to 
patients’ medication management with respect to the DRPs from the 
medical notes at the end of the clinic day. The resolution of a baseline 
active DRP was categorised as ‘Solved’ (if actions were taken to solve the 
identified DRP) or ‘Not solved’ (if no actions were taken to solve the 
identified DRP or if the implementation of the suggestion or action to solve 
the problems by CPs was not documented).  
The secondary outcomes were as follows: 
1. The severity of the DRPs: assessed by four judges  
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2. The drugs associated with DRPs: classified using the WHO-ATC 
classification system.  
3. The characteristics of DRPs: characterised according the adapted 
PCNE classification system using the proforma DRP-Rf (Appendix 8).  
 
As this study aimed to examine the feasibility of data collection process for 
an RCT, the primary and secondary outcomes were not evaluated. The 
methods used in measuring the outcomes have been explained in Chapter 
3.  
 
4.3.4 Results 
 
4.3.4.1 Recruitment 
A total of 75 patients were screened during this feasibility study, of which 
26 fulfilled the inclusion criteria. Out of 26 potential participants to whom 
the study-related materials were posted at three weeks prior to their renal 
clinic appointment, only 7 were successfully followed-up by telephone for 
verbal agreement (3 agreed to participate, 3 were undecided, and 1 
declined). Telephone calls to the remaining 19 potential participants were 
not successful despite three attempts. On the scheduled clinic days, all 3 
patients who had given verbal consent were enrolled in the study and 
another 3 patients who were initially undecided during telephone follow-ups 
opted to participate. Written consents were obtained from all 6 patients (4 
Intervention and 2 Control). Of the 4 patients who were allocated into the 
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Intervention arm, 1 did not receive the intervention. The result of 
recruitment is summarised in Figure 4.4. 
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75 Patients were screened for eligibility 
49 Were not eligible 
 
27 Were not on any medications 
12 Did not have medical notes available for screening 
  8 Were not patients with kidney disease  
  2 Above 18 years of age 
 
26 Patients were eligible 
1 Declined to be enrolled 
6 Patients attended clinic as scheduled and given written 
consent, baseline DRPs reviewed by the researcher   
2 Control arm   4 Intervention arm  
7 Patients were successfully contacted for verbal agreement to 
participate  
2 Received Standard Care 3 Received Intervention 
1 Did not receive Intervention  
Figure 4.4 Flowchart of patient recruitment and random allocation 
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4.3.4.2 Non-adherence to protocol  
One patient who was allocated into the Intervention arm did not receive the 
intended intervention. The reason for this scenario was that the CPs 
involved in the study were also the staff within the Trust and they were 
bound to commitments of their daily job descriptions especially during the 
shortage of staff. This situation limited the chances of all participants in the 
Intervention arm receiving the intervention according to the trial protocol.  
 
4.3.4.3 Opportunity window to conduct the intervention 
Identifying an appropriate opportunity to introduce interventions in the 
standard practice was a challenging task. Nevertheless, referring back to 
setting of the outpatient standard care as described in sub-section 3.2.2, 
there was a 10-20 minutes waiting period after phlebotomy assessment, 
prior to doctor’s consultation. This time period was seen as a window of 
opportunity to implement new healthcare intervention by pharmacists (see 
Figure 4.5). 
It was also feasible to create a window of opportunity at the point of 
dispensing rather than at the clinic; but this was not chosen for the present 
study because: 
1. The characteristics of DRPs identified would vary depending on the 
location of the data collection (Dean et al., 2005). At the point of 
dispensing, the service is focused on dispensing the right medicine to 
the right patient at the most appropriate  time. Therefore, data would 
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be bias towards prescription errors (Dean et al., 2005) and this would 
not represent the actual DRPs occurring at the renal clinic.  
2. The dispensing role at the dispensary is shared amongst a bigger 
team of pharmacists with different level of training in paediatric 
pharmacy practice - this would contribute to wide data variability.  
3. Not all potential participants could be included into the study because 
not all patients would receive prescriptions for new medications to be 
collected from the hospital pharmacy. 
4. The evaluation on the resolution of DRPs in this research is obtained 
from clinic notes entered at two time points: at baseline and after 
clinic session. Therefore, identifying DRPs at the point of dispensing 
would not be appropriate because collecting medicines from the 
hospital dispensary is the final stage in the outpatient clinic 
procedure. 
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Clinic registration at the clinic reception 
Blood tests, check for vital signs, 
phlebotomist (10-20 minutes)α 
Wait to be called to see the renal 
consultants/Clinical Nurse Specialist   
(20 minutes)a 
+/- See other healthcare provider if 
required (e.g. phlebotomist, social 
worker, play specialists) 
+/- Collect prescribed medicines at the 
dispensary, if necessary 
 
Notes:  
  α Approximate waiting time 
  
Possible opportunity for pharmacy 
intervention 
Figure 4.5 Window of opportunity to conduct pharmacist 
intervention at the renal outpatient clinic 
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4.3.4.4 Consideration in using the modified PCNE classification 
system for DRP 
The modified version of the PCNE classification system that was developed 
during the Feasibility Study (I) at the inpatient setting was practical for use 
in the outpatient setting. However, several new codes were added based on 
the characteristics of the identified DRPs (Table 4.2).  
 
4.3.4.5 Consideration in using the Gordon screening tool for 
identifying DRP 
The median time taken to identify DRPs from patient interviews using the 
Gordon screening tool at the renal outpatient clinic was 15 minutes per 
patient (range 10-20 minutes).  
As the allocated time for CPs interventions was 20 minutes, a simplified 
version of the tool was preferred as it allowed more time for the CPs to 
summarise and resolve the identified DRPs. Thus, the researcher and the 
CPs developed the Patient Interview Form by consensus. The form was 
divided into two parts. The first part contained a table for the CPs to write 
down patients’ medication during medication review. The second part of the 
form contained questions adapted from the Gordon screening tool for DRP. 
The form was developed as an additional proforma to the DRP-Rf (Appendix 
21).
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Table 4.2  Codes added to the modified version of the PCNE classification system for DRPs 
Codes Sub-categories Operational definition 
P4.3 Delay in treatment * 
C6.2 Difficulty in obtaining repeat prescription from 
the community 
There is a problem in obtaining repeat prescription(s) from 
the general practitioner (GP) or the community pharmacy  
C7.7 
 
Patient (parent/carer) forgets to obtain repeat 
prescription(s) from the community 
 
* 
C7.8 
 
Poor understanding of treatment plan and 
medications 
 
The patient (or parent/carer) had poor understanding of 
treatment plan and medications 
 
C8.4 Dependent on enteral feed tubes The patient is dependant on enteral feeding tubes for the 
administration of medicines  
C8.5 Difficulty in obtaining information from the 
general practitioner 
* 
C8.6 
 
New dose not altered by the general 
practitioner 
 
* 
*Self-explanatory 
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4.3.5 Discussion 
There were only six recruitments during this study. Further evaluation 
revealed that the list of patients who were expected to attend the renal 
clinics that was obtained at three weeks prior to the appointment did not 
portray the actual expected clinic attendance. Furthermore, there were also 
a number of patients who were newly added onto the clinic list but were not 
available to the researcher. In order to overcome this problem, the 
researcher would have to obtain an updated list for appointments that were 
scheduled at two weeks prior to the clinic date. Patients who were newly 
added to the latest list were screened for eligibility as potential participants 
and followed a similar procedure for recruitment. However, this group of 
patients may be contacted less than two weeks after receiving the study-
related materials. The clinical supervisors for the study suggested that all 
patients who have been posted the study materials should be approached 
regardless of whether or not they were able to be contacted by telephone. 
This is because failure to be contacted was not a definite indicator of not 
agreeing to participate in the study.  
In regard to the interview session using the Gordon screening tool for DRPs, 
the questions were originally designed for adult patients. In almost all 
cases, the questions were answered by the parent or carer. Hence, not all 
questions would be suitable to be adapted into the research proforma. In 
this study, the median time for an interview session was 15 minutes and 
longer interview times were required for patients with a more complex 
treatment. Gordon et al. reported an average of 12 minutes was required to 
conduct an interview using the same tool at the surgeries (Gordon et al., 
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2005). Therefore, a simplified version of the tool was preferred in order to 
achieve the objective. The process of using the original screening tool 
during this feasibility study offered a training ground to standardise the 
thought process for the CPs.   
 
4.3.6 Summary 
The RCT and the proposed CP interventions were deemed feasible. 
However, this study identified several limitations in the conduct of the trial: 
(1) the CPs’ commitments to their duty within the Trust may result in a 
number of patients in the Intervention arm not receiving the intended 
interventions, (2) as the researcher was the only person responsible for 
recruitment, there would be possibility that participants who have received 
the study material were not approached and (3) no agreement test was 
conducted to evaluate the agreement between the CPs in categorising the 
DRPs using the adapted screening tool.  
 
4.4 Conclusion  
The present feasibility studies managed to address the strategies to 
overcome the potential challenges in the proposed study designs. The 
standard operation definition developed for the modified PCNE classification 
system and the simplified Gordon classification would be able to standardise 
the process of data collection throughout the subsequent studies. The next 
chapter describes the work conducted to establish the incidence and nature 
of DRPs in children with kidney disease at the inpatient setting.    
 157 
 
CHAPTER 5                                      
Prospective Observational Study on the 
Characteristic of DRPs in Hospitalised 
Children with Kidney Disease
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5.1 Introduction 
The systematic literature review in Chapter 2 concluded that there is a lack 
of data on the epidemiology of DRPs in children with kidney disease and 
supports the need for further research. In Chapter 4, the Feasibility Study 
(I) showed that the characteristics of DRPs in this patient group can be 
evaluated using the modified PCNE classification system version 6.2. This 
chapter describes the work carried out to investigate the incidence, 
characteristics and the potential predictors for the occurrence of DRPs in 
hospitalised children with kidney disease. The ethical approvals were 
obtained from (1) the London-Westminster Research Ethics Committee and 
(2) the R&D Committee of Guy’s and St. Thomas’ Hospitals NHS Foundation 
Trust (GSTT) and Great Ormond Street Hospital for Children (GOSH). 
 
5.2 Hypothesis 
 
“Hospitalised children with CKD have higher DRP incidence compared to the 
general paediatric population, in whom the incidence is 33%” 
 
When this study was about to commence in 2010, the most recent data on 
the incidence of DRPs in children in the UK was reported as 33% (Rashed et 
al., 2011). Personal correspondence with the paediatric renal consultants 
and renal nurses at the participating hospitals came to an agreement that 
the incidence of DRPs in children with CKD could possibly be higher than in 
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the general paediatric population, and therefore the hypothesised the 
clinical estimates of DRP incidence in children with CKD was 50%.  
 
5.3 Aim and objectives  
This study aimed to determine the epidemiology of DRPs in hospitalised 
children with kidney disease. The study objectives were as follows: 
1. To identify the risk factors  
2. To measure the severity  
3. To identify the characteristics  
Of DRPs that developed during hospital stay in children with kidney disease 
at the inpatient setting. 
 
5.4 Methods 
 
5.4.1 Study design  
Prospective observational cohort study. The outline of the study design is 
illustrated in Figure 5.1.  
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 Observation and recording of DRPs identified by 
CPs during prescription chart review and clinical 
rounds  
 Characterisation of DRP using proforma DRP-Rf  
 
A
n
a
ly
s
is
  
Drug-related problems 
(DRPs) 
DRP Level 
 Demographic 
characteristics 
 DRPs risk factor 
assessment 
 Severity rating  
 Drugs associated 
with DRPs 
 Types and 
contributory factors 
for DRPs 
 Recommendations 
and resolutions 
Figure 5.1 Flowchart for data collection process and analysis 
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5.4.2 Sites and study period 
Data collection was performed over a ten-month period at the renal wards 
of ELCH and GOSH, London, UK. The data collection period at each study 
sites was as follows: 
 1st December 2011 to 30th April 2012: GOSH 
 1st May 2012 to 1st September 2012: ELCH 
The model of standard care in the inpatient setting in both hospitals has 
been described in sub-section 3.2.1. The main differences in the setting of 
the inpatient care between the two hospitals were (1) paper-based 
prescription charts at ELCH and (2) the use of the ePS at GOSH. 
 
5.4.3 Sample size calculation 
The clinical estimate of DRPs’ incidence in hospitalised children with CKD 
was 50%. The calculated sample size to detect the 95% confidence interval 
between 42% and 58% was a minimum of 156 patients. The sample size 
was calculated using the formula below: 
 
  
   (   )
  
 
  
 (   ) (     )
     
 
= 156 patients 
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Where,  
N = Sample size 
P = The proportion of the study population with at least one DRP during 
hospitalisation, which was 50% from clinical estimation.  
 =  The precision of 8% 
 
5.4.4 Inclusion criteria for study patients 
All children aged 18 years and younger who were admitted to the renal 
wards during the study period with the following criteria were included:  
1. Received at least one drug during their period of hospitalisation.  
2. Admitted to the ward for more than 24 hours. 
 
5.4.5 Study initiation phase 
 
5.4.5.1 Briefing to clinical team 
The researcher was given a 30-minute session for a PowerPoint 
presentation in the monthly Nephrology Department meeting at GOSH and 
ELCH. The renal consultants, registrars, ward staffs and the CPs attended 
the briefing sessions. The briefing at both hospitals was conducted on the 
first week of the data collection period at each site. The briefing session also 
included an introductory session to the concept of DRPs and the outline of 
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the study design. The study information leaflet on how the study was to be 
conducted was distributed to all ward staff (Appendix 9). 
 
5.4.5.2 Pilot test 
A pilot test was conducted for a week at each hospital prior to the initiation 
of data collection together with the feasibility study in conjunction with the 
pharmacy services evaluation. The pilot test was conducted to test the 
feasibility of the prospective observation study design and the data 
collection forms. The conduction of the feasibility test is described in section 
4.2. 
 
5.4.5.3 Training for CPs 
The CPs were involved in identifying and characterising the DRPs. During 
the pilot test, a one-hour session was allocated to train the CPs on the use 
of the study proforma (i.e. DRP-Rf) and the application of its operational 
definition. The CPs involved in collecting the data were also involved in the 
development of the operational definition and were familiar with the content 
of the DRP-Rf (Appendix 7). 
 
5.4.6 Detection of DRPs   
DRPs were detected using the prospective prescription chart review method 
by the CPs during routine clinical pharmacy practice on the wards. The 
recommendations for resolution were made through discussion with the 
clinical team during clinical rounds. For standardisation across the two 
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participating study sites, all identified DRPs were documented into the DRP-
Rf. Briefly, this proforma has main categories and sub-categories for types 
of DRPs, contributory factors of DRPs, recommendations to resolve the 
DRPs and outcomes for the recommendations. An example of how a DRP 
was characterised using the DRP-Rf was previously illustrated in Figure 3.5. 
The drugs involved with the DRPs were classified using the WHO-ATC 
system.  
Throughout the process of DRP identification, the researcher remained as a 
non-participant observer. Non-participant observation in the data collection 
process may be subjected to the ‘Hawthorne effect’ (Kumar, 2011).  The 
presence of the observer could potentially decrease or increase the 
identification of DRPs and the resultant actions taken. Within the scope of 
this project, it was not possible to totally exclude this effect but it was 
minimised by adopting the participant observation approach. The researcher 
introduced herself as a student  and did not make any conclusion or suggest 
any form of recommendations during the observation period. This was to 
ensure that the presence of the observer was as discreet as possible so as 
not to interfere with the work of the CPs and ward staff.  
The presence of the observer was necessary to ensure consistency in data 
collection, especially in the early stages when pharmacists were still getting 
used to the proforma and the operational definitions.  
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5.4.7 Data analyses 
Data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 21 for Windows® and presented as percentages (%), 
median (Md), interquartile range (IQR 1-3) and odd ratios (OR) with 95% 
confidence interval (CI). In all statistical tests p values of less than 0.05 
were considered statistically significant. For the descriptive analysis of 
patients and DRP characteristics, Chi-squared ( 2), Kruskal-Wallis Rank and 
Mann-Whitney tests were used as appropriate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
5.4.7.1 Incidence of and risk factors in DRPs 
The overall incidence of DRPs in the cohort was defined as the number of 
patients with at least one DRP during hospitalisation divided by the total 
number of patients reviewed by the CPs multiplied by 100.  
 
             
  
                                                             
                                            
     
 
For DRPs’ incidence and risk factor calculations, only the first admission 
during the study period was considered for investigating the association 
between DRPs’ incidence and potential risk factors.  
 
5.4.7.2 Logistic regression for assessing predictors of DRPs 
Logistic regression was performed to assess the impact of a number of 
predictors on the likelihood that DRPs would occur among the study 
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population during a hospital stay. Logistic regression allows the testing of 
binary outcomes for the presence of at least one DRP throughout 
hospitalisation; and the independent variables can be a mixture of 
categorical or continuous (Pallant, 2010). The backward stepwise model 
was chosen because it is less likely to eliminate predictors involved in 
suppressor effects and thus has a lower risk of making a Type II error (false 
negative). The differences between the forward and backward stepwise 
methods are summarised in Table 5.1. 
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Table 5.1 Differences in the process of the Logistic Regression Stepwise 
model (Peacock and Peacock, 2013) 
Forward Stepwise 
 Put each variable into the model alone 
 Discard variables that are not statistically significant 
 Of the remaining variables, the one which is most strongly 
related to the outcome variable is selected 
 Add the remaining variables one at a time in order of their 
strength of relationship with the outcome, until adding an extra 
variable does not contribute significantly to the model  
Backward Stepwise 
 Remove the first variable that has the weakest relationship with 
the outcome, one variable at a time  
 Of the remaining variables, the one which has the weakest 
relationship with the outcome is removed 
 The process is repeated until all the remaining variables are 
significantly related to the outcome. 
 
 
The regression analysis was conducted in three steps. First, preliminary 
analyses were conducted to ensure the assumptions of independence of 
errors, multicollinearity and linearity for logistic regression were adhered. 
Then, the univariate logistic regression was conducted to test the 
significance of individual predictors. Finally, the multivariate logistic 
regression model was conducted. The regression worked around one binary 
outcome (at least one DRP during hospital stay: Yes/No) and 6 independent 
variables: 
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(Age): Age in years  
(G): Gender (female versus male) 
(LOS): Length of hospital stay (days)  
(Rx): Numbers of medicines prescribed per child during hospital stay 
(Adm): Types of ward admission (elective versus non-elective) 
(RRT): RRT modality (Dialysis, Transplant and non-RRT) 
The factors that were analysed in the multivariable analyses included those 
found to be relevant in the literature and others of significance from the 
data in the current study or of pathophysiological significance (Grabe et al., 
1997; Hogg et al., 2003; Ibrahim et al., 2013; Kaplan et al. 1994a; Manley 
et al., 2003; Rashed et al., 2012b). 
 
5.4.7.3 Inter-rater agreement for severity assessment of DRPs 
The Intraclass Correlation Coefficient (ICC) measures the degree to which 
the four judges achieved identical ratings of DRPs’ severity under similar 
assessment conditions. The type of ICC method used was the two-way 
random effect ANOVA for absolute agreement. The two-way random effect 
model treats both the DRPs and the judges’ scores as random measures 
asserting that the DRPs assessed in this study represent problems from the 
hospitalised population of which the results should be generalised. The test 
also treats the judges’ scores as random factors as if the scores represent 
the measure of DRPs’ severity in hospitalised children with kidney disease. 
CHAPTER 5     PROSPECTIVE OBSERVATIONAL STUDY 
169 
 
The value of ICC ranges from 0 to 1, with higher values indicating greater 
reliability or agreement respectively (Field, 2009).  
 
5.5 Results 
A total of 132 patients were recruited (ELCH n=60, GOSH n=72). Of the 
132 patients, 5 were admitted as a cause of a DRP and thus were excluded 
from analysis.  
A total of 127 patients fulfilled the inclusion criteria and were included in the 
cohort. Of the 127 patients, 22 had multiple ward admissions (range 2-6) 
contributing to a total of 166 admissions during the study period. A total of 
203 DRPs were recorded from the 166 admissions. The study results are 
presented based on data analysis at Patient level (sub-sections 5.5.1 and 
5.5.2) and DRP level (sub-sections 5.3.3 to 5.5.7). Analyses at Patient level 
included the demographic characteristics and the risk factors for the DRPs in 
the 127 patients. Analyses at DRP level included the characteristics of the 
203 problems (i.e. the severity of the DRPs, the medicines associated with 
DRPs, the types and contributory factors of DRPs). The codes for the 
characteristics of DRPs presented in this chapter is according to the 
modified PCNE classification system for DRPs in Table 4.1. 
 
5.5.1 Patient characteristics 
A total of 127 patients were included in the analyses (ELCH n=57, GOSH 
n=70). Of the 127 patients, 65 (51.2%) had at least one DRP throughout 
hospitalisation. The incidence of DRPs in the study cohort was 51.2% (95% 
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CI 43.2-60.6%) of patients reviewed by the CPs. Of the 127 patients, 68 
(53.5%) were male. The median age of the study population was 6.6 years 
(IQR 1.8-12.5). The overall median length of hospital stay was 6 days (IQR 
3-12). The median length of hospital stay when the initial DRP was 
identified was 4 (IQR 1-12.5). There was a statistically significant difference 
in the number of patients who developed DRPs during hospitalisation 
compared to those who did not in regard to the length of hospital stay 
(p<0.001) and RRT modality (p=0.001). The total number of medicines 
prescribed in the study cohort was 3341 and the median number of 
medicines per child was 17 (IQR 9-31). Table 5.2 presents the demographic 
characteristics of the study cohort. 
Demographic characteristics of children from each hospital are shown in 
Table 5.2. GOSH reported significantly more number of patients who had 
DRPs (p<0.001), had longer length of hospital stay (p=0.02), receiving 
dialysis treatment (p=0.04) and more numbers of medicines prescribed per 
child (p<0.001).   
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Table 5.2 Patient demographic characteristics by occurrence of DRPs (n=127) 
Characteristics             All DRPs* No DRPs p value 
Total patients 127 (100) 65  (51.2) 62  (48.8) 0.78 
Gender 
Male 
Female 
 
68 
59 
 
(53.5) 
(46.5) 
 
37 
28 
 
31 
31 
 
0.44 
Median age 6.6 (1.8-12.5) 5.0 (1.3-11.9) 8.1 (2.1-13.2) 0.22 
Number of patients by age group  
0-1 month 
>1 month to ≤ 2 years 
>2 years to ≤ 6 years 
>6 years to ≤ 12 years 
>12 years to ≤ 18 years 
 
2 
34 
27 
29 
35 
 
(1.6) 
(26.8) 
(21.3) 
(22.8) 
(27.6) 
 
1 
20 
13 
16 
15 
 
1 
14 
14 
13 
20 
 
 
 
0.27 
      
Median length of hospital stay (days) 6.0 (3-12) 9  (4-20) 4    (3-7)  
Length of hospital stay 
 1-7 days 
 8 days and longer 
 
74 
53 
 
(58.3) 
(41.7) 
 
27 
38 
 
47  
15 
 
<0.001 
      
Type of ward admission 
Elective 
Non-elective 
 
76 
51 
 
(59.4) 
(40.2) 
 
41 
24 
 
35 
27 
 
0.45 
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Characteristics             All DRPs* No DRPs p value 
 
Renal replacement therapy  
         Dialysis  
Kidney transplant 
No RRT 
 
 
28 
29 
70 
 
 
(22.0) 
(22.8) 
(55.1) 
 
 
20 
18 
27 
 
 
8 
11 
43 
 
0.001 
Data are median and (IQR 1-3) or frequency (%),  
*Number of patients with at least one DRP during hospitalisation; Mann-Whitney Test 
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Table 5.3 Demographic characteristics of patients with at least one DRP throughout hospitalisation by study sites 
(n=65) 
Characteristics DRPs* ELCH  GOSH  p value 
Total patients with at least one DRP 
throughout hospitalisation  
65  (100) 26 (40) 39 (60) <0.001 
Gender 
         Male 
         Female 
 
37 
28 
 
16 
10 
 
21 
18 
0.54 
Median age 5.0 (1.3-11.9) 5.7 (0.9-12.5) 5.0 (2.0-10.6) 0.85 
Number of patients by age group  
0-1 month 
>1 month to ≤ 2 years 
>2 years to ≤ 6 years 
>6 years to ≤ 12 years 
          >12 years to ≤ 18 years 
 
1 
20 
13 
16 
15 
 
0 
11 
2 
5 
8 
 
1 
9 
11 
11 
7 
0.99 
Median length of hospital stay (days) 9  (4-20) 6 (3-11.3) 12 (7-28) 0.02 
Length of hospital stay 
 1-7 days 
          8 days and longer 
 
27 
38 
 
15 
11 
 
12 
27 
0.03 
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Characteristics DRPs* ELCH  GOSH  p value 
 
Renal replacement therapy  
Haemodialysis  
Kidney transplant 
         No RRT 
 
 
 
20 
18 
27 
 
 
 
3 
10 
13 
 
 
 
17 
8 
14 
 
 
 
0.04 
Types of ward admission 
Elective 
         Non-elective 
 
41 
24 
 
14 
12 
 
27 
12 
0.21 
Median number of medicines prescribed 
per patient 
28 (13-50) 15 (11-27) 37 (21-66) <0.001 
Data are median and (IQR 1-3) or frequency (%); Mann-Whitney Test 
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5.5.2 Risk factors for DRP  
 
5.5.2.1 Regression analysis 
The univariate regression showed a significant association between the 
occurrence of DRPs with dialysis (Dx), transplantation (Tx), longer hospital 
stay (LOS) and more number of medicines prescribed (Rx). In the 
multivariate modelling, only Rx remained significant (OR 1.06, 95% CI 
1.02-1.10, p=0.002) (Table 5.4). The odd ratio of 1.06 for variable Rx 
indicates that the chance of having a DRP is 6% higher with the addition of 
one medicine in the treatment on the wards, controlling for all other factors. 
The effect was calculated as follows: (1.06–1) x 100 = 6%. 
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Table 5.4 Risk factors for DRPs in hospitalised children in the study cohort (n=132) 
 Univariable OR  
(95% CI) 
p-value Full model OR  
(95% CI) 
p value 
Gender (female vs. male) 0.76 (0.38-1.52) 0.44 1.03 (0.43-2.44) 0.95 
 
Age (year) 0.96 (0.90-1.02) 0.17 0.96 (0.89-1.03) 0.24 
 
Type of ward admission  
(elective vs. on elective)  
 
 
1.32 (0.65-2.68) 
 
0.45 
 
1.76 (0.70-4.42) 
 
0.23 
Renal replacement therapy     
Not on dialysis or transplant 1.00 (Reference) - 1.00 (Reference) - 
Dialysis 3.98 (1.54-10.30) 0.004 2.10 (0.68-5.52) 0.22 
Post-transplant 2.61 (1.07-6.35) 0.04 1.93 (0.68-5.48) 0.20 
     
Length of hospital stay (days) 
 
1.11 (1.05-1.17) <0.001 1.05 (0.99-1.10) 0.10 
Number of medicines prescribed  
per child 
1.07 (1.04-1.11) <0.001 1.06 (1.02-1.10) 0.002 
Note: 
Full model using Backward Stepwise Regression 
Odd ratio (OR) at 95% confidence interval (CI) 
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5.5.3 Severity assessment of DRPs 
All 203 DRPs were listed for severity assessment. The completed scoring 
sheets were obtained from all four judges, four weeks after the sheets were 
sent out. 
 
5.5.3.1 Inter-rater level of agreement in rating the DRP severity 
The ICC coefficient was 0.69 (95% CI 0.57-0.78, p<0.001), indicating that 
there was moderate agreement among the four judges relative to each 
other on average in rating the DRP severity.  
 
5.5.3.2 Analysis of severity  
The mean severity scores ranged from 0.1 to 6.8 and none of the DRPs 
were scored as severe. Of the 203 DRPs, 138 (68%) were scored as minor 
and 65 (32%) were moderate in clinical significance (Figure 5.2). The 
majority of DRPs that were scored as minor was (P3.2) unnecessary drug 
treatment (26.1%, n=36/138). Category (P2.3) toxic adverse reaction were 
mostly scored as moderate (40%, n= 26/65).  An example description of a 
minor DRP is when a patient has completed treatment with broad-spectrum 
antibiotics but nystatin for candidiasis prophylaxis not stopped (DRP no. 
36). Moderate significance DRP cases included the administration of 500mcg 
of intravenous prazosin when the prescribed dose was 50mcg in a neonate 
with compromised renal function (DRP no. 133). The full description of the 
DRPs are enclosed in Appendix 24.  
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Figure 5.2 Number of DRPs by severity rating according to DRP categories (N=203) 
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5.5.4 Drugs associated with DRPs 
Using the first level of the WHO-ATC classification system for medications, 
the groups of medication most often associated with DRPs were ‘(A) 
Alimentary tract and metabolism’ (n=52/203, 25.6%), followed by ‘(J) 
Systemic anti-infectives’ (n= 49/203, 24.1%), and ‘(B) Blood and blood 
forming organs’ (n=27/203, 13.3%) (Figure 5.3). There was no significant 
difference in the types of medicines associated with DRPs between study 
sites. The full list of the drugs involved is presented in Appendix 23. 
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Figure 5.3 The drugs associated with DRPs by WHO-ATC classification system (N=203) 
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5.5.5 Types of DRPs  
A total of 203 DRPs were identified from 166 admissions during the study 
period. More than half of the total DRPs were potential in nature (55.1%, 
n=112/203). The most frequently reported DRPs were (P1) drug effect 
(33.1%, n=67/203), followed (P2) adverse drug event (31.5%, n=64/203) 
and (P3) treatment cost (20.2%, n=41/203). At the sub-category level, the 
most frequently recorded problems were (P1.2) sub-optimal drug effect 
(21.7%, n=44/203), followed by (P3.1) unnecessary treatment (20.2%, 
n=39/203) and (P2.3) toxic adverse reaction (19.2%, n=39/203).  
At the hospital level, the number of DRPs identified at GOSH is 42.9% more 
than at ELCH (75.4% versus 32.5%). All DRPs pertaining to (P1.1) no drug 
effect was only reported at GOSH whilst (P2.2) allergic reaction were 
reported from ELCH. An example of ineffective treatment is a case of 
medicine prescribed for the wrong site e.g. Maxitrol eye ointment 
preparation, which was intended for topical application at the gastrostomy 
site, was prescribed for administration on both eyes (DRP no. 135). All 
three cases of allergic drug reaction at ELCH did not have history of drug 
allergy recorded on the medication chart. An example is a case with the 
manifestation of an allergic reaction to cyclizine injection in a patient who 
had a history of allergy to cyclizine in previous hospital admissions but this 
had not been documented on the patient's medication chart (DRP no. 23). 
The description of the DRPs cases are presented in Appendix 24. The 
summary of the main categories and sub-categories in the types of DRPs is 
given in Table 5.5.  
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Table 5.5 Types of DRPs identified in the study cohort by main and sub-categories (N=203) 
Main category for 
Types of DRPs 
Sub-categories

 Total 
(% of N) 
Potential DRPs* 
(n of N) 
ELCH 
(n of N) 
GOSH 
(n of N) 
 
Total DRPs 
 
  
203 (100) 
 
112 (55.1) 
 
66 (32.5) 
 
153 (75.4) 
P1 Drug effect  
(n=67, 33.1%) 
P1.1 No effect of drug 
treatment  
    3 (1.5) 1 0 3 
 P1.2 Sub-optimal effect   44 (21.7) 33 16 28 
 P1.4 Untreated indication   20 (9.9) 6 4 16 
      
P2 Adverse drug 
event 
(n=64, 31.5%) 
P2.1 Non-allergic reaction    22 (10.8) 13 8 14 
P2.2 Allergic drug reaction     3 (1.5) 2 3 0 
P2.3 Toxic adverse reaction   39 (19.2) 32 
 
8 31 
P3  Treatment cost 
(n=41, 20.2%) 
 
P3.1 Unnecessary treatment   41 (20.2) 4 
 
6 35 
P4  Others 
(n=31, 15.3%) 
P4.2 Drug administration 
problems 
  30 (14.8) 21 11 19 
 P4.1 Patient dissatisfaction     1 (0.5) 0 1 0 
 
*Potential DRPs refers to drug problems that were identified before the patient experienced harm 
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5.5.6 Contributory factors in DRPs 
A total of 387 contributory factors were reported from 203 DRPs. Of the 387 
contributory factors, the most recorded categories were (C5) medication 
errors (46.8%, n=181/387), followed by (C3) dose selection (22%, 
n=97/399) and (C1) drug selection (18.6%, n=72/399). At the sub-
category level, the most recorded were (C5.8) prescribing errors (45.5%, 
n=176/399), followed by (C3.2) doses too high (5.9%, n=23/399) and 
(C1.7) required synergistic/preventive drug not prescribed (5.2%, 
n=20/399). Table 5.6 summarises the full description of contributory 
factors.  
Evaluation of DRPs’ contributory factors between the study sites showed 
relatively different trend. The three most frequent categories reported from 
ELCH were (C5) medication error followed by (C3) dose selection and (C1) 
drug selection. At GOSH,  the predominant categories were (C5) medication 
error, (C2) dose selection and (C8) other factors (i.e. mainly poor 
medication reconciliation). This could be due to the use of ePS in the 
screening of prescription charts which was only available at GOSH.  
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Table 5.6 Contributory factors of DRPs by study sites (n=399) 
 Contributory factors main category / sub-category N (%)  ELCH 
(n of N) 
GOSH 
(n of N) 
Treatment C1 Drug selection 72 18.0 13 59 
process C1.7 Synergistic/Preventive drug not prescribed 20 5.0 1 19 
 C1.9 No indication 13 3.3 2 11 
 C1.1 Inappropriate drug 10 2.5 3 7 
 C1.3 Inappropriate drug duplication 9 2.3 1 8 
 C1.4 Indication for drug not noticed 7 1.8 0 7 
 C1.5 Too many drugs unnecessarily for same indication 6 1.5 1 5 
 C1.2 Inappropriate drug combination 5 1.3 3 2 
 C1.6 More cost-effective alternative available 1 0.3 1 0 
 C1.8 New indication 1 0.3 1 0 
 C2 Inappropriate drug form 7 1.8 5 2 
 C3 Drug dosage 97 24.3 30 67 
 C3.2 Dose too high 23 5.8 5 18 
 C3.1 Dose too low 17 4.3 7 10 
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 Contributory factors main category / sub-category N (%)  ELCH 
(n of N) 
GOSH 
(n of N) 
 C3.4 Dosage regimen too frequent 15 3.8 5 10 
 C3.7 Deterioration/improvement of disease state 10 2.5 4 6 
 C3.3 Dosage regimen not frequent enough 8 2.0 3 5 
 C3.6 Pharmacokinetic problem requiring dosage adjustment 8 2.0 3 5 
 C3.5 No therapeutic monitoring 3 0.8 1 2 
 C3.8 Dose difficult to measure 13 3.3 2 11 
 C4 Treatment duration 15 3.8 2 13 
 C4.2 Too long  13 3.3 1 12 
 C4.1 Too short 2 0.5 1 1 
Drug use process C5 Medication errors 181 45.4 46 135 
C5.8a Prescribing error in decision making 104 26.1 23 81 
C5.8b Prescribing error in prescription writing 72 18.0 20 52 
 C5.2 Drug over administered 2 0.5 2 0 
 C5.1Inappropriate timing of drug administration/dosing intervals 2 0.5 1 1 
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 Contributory factors main category / sub-category N (%)  ELCH 
(n of N) 
GOSH 
(n of N) 
 C5.9 Dispensing error 1 0.3 0 1 
 C7 Patient factors 1 0.3 0 1 
 C7.5 Refuse to take medicines 1 0.3 0 1 
 C8 Other factors   26 6.5 12 14 
 C8.2 Unwanted side effects 14 3.5 8 6 
  C8.1 Poor medication reconciliation 12 3.0 4 8 
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From the 203 DRPs, 45 (22.2%) had a single contributory factor, 126 
(62.1%) had two and 32 (15.8%) had three contributory factors. It is worth 
noting that, in most occasions, the contributory factors were multifactorial 
and interacted with each other. Of the 203 DRPs, 29 (14.3%) had PE as the 
only contributory factor, and 147 DRPs (72.4%) had PE as one of the 
contributory factors. Of the 147 DRPs that had two or more contributory 
factors, the most frequent combination factors were (C5.8) prescribing error 
with (C3) dose selection, 51.7% (n=76/147) and, (C5.8) prescribing error 
with (C1) drug selection, 29.9% (n=44/147). 
 
5.5.7 Recommendations and resolutions for DRPs 
The CPs provided a total of 228 recommendations to solve the 203 DRPs. 
The majority of recommendations to solve the DRPs were at the Drug Level, 
which included changes to the drug doses, dosing frequency and selection 
of drug treatment. DRPs that received the highest numbers of 
recommendations were (P1.2) sub-optimal drug effect, (P2.3) toxic adverse 
reaction and (P3.2) unnecessary drug treatment. Table 5.7 shows the types 
of recommendations at different levels. 
The acceptance rate for the provided recommendations was 99.5%% 
(n=227/228). Of the 228 recommendations, the clinical team did not agree 
to only one and this is referred to as DRP number 187. In this case, the 
recommendation was to stop prescribing lactulose in a patient who was 
reluctant to take the drug as prescribed. The problem was acknowledged by 
the clinical team but they insisted on trying to persuade the patient to 
adhere to treatment. 
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The recommendations solved 96% (n=195/203) of the DRPs as a result of 
ward pharmacy practice. Out of the remaining 8 DRPs, 5 (2.5%) DRPs were 
partially solved and required follow-ups at the outpatient clinics (DRP no. 
31, 89, 91, 103 and 116). Another 3 DRPs (1.5%) were unsolved because 
of lack of patients’ cooperation on taking the medicines as prescribed (DRP 
no. 67, 187and 190). The descriptions of the DRP cases mentioned above 
are presented in Appendix 24. 
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Table 5.7 Recommendations to solve DRPs by clinical pharmacists (n, % of 228) 
Main category for recommendations to 
solve DRPs 
Sub-categories         Total 
        n (%) 
I2 Recommendations at I2.2 Dosage changed      59 (25.8) 
drug level I2.7 Dosing frequency changed   36 (15.8) 
(n=196, 86%) I2.5 Drug stopped 31 (13.6) 
 I2.6 New drug started 23 (10.1) 
 I2.1 Drug changed 12 (5.3) 
 I2.4 Instructions for use changed 11 (4.8) 
 I2.9 Treatment duration changed 10 (4.4) 
 I2.3 Drug form/formulation changed 9 (3.9) 
 I2.8 Route/site of administration changed 5 (2.2) 
    
I3 Recommendations at  I3.1 Patient (medication) counselling   9 (3.9) 
patient/carer level  I3.3 Referred patient to prescriber 3 (1.5) 
(n=12, 5.3%)    
    
I4  Recommendations at I4.1    
other level (n=20, 8.8%) Request for new prescriptions 10 (4.4) 
 Update information on prescription charts   10 (4.4) 
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5.6 Discussion  
The findings in this study support the hypothesis that hospitalised children 
with kidney disease have higher incidence of DRPs compared to the general 
paediatric population. While not all predicted risk factors for DRPs were 
significant, the overall characteristics of DRPs in the study cohort shared 
some similarities to the children hospitalised in the medical wards. These 
results also supported previous studies that have shown the effectiveness of 
ward pharmacy practice and the potential benefit of ePS in managing DRPs.  
 
5.6.1 Incidence of DRPs in children with CKD 
The incidence of DRPs observed in this study cohort was 51.2% (95% CI 
43.2-60.6%) of patients. This incidence is higher compared to the incidence 
reported in children hospitalised in other specialties including those 
receiving care in the paediatric intensive care units, which was reported as 
45.2% (95% CI, 41.5-48.8) of children (Rashed et al., 2012b). The same 
study also reported the DRP incidence in the UK cohort was 39.4% (Rashed 
et al., 2012b). One possible explanation for higher incidence in the renal 
units is the complexity of cases seen. Furthermore, in patients with kidney 
disease, the drug doses and frequency require frequent adjustment 
according to the estimated GFR. A drug dosing service in a renal unit has 
shown to minimise DRPs (Daschner, 2005; Hassan et al., 2009).  
Data from the five patients who required admission because of a DRP were 
excluded from analysis because this study was designed to only evaluate 
DRPs that occurred during inpatient treatment. The information on DRPs 
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that led to admission for these five patients was a finding by chance and did 
not represent the study population.    
 
5.6.2 Risk factors for DRPs  
The number of drugs prescribed per child was the only factor that was 
statistically significant in the full model logistic regression analysis. The 
current study shows that  an addition of one medicine increases the chance 
of DRPs’ occurrence during hospital treatment by 6%. The cut-off point for 
DRPs or MEs at which there is no clinical significance is not known. Ideally, 
safe and effective treatment should be free of DRPs or errors of any sort. As 
most DRPs in this study were found to be minor (severity score 0-2.9) and 
potential in nature, it is unlikely that the DRPs would be associated with 
fatal consequences (i.e. severity score 7-10).  
In this study population, the median prescription per patient was 17 and 
ranges between 10 and 31. Studies of adult renal patients acknowledged 
the use of five or more drugs and a regimen involving twelve or more doses 
a day as factors associated with DRPs (Grabe et al., 1997; Kaplan et al., 
1994b; Koecheler et al., 1989; Manley et al., 2003). Polypharmacy with 
complex regimen has been recognised to be a risk factor for adverse drug 
events and other types of DRPs in previous studies of children and adults 
(Bates et al., 1999; Fattinger et al., 2000; Koh et al., 2005; Mason, 2011; 
Rashed et al., 2012a; Rashed et al., 2012c).  
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5.6.3 Severity of DRPs  
The majority (68%) of DRPs identified in the current study were minor in 
clinical significance. It is a challenge to compare the severity of DRPs in the 
current study to others because of the variation in definitions of levels of 
severity and in the methods used for the severity assessment. As an 
example, the majority of DRPs (74%) in hospitalised children in general 
medical wards were also found to be minor in significance (Rashed et al., 
2012b). This aforementioned study also adapted the Dean & Barber (1999) 
scale to assess the severity of DRPs; however, the evaluation on the degree 
of severity for the DRPs was conducted by face-to-face discussions (rather 
than individual scoring) among three (rather than four) judges.  
Castelino et al. (2011) studied the clinical significance of DRPs in adult renal 
patients and reported that the majority of DRPs were minor (72%).  In the 
aforementioned study, the assessment was made using the Alderman 
Criteria which was developed to describe clinical pharmacy interventions in 
a psychiatric unit. The Alderman criteria defined minor DRPs as problems 
requiring small adjustments and optimisation to therapy which were not 
expected to significantly alter hospital stay, resource utilisation or clinical 
outcome. The Dean and Barber scale (1999) which was used in the present 
study defined minor DRPs as problems that were unlikely  to have any 
adverse effects.  
 
5.6.4 Drugs associated with DRPs 
Drugs in the class of ‘alimentary tract and metabolism’ (n=51/203) and 
‘systemic anti-infective’ (n=49/203) were the most frequently associated 
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with DRPs in this study. These two classes of medicines were also reported 
to be the most frequently associated with DRPs in children in the UK 
(Rashed et al, 2012b). Anti-infectives were reported as the predominant 
class of drugs associated with DRPs in other research on medicine use in 
children (Kaushal et al., 2001; Kunac and Reith, 2008). Infection is known 
to be one of the main causes of mortality in children with kidney disease 
(Harambat et al., 2012; Warady and Chadha, 2007; Pruthi et al., 2012b). 
This could possibly explain the high usage of anti-infective in the study 
cohort. 
Anti-infective were also reported to be associated with DRPs in the adult 
renal patients but were not as common as cardiovascular agents and anti-
diabetics (Castelino et al., 2011; Kaplan et al., 1994a; Manley et al., 2005). 
The difference in the types of drugs associated with DRPs between children 
and adult patients with CKD could be due to the aetiology of the disease. 
Kidney disease in adult patients is secondary to long standing of metabolic 
disorders such as hypertension and diabetes mellitus. In the paediatric 
population, almost one-half of all CKD cases are due to congenital kidney 
disorders (Kim et al., 2013; Warady and Chadha, 2007).  
 
5.6.5 Types and contributory factors of DRPs   
The most common DRPs in the study cohort were sub-optimal drug effect 
and unnecessary treatment (Table 5.5). These DRPs were associated with 
drug selections and dosage errors. Similar findings were reported in other 
studies focusing on medication errors and have reported that dosing errors 
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as the most common errors affecting the paediatric population  (Ghaleb et 
al., 2006; Ghaleb et al., 2010; Jani et al., 2008; Kaushal et al., 2001). 
One reason for the high frequency of dosing problems identified in the study 
cohort might be due to the effect of dialysis on the pharmacokinetic 
properties of medicines (Hassan et al., 2009; Veerback and Musuamba, 
2009). Dialysis increase drug elimination and result in sub-optimal drug 
effect (Verbeeck and Musuamba, 2009). This scenario complicates the 
calculation for a dose in children that is known to be dependant on many 
factors such as the weight, age, BSA and associated clinical conditions 
(Conroy and Carroll, 2009; Ghaleb et al., 2010).  
Problems pertaining to unnecessary drug treatment in the study cohort 
reflects that medications should not only be adjusted according to the 
estimated GFR (Corsonello et al., 2012) but also frequently monitored 
according to the patients’ updated clinical condition to prevent the 
occurrence of adverse drug events (Hassan et al., 2010).   
Frequent monitoring of medications also involves medication reconciliation 
on admission and at hospital discharge which can reduce discrepancies that 
may cause potential harm. Medication discrepancies in children were 
reported to range from 22% to 72.3% (Huynh et al., 2013b). Future 
research is required to address problems in medication discrepancies for 
patients with kidney disease, especially those who are dialysis-dependent 
(Pai et al., 2013). 
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 5.6.6 Recommendations and resolutions for DRPs 
The high acceptance rate (99.5%) towards CPs’ recommendations in 
resolving DRPs by the clinical team may have been attributed by several 
factors. Other than the integration on clinical pharmacy practice at the 
inpatient setting, the clinical skills and experience of the CPs also played an 
important role. The CPs involved in this study had more than 10 years of 
experience in renal pharmacy practice. Furthermore, the professional 
relationship built between the CPs and other member of the clinical team 
had established the role of CPs in decision making for patient care. 
Professional interpersonal relationships between pharmacists and physicians 
has shown to contribute to higher acceptance rates towards pharmacists’ 
recommendations and improve treatment outcomes in previous studies 
(Altavela et al., 2008; Bodgen et al., 1998; Leape et al., 1999).  
Although the present study did not measure whether acceptance of 
recommendations led to the resolutions of DRPs resulted in improved 
clinical outcomes, but it did reflect positive multidisciplinary decision making 
in managing DRPs.  
 
5.7 Strengths and limitations 
The strength of this study lies in the prospective measures of DRPs in the 
current clinical practice; and it is the first study to evaluate the 
characteristics of DRPs in children with kidney disease at the inpatient 
setting. Certain limitations must be considered when interpreting the 
findings, including the difference in the data collection time period and the 
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use of ePS which may introduce variability to characteristics of DRPs 
identified in ELCH and GOSH. Although data-collection training was given to 
the CPs to optimise the consistency of the collected data using a 
standardised proforma, no inter-rater test was performed to evaluate the 
agreement on classifying the characteristics of DRPs.  
 
5.8 Summary 
This study was able to explain the underlying reasons of higher incidence of 
DRPs in hospitalised children with kidney disease compared to those in the 
general medical inpatient settings. Sub-optimal drug effect is the 
predominant DRP in the study cohort and the majority of the problems were 
contributed by drug and dosing errors. Whilst many factors may be 
associated with DRPs in children and their associations may be cumulative 
and interdependent, the only independent predictor for the occurrence of 
DRPs in this study group was the greater number of medicines prescribed 
per child during hospital treatment. The majority of the DRPs were minor in 
significance and were solved as a result of ward pharmacy services. 
Findings from this study provide a starting point for future studies on DRPs 
at the renal outpatient clinic setting, which would give more information on 
consideration of providing clinical pharmacy services to paediatric 
nephrology patients. The next chapter describes the work on investigating 
the characteristics of DRPs and the impact of CP interventions in resolving 
DRPs at the renal outpatient clinic. 
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CHAPTER 6                                             
The effect of clinical pharmacist 
interventions in resolving DRPs at the 
renal outpatient clinic: A randomised 
control trial 
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6.1 Introduction 
In Chapter 5, an observational study in hospitalised children showed that 
the occurrence of DRPs in those with kidney disease is 11.8% (51.2% vs 
39.4%) higher compared to those admitted to other specialties (i.e. Medical 
and Paediatric intensive care units) in the UK reported by Rashed et al., 
(2012b). This chapter describes the work to investigate the nature of DRPs 
in outpatient settings in a busy tertiary paediatric nephrology clinic and the 
impact of CP interventions in these circumstances. This study obtained 
ethical approval from the London-Hampstead Research Ethics Committee, 
London, UK.  
 
6.2 Hypothesis 
 
“The baseline incidence of patients with active DRPs at the paediatric renal 
outpatient clinics is 40% of patients and intervention resolves the baseline 
DRPs by at least 15% more than the Standard Care” 
 
6.3 Aim and objectives  
This study aimed to evaluate the impact of CP interventions on the 
resolution of DRPs and to determine the epidemiology of DRPs in children 
attending the renal outpatient clinic.  
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6.3.1 Primary objective  
To determine whether CPs’ intervention at the outpatient clinic setting were 
effective in resolving at least 25% of the active DRPs identified in the 
Control versus Intervention arm at baseline. Active DRPs were identified at 
baseline from eMR documentation and referred to problems which were not 
yet solved at the point of enrolment.  
 
6.3.2 Secondary objectives 
1. To determine the risk factors  
2. To measure the severity  
3. To identify the characteristics  
Of DRPs documented in the medical records of children with kidney disease 
who were attending the renal outpatient clinics.  
 
6.4 Methods 
 
6.4.1 Study design  
This was a single centre, simple randomisation, parallel group-study.  
 
6.4.2 Site and study period 
This trial was conducted at the ELCH paediatric outpatient renal clinic from 
18th February to 18th September 2013. The setting of the study site has 
been explained in Chapter 3. 
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6.4.3 Sample size calculation 
The clinical estimate of the event rate in the Control arm was 40%. It was 
not possible to determine the desired effect size of pharmacists’ 
intervention based on previous studies in the CKD population due to 
heterogeneous outcomes and variability in the quality of published research 
(Salgado et al., 2012). Assuming an intervention difference of 25 
percentage points (40% in control arm and 15% in intervention arm), with 
105 in each arm, this trial would have enough participants to estimate the 
difference in proportion of patients with DRPs with 95% confidence interval 
± 25 percentage points. The width of the confidence interval used in the 
sample size calculation was selected such that the number per arm was 
feasible to recruit and it would enable the researcher to estimate the 
intervention difference with a desired degree of accuracy. The calculated 
sample size was 210 patients (105 patients per arm). The sample size was 
calculated assuming =0.05, power=0.95 and equal samples in both arms 
using the following formula (Schulz and Grimes, 2005):  
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Where, 
n = the sample size in each arm 
P = event rate in the Intervention arm = 0.15 
Q = event rate in the Control arm = 0.40 
R = risk ratio (
 
 
) = 0.15/0.40 = 0.38 
 
6.4.3.1 Interim analysis 
An interim analysis was performed when 47.6% (n=100/210) of patients 
had been recruited.  The achieved difference in the event rate between the 
Control and Intervention arms was calculated to determine the actual 
sample size that was required to estimate the intervention difference with a 
desired degree of accuracy. 
 
6.4.4 Trial protocol  
The trial protocol has been explained in Chapter 4 (Feasibility Study (II)) 
and the following is a brief summary. Baseline DRPs (i.e. active and inactive 
DRPs) were identified by the researcher for all patients in the Control and 
Intervention arms. After baseline DRPs were identified, patients were 
assigned into one of two groups at random. Patients in the Control group 
received the standard care and those in the Intervention group received 
CPs’ interventions. At the end of the clinic day, the resolution of the active 
DRPs at baseline for participants in both arms were identified from the 
doctor’s notes. The diagram of the study design is shown in Figure 4.3. 
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Active DRPs refers to problems that were not yet solved when the patients 
were enrolled. Inactive DRPs refers to problems that had been solved when 
the patients were enrolled.  
 
6.4.5  Study initiation phase  
The timeline for the study initiation phase is shown in Figure 6.1. 
 
6.4.5.1 Briefings to clinical team  
Three briefings were conducted. In the first briefing (14th February 2013), 
the researcher was given a one-hour session for a PowerPoint presentation 
which introduced the concept of DRPs, the results of the observational 
cohort study (Chapter 5), the proposed method for the current RCT and the 
potential effect of the trial on the work process at the renal clinic. The 
second and third briefings (3rd and 18th April 2013) were requested by the 
renal consultants for an update on the patient recruitment process. All 
briefings were held during the monthly Nephrology Department meeting at 
ELCH and were attended by all renal consultants, registrars and CPs. 
Information leaflets on the study method were distributed to all clinical 
team members after the briefings (Appendix 22). This strategy increased 
the likelihood of documenting information related to the use of medicines in 
patients’ case notes. A similar approach was applied previously (Eguale et 
al. 2008). 
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6.4.5.2 Briefings to clinical pharmacists 
In the first briefing (14th February 2013), an additional one-hour session 
with the CPs was conducted. During this session, the CPs were briefed on 
the conduct of interventions proposed (and agreed by the CPs) in the trial 
protocol. The operational definitions of DRPs and the components of the 
study proformas were also explained.   
 
6.4.5.3 Piloting the study proformas 
The researcher and the CPs piloted the study proforma on three occasions 
(19th & 27th February and 2nd March 2013). The proforma for the semi-
structured patient interview was piloted during clinic session in the doctor’s 
consultation room. During this session, the doctor had a trial of interviewing 
two patients on their medicine-taking behaviour using the proforma. The 
proformas for medication review were piloted by having the researcher and 
the CPs review the eMR of a test patient. Minor changes to the proformas 
were mainly on the layout of the form rather than the content, and 
therefore ethics approval for the amendments was not required.  
 
6.4.5.3 Feasibility study 
The report of the feasibility study has been described in Chapter 4 
(Feasibility Study (II)). It is important to note that a strategic approach is 
required to determine the practicality of the chosen study design at the 
clinical setting (Wong, 2004). Therefore, the aim of the feasibility study 
(18th February to 11th April 2014) was to identify difficulties in the data-
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collection process for an RCT.  The feasibility study was to assess the 
process rather than the outcome of the trial. By the 26th March 2014 (Figure 
6.1), the difficulties in the process of data collection were rectified. The 
initial recruitment process involved a two-week period of posting study 
information packages to eligible patients via clinic letters. Therefore, it was 
necessary to start the recruitment process early (from 26th March to 11th 
April), to ensure that all potential participants were recruited. The first 
attempt to approach patients at the clinic started on 14th April, which was 
after the feasibility study. 
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18th Feb 
Obtained ethical approval from the 
REC and R&D 
 
18th Sept 
End of recruitment  
February        March         April                  May 
 
2013   
14th Feb 
Briefing (1) 
26th Mar 
Recruitment preparation started  
 
3rd Apr 
Briefing (2) 
 
18th Apr 
Briefing (3) 
 
Figure 6.1 Timeline for the study at the outpatient renal clinic from 14th February to 18th September 2013 
27th Feb 
Piloting study 
proformas (2) 
  
 
2nd Mar 
Piloting study 
proformas (3) 
  
 
18th Feb – 11th Apr  
Feasibility study  
 
19th Feb 
Piloting study 
proformas (1) 
 
 
14th Apr 
Day 1 recruitment 
 
27th Feb 
Piloting study 
proformas (2) 
  
 
19th Feb 
Piloting study 
proformas (1) 
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6.4.6 Data analyses 
Data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 21 for Windows® and presented as percentages (%), 
median, interquartile range (IQR 1-3) and odd ratios (OR) with 95% 
confidence interval (CI). In all statistical tests p values of less than 0.05 
were considered statistically significant. For the descriptive analysis of 
patients and DRP characteristics, Chi-squared (2), Kruskal-Wallis Rank and 
Mann-Whitney tests were used as appropriate.  
 
6.4.6.1 Intention-to-treat and Per protocol analysis 
The effect of intervention on the resolution of active DRPs between both 
group were analysed using the ITT and the Per protocol principles. In the 
Per Protocol analysis, patients in the Intervention arm who did not receive 
intervention were treated as Controls. To report the significance difference 
between the resolution of DRPs in subject Control versus Intervention arm, 
the difference in the number of unresolved active DRPs before and after 
intervention was compared using Mann-Whitney test.   
 
6.4.6.2 Logistic Regression for assessing predictors of DRPs 
The principle of Logistic Regression was explained in the data analysis 
section of Chapter 5. The potential risk factors that were tested comprise 
of: age in years (Age), gender (G), total number of medicines prescribed 
(Rx) and stages of CKD (CKD). 
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6.4.6.3 Inter-rater agreement for severity assessment of DRPs 
The Intraclass Correlation Coefficient (ICC) measures the degree to which 
the four judges achieve identical ratings of DRPs’ severity under similar 
assessment conditions. The principle of ICC was previously described in 
sub-section 5.4.7.3.  
 
6.4.6.4 Descriptive analysis 
6.4.6.4.1 Incidence of patients with newly identified active DRPs  
The incidence of patients who were newly identified with active DRPs at 
baseline was defined as the number of patients with at least one active DRP 
when attending the clinic divided by the total number of patients reviewed 
by the researcher at baseline multiplied by 100. For the calculation of DRP 
incidence, only patients with active DRPs that were newly identified at 
baseline were included.  
 
             
  
                                                                       
                                                                   
        
 
6.4.6.4.2 Characteristics of DRPs 
The descriptive analysis for the characteristics of DRPs includes: 
1. Drugs associated with DRPs 
2. Types, contributory factors and severity scores of DRPs   
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6.5 Results 
This trial had an early termination based on the interim analysis that 
showed small possible effect and a large number of patients were required 
to estimate the true effect of the interventions.  Thus, the statistical tests 
would lack power to detect the true estimation of the endpoint. Whilst 
statistical comparison showed no significance difference between the 
Control and Intervention groups, findings on the characteristics of DRPs 
offer a new insight for the management of DRPs in children attending the 
renal clinic. Table 6.1 summarises the sequence of results presentation. The 
codes for the characteristics of DRPs presented in this chapter is according 
to the modified PCNE classification system for DRPs in Table 4.1 and Table 
4.2. 
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Table 6.1 Sequence of result presentation 
Sub-sections  Result presentation  
6.5.1 Interim analysis 
6.5.2 Recruitment 
6.5.3 Patients’ characteristics 
6.5.4 Effect of interventions on the resolution of active DRPs 
between the Control and Intervention group. This result 
was analysed using the IT and per Protocol principle  
6.5.5 Risk factors for DRPs. This analysis evaluated the risk 
factors for the occurrence of all DRPs (active and inactive) 
that were identified at baseline from retrospective review of 
eMR using regression analysis 
6.5.6 Severity scores of all DRPs (N=64) assessed by four judges 
6.5.7 Drugs associated with DRPs  
6.5.8 Characteristics of DRPs (N=64). This section described the 
types and contributory factors of the DRPs  
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6.5.1 Interim analysis 
An interim analysis was conducted when almost half of the expected 
number of participants were recruited (47.6%, n=100/210). The achieved 
intervention difference was 2%, calculated as follows: event rate in Control 
minus event rate in Intervention (0.19-0.17=0.02). Based on this 
percentage point, the sample size that was required to show a significant 
difference in the proportion of resolved DRPs between the Control and 
Intervention arm was calculated. The trial was terminated based on the 
interim analysis that showed a large number of patients (N=8500) were 
required. The calculated sample size in the interim analysis is as follows:  
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Where,  
n = the sample size in each arm 
P = achieved event rate in the Intervention arm = 0.17 
Q = achieved event rate in the Control arm = 0.19 
R = risk ratio (
 
 
) = 0.17/0.19 = 0.89 
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6.5.2 Recruitment 
A total of 659 patients were screened for eligibility as potential participants. 
Of the 659 patients, 317 (48.1%) were excluded. The main reason for 
exclusion was because the patients were not on any medications. Of the 
remaining 342 (51.9%, N=659) patients, 148 (43.3%, N=342) were 
approached during the trial period. The reasons for not being able to 
approach all 342 eligible patients were because either they were already 
called to see the doctor before being invited into the trial, had their clinic 
appointments rescheduled, or did not attend the clinic.  
From the 148 patients who were approached, 100 were recruited from 26th 
March to 10th September 2013 in 39 clinic days (280 clinic sessions). Of the 
148 patients, consents were not obtained from 48 patients. Sixty-five 
percent (n=31/48) of the 48 patients were boys and the median age (IQR) 
was 10.9 (5.4-15.1) years. Forty-four percent (n=21/48) of those who 
declined to participate were not interested to take part in research of which 
five mentioned that they had participated in research within the past 12 
months. The 21 patients whose parent/carer was not interested tin them 
taking part in any research were five years and younger, with median (IQR 
3 -3.5). 
All the 100 patients, before randomised into one of the two groups, had 
their medical notes reviewed retrospectively using the eMR by the 
researcher in order to identify DRPs at baseline. In the Intervention arm, 
23.4% of patients (n=11/47 patients) did not receive intervention because 
they were called for a doctor’s consultation before being seen by the CPs. 
The trial participant flow is shown in Figure 6.2.   
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659 Patients were assessed for eligibility 
317 Were not eligible 
 
154 Were not any medications 
84 Did not have medical notes available for screening 
 (44 New referral patients; 37 Medical notes not available 
in ePR; 3 Were transferred to other hospital) 
36 Were not patients with kidney disease 
25 Were already involved in other interventional studies 
18 Above 18 years of age 
342 Patients were eligible 
48 Declined to be enrolled 
21 Were not interested to participate in any research at 
the current  moment 
12 Were interested to participate in this study but 
wanted to be enrolled in the next clinic visit 
12 Did not want to mention any reasons (personal) 
3 Claimed not to have any problems with medications 
 
100 Patients underwent randomisation and had eMR reviewed by 
the researcher at baseline  
53 Control arm   47 Intervention arm  
148 Patients were approached during clinic 
47 Were included in 
intention-to-treat analysis 
53 Were included in 
intention-to-treat analysis 
(+11 per protocol) 
53 Received Standard Care 36 Received Intervention  
Figure 6.2 Participant flow 
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6.5.3 Patient characteristics 
The characteristics of the randomised patients were similar in both arms 
(Table 6.3). The median age of the randomised patients was 9.7 (SD 4.8) 
years, 55% (n=55/100) were male and a mean of 5 (SD 3) medicines were 
prescribed per patient. Nine of the patients did not have CKD staging 
recorded in the medical notes and their serum creatinine levels were also 
not available to calculate the GFR value. A total of 32 patients had at least 
one DRP recorded in their medical notes in the previous six months of which 
18 of them still had active DRPs on the day of recruitment (Control, 
n=10/53; Intervention, n=8/47). The incidence of patients with active DRPs 
was 18% (95% CI 11.3-26.7%) (Table 6.2). 
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Table 6.2 Characteristics of patients' demography 
 Control (N=53) Intervention (N=47) p value 
 
Age (years) 
 
8.9 (5.7-13.8) 
 
8.7 (5.3-15.1) 
 
0.76 
Gender (Boys) 29 (54.7) 26 (55.3) 0.41 
CKD Staging (GFR mL/min/1.73m2): 
Stage 1   (>90) 
Stage 2   (60-89) 
Stage 3A (59-45) 
Stage 3B (44-30) 
Stage 4   (15-29) 
Stage 5   (<15) 
Post kidney transplant 
Not recorded in medical notes 
 
12 (22.6) 
6 (11.3) 
4 (7.5) 
6 (11.3) 
7 (13.2) 
5 (9.4) 
10 (18.9) 
3 (5.7) 
 
6 (12.8) 
4 (8.5) 
3 (6.4) 
7 (14.9) 
9 (19.1) 
3 (6.4) 
9 (19.1) 
6 (12.8) 
0.90 
Medicines prescribed per patient  5 (3-7) 5 (3-7) 0.65 
Patients with at least one active DRPs identified 10 (18.9) 8 (17.0) 0.33 
Number of DRPs identified  
Active DRPs 
Inactive DRPs 
 
14 (10 patients) 
19 (11 patients) 
 
17 (8 patients)β 
14 (7 patients) 
 
Data are median and (IQR 1-3) or frequency (%) 
Of the 8 patients, 1 did not receive intervention;   
βOf the 17 active DRPs, 1 belonged to the patient who did not receive the intervention  
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6.5.4 Resolution of active DRPs between patients in Control and 
Intervention arms  
In the Control group, 10 patients were identified with a total of 14 active 
DRPs. In the Intervention group, 8 patients were identified with a total of 
17 active DRPs. Using the ITT and Per Protocol analysis, there was no 
significant difference in the resolution of DRPs between both groups (ITT: 
p=0.96; Per Protocol: p= 0.81) (Table 6.3 and Table 6.4).  
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Table 6.3 Resolution of active DRPs between patients in Control and Intervention arms (ITT analysis) 
 
 
 
 
 
Table 6.4 Resolution of active DRPs between patients in Control and Intervention arms (Per Protocol analysis)* 
 
 
 Resolution of active DRPs before and 
after intervention 
  
 Before After  (before-after) P value 
Control (n=10) 14 11 3  
0.96 
Intervention (n=8) 17 14 3 
 The number of resolved active DRPs before and after intervention  
 Resolution of active DRPs before and 
after intervention 
  
 Before After  (before-after) P value 
Control (n=11) 15 12 3  
0.81 
Intervention (n=7) 16 13 3 
*One patient in the Intervention who did not received the intervention was treated as Control in the Per Protocol 
analysis 
 The  number of resolved active DRPs before and after intervention 
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In total,  6 active DRPs were solved (3 DRPs in each arm). Table 6.5 shows 
that 5 out of the 6 resolved active DRPs were (P1.2) sub-optimal drug effect 
(Control, n=2; Intervention, n=3) and mostly contributed by patients’ poor 
understanding of treatment plan and medications. It is worth noting that for 
DRP (P4.2) drug administration problems in the Control group, even though 
(C8.4) was the main contributory factor, the resolved problem in this 
category was contributed to (C6.2) difficulty in the process of obtaining refill 
prescription from the community. 
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Table 6.5 Types of Active DRPs identified at baseline in the Intervention and Control arm (n=31) 
       Intervention (n=16)                      Control (n=15) 
 
Main and sub-categories for  
types of DRPs 
n 
(solved) 
Most common contributory  
factors 
 n (solved) Most common 
contributory factors 
 
P1 Drug effect 
     
P1.2 Sub-optimal effect 
(n=16, 51.6%) 
9 (2) C7.1 Patient forgot to take the 
prescribed medications 
 7 (3) C7.8 Poor 
understanding of 
treatment plan and 
medications 
P1.3 Untreated indication 
(n=1, 3.2%) 
1 (0) C7.5 Patient refused to take the 
prescribed medications 
 0  
 
P2 Adverse drug event 
     
P2.1 Non-allergic ADR  
(n=5, 16.1%) 
1 (0) C8.2 Unwanted side effect  4 (0) C8.2 Unwanted side 
effect 
 
P4 Others 
     
P4.2 Drug administration problems 
(n=9, 29%) 
 
5 (1) C8.4 Dependent on NG or PEG 
tubes for enteral feeding 
including oral medicationsδ 
 4 (0) C6.2 Difficulty in the 
process of obtaining 
refill prescription from 
the community 
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δ Nasogastric (NG), Percutaneous Endoscopic Gastrostomy (PEG) 
The descriptions of the DRPs are presented in Appendix 25 
Control group: Case number 37, 93, 94; Intervention group: Case number 57, 70, 72 in Appendix 25 
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6.5.5 Risk factors for DRP  
The multivariate binary logistic regression showed that none of the 
predicted risk factors were associated with the occurrence of DRPs at the 
renal outpatient clinic (all p>0.05). The CKD staging was listed in Table 6.6 
because the results from the DRP study at the inpatient setting (Chapter 5) 
that showed a trend of higher DRPs in children on dialysis. This analysis 
showed that higher stages of CKD did not contribute to the occurrence of 
DRPs at the renal outpatient clinic.  
 
Table 6.6 Multivariate logistic regression predicting likelihood of DRPs 
occurring in renal outpatient clinics (N=100) 
 
 
Potential predictors 
Full model 
OR (95% CI) 
p-value 
Gender (female vs. male) 1.12 (0.48-2.60) 0.80 
Age (year) 1.01 (0.93-1.10) 0.83 
CKD Staging   
Stage 1 – 3A  1.45 (0.59-3.53) 0.42 
Stage 3B – 5 1.00 (reference) - 
Number of drugs prescribed  1.05 (0.91-1.21) 0.53 
Odd ratio (OR) at 95% confidence interval (CI) 
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6.5.6 Severity assessment of DRPs 
A total of 64 DRPs were listed in the scoring sheet for severity assessment. 
Four judges who were involved in the assessment of DRP severity in the 
previous observational study (Chapter 5) were invited to participate. The 
fourth judge was not able to participate due to work commitments and 
recommended a colleague in the same specialty as a replacement. The new 
selected judge has been involved in the initial work of the current study. 
The researcher provided training on the scoring method to the new judge 
before the list of DRPs were distributed.  
 
6.5.6.1 Inter-rater agreement for severity assessment 
The ICC coefficient was 0.43 (95% CI 0.10-0.65, p<0.001) indicating low 
agreement among the four judges relative to each other on average in 
rating the severity of DRPs.  
 
6.5.6.2 Analysis of severity  
Majority of the DRPs were classified as moderate in severity (90.6%, 
n=58/64) and minor problems accounted for 9.4% (n=6/64). The median 
(IQR) severity score was 4.1 (1.2). There was no significant difference in 
the severity score between the active and inactive DRPs (p=0.58). Most 
problems were manifested in nature (64.1%, n=41/64) but had not caused 
any harm. 
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Moderate
Minor
P1.2 Sub-optimal drug effect 
P4.1 Patient dissatisfied with therapy 
P2.1 Non-allergic adverse reaction 
P4.3 Delay in treatment 
P2.3 Toxic adverse reaction 
P1.4 Untreated indication  
P4.2 Drug administration problem 
P2.2 Allergic adverse reaction 
 
Figure 6.3 Number of DRPs by severity according to categories (N=64) 
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6.5.7 Drugs involved in the occurrence of DRP 
Using the first level of the WHO ATC classification system for medications, 
the three most often involved in DRPs were medicines in the ‘(B) blood and 
blood forming organ’ (24.3%, n=15/64), followed by ‘(A) alimentary tract 
and metabolism’ (18.8%, n=12/64) and ‘(J) anti-infectives for systemic use’ 
(17.2%, n=11/64) (Figure 6.4). Prednisolone (15.6%, n=10/64) and 
Sodium bicarbonate (9.3%, n=6/64) were the two medicines frequently 
associated with DRPs in the study cohort. The full list of drugs associated 
with DRPs is presented in Appendix 26. 
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Figure 6.4 Medicines associated with drug-related problems by the WHO ATC classification system (N=64) 
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6.5.8 Characteristics of DRPs (n=64) 
6.5.8.1 Types of DRPs  
A total of 64 DRPs were identified from retrospective eMR review. Of the 64 
DRPs, 31 were active DRPs and 33 were inactive DRPs. Sixty-four percent 
(n=41/64) of the DRPs were Manifested and 36% (n=23/64) were Potential 
in nature.  
The most frequently identified DRPs were (P1) drug effect (40.6%, 
n=26/64), followed by (P4) Other groups of DRPs (30.1%, n=25/64) and 
(P2) adverse drug event (21.9%, n=14/64). At the sub-category level, the 
most frequently documented problems were (P1.2) sub-optimal drug effect 
(39.1%, n=25/64), followed by (P4.2) drug administration problem (29.7%, 
n=19/64) and (P2.1) non-allergic adverse reaction (17.2%, n=11/64). The 
description of DRPs is presented in Appendix 25. 
Participants’ (i.e. parent/carer and child at appropriate age) poor 
understanding of treatment plan and medications was documented as the 
most common contributory factors for sub-optimal drug effect. Unwanted 
side effect was one of the factors contributing to adverse drug events and 
the use of feeding tubes contributed to difficulty in administering 
medications (Table 6.7).  
From the total 64 identified DRPs, 11 were categorised as non-allergy ADR. 
Out of the 11 DRPs, 6 were associated with side effects of Prednisolone and 
the remaining 5 were associated with Azathioprine, Dexamphetamine, 
Ferrous Fumarate, Fluoxetine and Itraconazole. Prednisolone was 
documented to cause side effects affecting the skin (acne, facial stigmata), 
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central nervous system (mood swing), gastrointestinal tract (abdominal 
pain) and metabolic (cushingoid).  All side effects of Prednisolone were 
assessed as moderate in severity by the judges and the scores ranged 
between 3.2 to 5.3. Prednisolone side effect with the highest score, 5.3, 
was abdominal pain when taken with Mycophenolic Acid without prophylaxis 
for steroid induced gastritis (DRP no. 107 in Appendix 25).  
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Table 6.7 Types of DRPs identified by the researcher at baseline by main and sub-categories (N=64) 
Types of DRPs 
 
Main category            Sub-categories 
Total 
(% of N) 
Potential 
DRPs 
(n of Total) 
Most common contributory factors 
 
P1  Drug effect 
 
P1.2 Sub-optimal effect 
 
25  (39.1) 
 
14 
 
C7.8 Poor understanding of treatment plan 
and medications 
 
(n=26, 40.6%) P1.4 Untreated indication 1    (1.6) 0 
P2 Adverse drug event  
(n=14, 21.9%)  
P2.1 Non-allergic ADR  11  (17.2) 3 C8.2 Experience unwanted side effect of the 
prescribed drug  P2.2 Allergic ADR 1    (1.6) 0 
P2.3 Toxic ADR 
 
2    (3.1) 
 
1 
P4  Others  
(n=25, 30.1%) 
P4.2 Drug administration 
problems 
19  (29.7) 1 C8.5 Dependent on NG or PEG tubes for 
enteral feeding including oral medications 
 P4.3 Delay in treatment  5    (7.8) 5 
  
Total 
 
64  (100) 
 
23 
Data are in count (%) 
Nasogastric (NG), Percutaneous Endoscopic Gastrostomy (PEG) 
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6.5.8.2 Contributory factors of DRPs  
A total of 73 contributory factors were documented from the 64 DRPs. 
Ninety percent of the DRPs identified at the renal outpatient clinics were 
largely contributed by factors of the drug use process i.e. (C7) patient 
factors (42.5%, n=31/73), (C8) other factors (35.6%, n=26/73) in which 
the majority were unwanted side effects and (C6) drug supply (11%, 
n=8/73) in which all were problems in obtaining repeat prescriptions from 
the community.  
Prescribing error in the community contributed to a case of potential sub-
optimal drug effect, which involved prescription of One Alpha Calcidol 
dispensed as Cholecalciferol (Vitamin D3). This error occurred for eight 
months before it was discovered and documented in the medical notes. This 
case was rated as moderately severe, but did not cause harm to the patient 
(DRP no. 11). The list of DRPs contributory factors is available in Table 6.8. 
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Table 6.8 Contributory factors for DRPs (n=73)  
 Contributory factors main category / sub-category n (% of N) 
 
Treatment process 
 
C1 Drug selection 
 
3  
 
(4.1) 
 C1.1 Inappropriate drug 1 (1.4) 
  C1.3 Inappropriate drug combination 1 (1.4) 
  C1.8 Synergistic/Preventive drug not prescribed 1 (1.4) 
  C3 Drug dosage 4  (5.5) 
  C3.1 Dose too low 2 (2.7) 
  C3.2 Dose too high 1 (1.4) 
  C3.5 No therapeutic drug monitoring  1 (1.4) 
 
Drug use process C5 Medication errors 1  (1.4) 
  C5.8a Prescribing error in decision making 1 (1.4) 
  C6 Drug supply  8 (11.0) 
C6.2 Problems with the process for obtaining repeat prescriptions from the 
community 
8 (11.0) 
  C7 Patient factors 31  (42.5) 
  C7.1 Patient forgot to take the drug 10 (13.7) 
  C7.5 Refused to take medicines 6 (8.2) 
 C7.7 Forgot to ask for refill prescription from community 1 (1.4) 
 C7.8 Poor understanding of treatment plan and medications 14 (19.2) 
  C8 Other factors 26  (35.6) 
  C8.2 Unwanted side effects 12 (16.4) 
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 Contributory factors main category / sub-category n (% of N) 
C8.4 Dependent on NG/PEG for medications 8 (11.0) 
 C8.5 Difficult to obtain information from GP 5 (6.8) 
 C8.6 New dose not altered by the GP 1 (1.4) 
Data are count or percentage (%) 
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6.6 Discussion 
The primary objective of this study was to determine the effectiveness of CP 
interventions in resolving DRPs at the renal outpatient clinic. This study was 
terminated after the interim analysis showed that the possible effect was so 
small (2% difference) and required a huge number of patients (N=8500) to 
show statistical significance between Control and Intervention arm. The 
incidence of patients with DRPs was 33.2% lower than the incidence of DRP 
reported from the observational study at the inpatient setting in Chapter 5 
(18% [95% CI: 11.3-26.7%] vs.51.2% [95% CI 43.2-60.6%]). There was 
no statistical significance in the resolution of DRPs between both arms and 
the predicted risk factors for DRPs. The medicines that were associated with 
DRPs the most were in the ‘blood and blood forming organ’ group. The 
predominant types of DRPs were sub-optimal drug effect and the most 
frequently reported contributory factor was related to patients’ cognitive 
behaviour towards medications. The majority of DRPs (90.6%) had minor to 
moderate clinical significance. 
 
6.6.1 Trial termination  
This study recruited 100 out of the 210 patients and this was 52% less than 
the calculated sample size. The interim analysis showed that the required 
number to estimate a true difference on the effect of intervention was 
approximately 8500 patients, which was not feasible within the 
circumstances of this trial. Nevertheless, findings from this study 
contributed to new knowledge in understanding the medicine management 
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of children with kidney disease as well as to develop strategies in designing 
a pharmacy-based interventional study in the future. 
 
6.6.2 Incidence of patients with DRPs attending the renal clinic 
The incidence of patients with active DRPs when attending the renal clinic is 
18% (95% CI 11.3-26.7%), which was lower than the incidence reported 
from the DRP study at the inpatients setting in Chapter 5 (51.2% [95% CI 
43.2-60.6%). There could be several possibilities for the lower incidence of 
DRPs at the renal outpatient clinics setting than the inpatient setting. 
Patients in the ambulatory care received fewer prescriptions, and had less 
complex complications compared to those who received treatment on the 
wards (median number of medications per child: inpatient 17, outpatient 5). 
Furthermore, problems that occurred more frequently but with less causality 
were not likely to be documented (Brown et al., 2008a). Interviewing the 
patients (and family) have shown to be a more effective method than 
medical charts review in identifying DRPs at the outpatient setting. Jameson 
and Vannwoord (2001) in a study at the ambulatory care setting, reported 
that 73% of pharmacotherapy problems were recognised through patient 
interview and the remaining problems were identified from medical chart 
reviews and health database.  
The present study chose the retrospective eMR review method because the 
study objective was to identify the types of DRPs documented by the 
clinicians. Should this study use other methods, different characteristics of 
problems would be generated (Franklin et al., 2009). 
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6.6.3 Resolution  of active DRPs 
The interventions in this study did not show superiority over non-
intervention in resolving DRPs in children attending the renal outpatient 
clinics.  
The types and contributory factors for the 31 active DRPs (Table 6.5) shows 
that 5 out of 6 solved problems related to sub-optimal drug effect and these 
problems were contributed by patient factor. This finding supports the need 
for consultancy sessions on medicines to empower participants’ knowledge 
on treatment, as reported by So et al (2011).  In young patients undergoing 
long-term therapy, interventions to improve their cognitive behaviour 
towards medicines involve a complex psychological assessment that are not 
fully understood (Dean et al., 2010; Salema et al., 2011). More often than 
not, the strategies for such interventions require continuous assessment for 
at least 6 months (Haynes et al., 2008).  
The second highest active DRPs were problems in administering the 
prescribed medications. This problem was mainly contributed by two 
factors: patients’ dependency on using the feeding tubes (which was also 
used in the administration of medicines) and the difficulty in the process of 
obtaining repeat prescriptions from the community.  
Children with CKD may show anorexia, vomiting and poor appetite which 
may result insufficient protein intake to maintain growth (Rees and Shaw, 
2007). Enteral feeding is indicated when dietary manipulation and 
medication fail to optimise nutrition intake.  Tube feeding is important when 
struggling with oral intake in an anorexic child causes intolerable strains 
within family; and is also used for the administration of medications in such 
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circumstance (Rees and Brandt, 2010). The stresses on the family trying to 
feed or administer medications to a struggling child using the feeding tube 
could be overwhelming. In the current study, problems in administering 
medications via the feeding tube were unsolved and patients with this 
problem were documented to be struggling with oral intake.  
According to the causal chain linking interventions to outcomes in patient 
safety research (Brown et al., 2008c) previously described in Chapter 3, 
difficulties in the process of obtaining refill prescriptions from the 
community is related to the structure of the healthcare system. i.e. external 
factors that are beyond the control of the managers within a particular 
health organisation such as national directives, licensing products and 
budget constraints. This  was reflected in the small proportion of DRPs that 
could be solved by the CPs in the current study.  
From the pharmacy practice perspective, referring patients from the 
community back to the hospital for medicine supplies may not be the 
optimum solution. Alternative solutions include empowering the services in 
the community through programmes such as the New Medicine Service 
(NMS), Effective Shared Care Agreement (ESCAs) and homecare services 
(ESCAs, 2014; RPS, 2014a; RPS, 2014b).  
The NMS focuses on patients with long-term conditions who have been 
prescribed with new medication or had changes made to their existing 
medication. The service involves an intervention in which the community 
pharmacists provide information and reassurance to address patients’ 
concerns during the first month of a new medicine or new dosage regimen. 
At present, the service is only available for adults who have been prescribed 
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new medicines for asthma, chronic obstructive pulmonary disease, type 2 
diabetes and high blood pressure (NHS, 2013).  
An effective shared care agreement can assist in the seamless transfer of 
patient treatment from secondary care to general practice, as it provides 
information on the medication, together with guidance on the prescribing 
and monitoring responsibilities (ESCAs, 2014). Communication barriers in 
the transfer of patient care may result in serious harm to patients due to 
failure in continuity of care (NHS, 2014a). The medications listed for the 
ESCAs in childrenare limited and this is currently under review for future 
improvement (NHS, 2014b).   
There is also considerable shift towards homecare services as a way of 
providing medication that is not suitable or available for shared care 
agreements. The medicines that are included in this scheme for patients 
with kidney disease (all ages) are renal dialysis solutions and epoetin. The 
post renal transplant immunosuppressants will eventually be delivered via 
homecare, but for the time being this change is on hold due to some 
technical problems with the service provider (NHS, 2014b). Different 
delivery options are being explored by the procurement experts with the 
expectation that homecare will be possible starting in April 2015 (NHS, 
2014b). 
Medicine management programmes at the community level, such as the 
examples above, can be seen as increasingly offering opportunities to 
redesign patient care pathways, which may have a positive impact in 
reducing DRPs.  
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6.6.4 Risk factors of DRPs  
Children attending the renal outpatient clinics did not have similar risk 
factors to those hospitalised on the wards. Nevertheless, it would be 
valuable to investigate whether problems in obtaining drug supply from the 
community is a latent risk factor for DRPs in this group of patients. An adult 
study reported higher incidence of DRPs resulting in emergency department 
visits, which was 33% of patients; of whom approximately 20% were 
related to patients not receiving the required medications (Baena et al., 
2006). 
 
6.6.5 Severity of DRPs 
The majority of the DRPs identified in this study were rated as moderate in 
significance to clinical practice, i.e. likely to cause adverse effects or 
interfere with therapeutic goals. Most of these problems contributed to 
patients’ intentional and non-intentional non-adherence and difficulties in 
obtaining prescribed medications from the community (Table 6.5 and Table 
6.7). The proportion of these problems that led to visits to healthcare 
professionals was not evaluated in this study. A study in the paediatric 
population showed that the incidence of DRPs in children at the emergency 
department was 21.7% but the concerns were related to dosing problems 
and ADR (Rashed et al., 2013). 
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6.6.6 Drugs associated with DRPs 
The drug classes most frequently involved in DRPs were ‘blood and blood 
forming organ’, ‘alimentary tract and metabolism’ and ‘anti-infectives for 
systemic use’. This is not surprising as these drug classes are usually 
prescribed for managing the complications of kidney impairment (Belaiche 
et al., 2013; Kaplan et al., 1994a; Manley et al., 2003).  Prednisolone and 
Sodium bicarbonate were frequently reported with DRPs in this study 
cohort. These medicines are essential treatment in the management of 
kidney disorders. 
Prednisolone is an anti-inflammatory agent which was mostly prescribed  
long term for the management of nephrotic syndrome and as an adjunct 
immunosuppressant in post-transplantation. Its long term use is usually 
accompanied with metabolic syndrome in childhood (Litwin and Niemirska, 
2014).  Metabolic syndrome leads to obesity, hypercholesterolemia, 
hypertension and impaired blood glucose control (Zimmet et al., 2007).   All 
these complications increase the risk of cardiovascular disease in children 
with kidney disease (Litwin and Niemirska, 2014). Sodium bicarbonate is an 
alkaline agent for the management of metabolic acidosis, a common 
complication in patients with kidney disorders. Metabolic acidosis has been 
reported to accelerate CKD progression, impair nutritional status and, in 
children, cause growth disruption (Abramowitz et al., 2013; de Brito-
Ashurst et al., 2009).  
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6.6.7 Types and contributory factors of DRPs 
This study found that the most frequently identified DRPs documented in 
the clinical notes were (P1) drug effect, (P4) others and (P2) adverse drug 
event (Table 6.7). The types and contributory factors for the first two DRP 
categories were similar to the ones that had been previously discussed in 
6.6.3 (i.e. sub-optimal drug effect and drug administration problems which 
were contributed by patient factors and difficulty in obtaining repeat 
prescriptions). Thus the discussion in this this sub-section is focused on (P2) 
adverse drug event. 
Children were thought to be at higher risk for adverse drug events than 
their adult counterpart due to their physiology and immature mechanism of 
drug metabolism (Impicciatore et al., 2000). In children with kidney 
disease, adverse drug events are also affected by pharmacokinetic 
alteration in dialysis and changing GFR. This study showed that unwanted 
side effect of the prescribed medicines as the main contributing factors for 
the adverse drug events.  
Six out of the 11 non-allergy ADRs were contributed by side effects from 
chronic use of Predisolone. Appendix 25 described the DRPs and the ones 
related to Prednisolone side effects were numbered 5, 28, 60, 77, 99 and 
107 – these DRPs occurred in patients who required long term use of 
steroid. Side effects from chronic use of steroid cause complications such as 
severe infection and metabolic syndrome. The current clinical practice 
guideline for post renal transplantation and glomerular diseases are shifting 
towards minimum use of steroid immunosuppressive regimen. However, 
alternatives to minimise the use of corticosteroids are expensive and 
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require further research on safety and efficacy in children (Pravitsitthikul et 
al., 2013).  
One case of an allergic adverse reaction reported in this study was 
associated with Amoxicillin. Anti-infective agents were described as most 
frequently associated with adverse drug reactions in children (Rashed et al., 
2012a; Smyth et al., 2012). Two DRPs of toxic adverse drug reactions were 
associated with the use of Metformin for weight loss and Tacrolimus as 
immunosuppressant in post kidney transplant – both medicines are not 
licensed for use in children (BNFc, 2009).  A meta-analysis of 17 articles on 
adverse drug reactions in paediatric at the inpatient and outpatient settings 
concluded that the use of unlicensed and off-label medicines in children 
increased the risk of adverse reactions (Impicciatore et al., 2001) however, 
there is still a lack of clarity on their risk factors (Mason et al., 2012).  
 
6.7 Strengths and limitations 
To the researcher’s knowledge, this is the first RCT on CP interventions at 
the renal outpatient clinic for children. Findings in this study provide a 
better understanding on the characteristics of DRPs. The limitations of this 
study include low statistical power to show any significance of the 
interventions. The possible effect of the intervention was so small FOR 
statistical significance with the achieved sample size. Only one person (the 
researcher) was involved in recruiting potential patients and thus not all 
patients who were interested in participating were invited before they were 
called for a doctor’s consultation. Although the identification of baseline 
DRPs from the eMR was conducted explicitly and guided by the DRP-Rf to 
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ensure consistency, the retrospective review method is still bound to 
interpretation bias because the hospital medical notes are not recorded for 
research purposes. The economic impact of clinical pharmacy services in 
resolving DRPs was not evaluated because it was beyond the scope of this 
research. However, it is important to consider the direct and indirect costs 
incurred by the NHS in future research  
 
6.8 Summary 
This study concludes that the majority of DRPs identified at the paediatric 
renal outpatient clinic are moderate in clinical significance to treatment 
outcomes; however, a more complex and long-term intervention is required 
to effectively resolve these problems. Sub-optimal drug effect and drug 
administration problems were the two most common DRPs identified – both 
were largely contributed by patients’ medicine-taking behaviour and the 
structure of medication supply in the community. The proforma used to 
interview patients in this study could be a potential tool in practice to aid 
the DRP identification and documentation. 
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CHAPTER 7                                         
Overall Discussion 
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7.1  Overview of the research key findings 
The aims of this thesis were to investigate the epidemiology of DRPs using 
standardised definitions and methods, and the effect of CPs’ interventions in 
resolving DRPs in paediatric nephrology patients. Multiple methodological 
approaches were used to describe the incidence, the risk factors, the 
characteristics and the resolution rate of DRPs in children with kidney 
disease at the tertiary healthcare settings in two paediatric hospitals in 
London.  
 
7.1.1 DRPs in children with kidney disease: Inpatient setting 
In hospitalised children with CKD, the incidence of DRPs was 51.2% (95% 
CI 43.2-60.6) of patients reviewed and the number of medicines prescribed 
per child was the only predominant risk factor for DRPs (OR 1.06, 95% CI: 
1.02-1.10, p=0.002). The majority of the DRPs were scored as minor in 
clinical significance (68%, n=138/203). Medicines that were most 
commonly associated with DRPs was in the ‘alimentary tract and 
metabolism’ drug group (25.1%, n=51/203).  
The predominant DRPs were sub-optimal drug effect (21.7%, n=44/203), 
followed by unnecessary drug treatment (20.2%, n=41/203) and toxic 
adverse reaction (19.2%, n=39/203). The most frequently reported 
contributory factors for these problems were inappropriate drug selection 
and dosage error. Almost all of CPs’ recommendations in managing DRPs 
were accepted by the clinical team (99.5%, n=227/228) and 96% 
(n=195/203) of the identified DRPs were solved as a result of ward 
pharmacy practice.   
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7.1.2 DRPs in children with kidney disease: Outpatient renal clinics  
The incidence of patients with active DRPs when attending the renal clinic 
during the study period was 18% (95% CI 11.3-26.7). There was no 
statistical significance in the resolution of DRPs between the Control and 
Intervention arms (ITT analysis, p=0.96; Per Protocol analysis, p=0.81). In 
addition, none of the predicted risk factors for DRPs were significant. 
Majority of the DRPs were classified as moderate in clinical significance 
(90.6%, n=58/64). The drug class most frequently involved in DRPs were 
‘blood and blood forming organ’ (23.4%, n=15/64). The predominant DRPs 
was sub-optimal drug effect (39.1%, n=25/64), drug administration 
problem (29.7%, n=19/64) and non-allergic adverse reaction (17.2%, 
n=11/64). 
The most frequently reported contributory factors for these problems were 
related to patients’ cognitive behaviour, which is not easily corrected by 
healthcare professionals in tertiary care. Community-based medication 
reviews that are incorporated in the NMS, ESCAs and homecare schemes 
could improve medicine management at the community setting and 
subsequently reduce DRPs in children receiving outpatient treatment.  
Direct comparison of data obtained in this research to what has been 
reported in other population could be discussed with consideration of the 
differences in the research methods and data evaluations.  
 
  
244 
 
7.2 Comparison of DRP data with adult renal patients  
Compared to the adult patients, children with kidney disease had at least 
half the incidence of DRPs. Almost all studies on DRPs in adult populations 
reported that all renal patients have at least one DRP (Cardone et al., 2010; 
Castelino et al., 2011). This could be due to the difference in the selection 
of patients and the calculation of incidence. The majority of studies 
evaluating DRPs in the adult renal patients were conducted in those with 
ESKD on regular dialysis (Cardone et al., 2010; Salgado et al., 2012) but 
less than 30% of the study cohort of this research were on dialysis (Study 
1: 22%, n=28/127; Study 2: 8%, n=8/100) . Furthermore, the calculation 
for the incidence of DRPs in the adult renal populations were not clearly 
defined and most probably included readmissions. In the present research, 
for the calculation of incidence of DRPs, only the first admissions during the 
study period were considered. 
The predominant DRPs reported from studies in the adult renal populations 
at the inpatient setting were toxic adverse reactions due to inadequate 
monitoring of biochemistry markers and serum blood levels (Salgado et al., 
2012). Whereby in children, the main problems were sub-optimal drug 
effect and unnecessary treatment due to inappropriate drug selection and 
prescribing error. Other than the difference in physiology and prescribing 
pattern between adults and children, the differences in the characteristics of 
DRPs are also due to the distinction of the DRPs’ classification systems 
used. The majority of studies in the adult renal patients adapted the Hepler 
and Strand classification (1990) (Cardone et al., 2010; Salgado et al., 
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2012) whereby the present research adapted the PCNE classification for 
DRPs.  
Thus direct comparison of the characteristics of DRPs found in this research 
to the findings in the adult renal patients is challenging. Nevertheless, 
problems related to drug and dosing are a concern in renal patients, adults 
and children alike. In children, medication errors, particularly prescribing 
errors is a common contributory factor to the occurrence of DRPs. The study 
on the element of errors in the process of drug use for adult renal patients 
is limited and suggest for future research. 
Appendix 27 summarises findings on the characteristics of DRPs between 
the two studies of the present research (Study 1 and Study 2) to three 
other studies: (1) a study on DRP in children hospitalised in the other 
specialties (Rashed et al., 2012b), (2) a study on DRPs in pre-dialysis adult 
CKD patients (Castelino et al., 2011) and (3) a systematic review on DRPs 
in adult renal patients in whom the majority were on dialysis (Cardone et 
al., 2010). 
 
7.3 Comparison of DRP data with children in the general 
medical wards 
The overall incidence of DRPs reported in children hospitalised in the 
medical and the paediatric intensive care units was 45.2% (95% CI 41.5-
48.8) (Rashed et al., 2012b) and the incidence in the UK population was 
39.5% (95% CI 34.4-44.6). The aforementioned study also reported the 
incidence of DRPs in the paediatric care unit as 59.7% (95% CI 47.0-71.5). 
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Thus, compared to the finding in the present research it can be concluded 
that even though the incidence of DRPs in hospitalised children is relatively 
higher than those hospitalised in the medical unit (51.2-45.2%=6% 
difference), but the incidence is lower than those who are critically ill (51.2-
59.7%= - 8.5% difference). 
Findings on the characteristics of DRPs in the present study at the inpatient 
setting were similar to those reported by Rashed et al. (2012b). Both 
studies reported ‘alimentary tract and metabolism’ and ‘anti-infectives’ as 
the main drug group causing DRPs – this reflects the prescribing pattern in 
paediatrics. Further analysis on the specific types of medicines associated 
with DRPs in the study cohort of the current research also indicate the 
prescribing pattern in managing kidney failure. Sub-optimal drug effect was 
the predominant DRPs and the problems were contributed by drug and 
dosing errors. Most of CPs recommendations in solving the DRPs in both 
studies were at the drug level and the majority of the DRPs were minor in 
clinical significance. The only dissimilarity in the characteristics between the 
DRPs of both studies was the significant risk factors. The number of 
medicines prescribed per child is the only risk factors for DRPs in the 
present study whereby, in children without kidney disease the additional 
risk factor is when transferred from another hospital or ward.  
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7.4 Comparison of DRP data in children with kidney 
disease at the inpatient and outpatient settings  
It is worth mentioning on the differences in the demographic characteristics 
between study subjects involved in evaluating DRPs at the inpatient and 
outpatient setting in the current research. Even though both study 
populations were children with kidney disease, the majority of those seen at 
the renal clinics were in the predialysis stage. Whereby, children receiving 
inpatient treatment were more ill due to complications of the disease 
progression or the RRT. CKD children receiving inpatient treatment required 
three times more number of medicines compared to those attending the 
outpatient clinic (median 17 vs. 5 medicines per child).  
Many studies have previously demonstrated that patients at the late stage 
of CKD and on dialysis require more complex drug therapy and which 
subsequently exposed  them to higher chances of having DRPs (Cardone et 
al., 2010; Fernandez-Llimos et al., 2004; Salgado et al., 2012). The above 
circumstances explained the lower incidence of DRPs reported in children 
attending the renal outpatient clinics compared to those hospitalised on the 
renal wards (51.2% [95% CI: 43.2-60.6%] vs. 18% [95% CI: 11.3-
26.7%]).  
Interestingly, despite of having more serious clinical conditions, in 
hospitalised patients, the majority of DRPs were scored as minor in clinical 
significance (68%, n=138/203) compared to the DRPs identified at the 
outpatient setting in which 90.6% (n=58/64) were moderate. The possible 
reason to this circumstance could be explained using the model for causal 
chain linking interventions to outcome (Brown et al., 2008c) in the context 
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of medicines management. The concept of this model was explained in 
Chapter 3.  
Drug problems occurring on the wards are ‘active errors’ in the clinical 
process of the model. The majority of the ‘active errors’ in the current 
research were caused by drug-dosing errors which could be rapidly rectified 
and the outcome could be carefully monitored by healthcare professionals. 
Thus, the errors are less likely to cause harm as a result from the 
interventions. As an example, sub-optimal Tacrolimus dose in the 
management of post kidney transplantation on the ward could be adjusted 
from post 12-hour Tacrolimus serum drug levels. Changes to drug regimen 
are directly monitored by multidisciplinary healthcare professionals and 
patients receiving inpatient treatment are likely to adhere to the prescribed 
therapy. In contrast, drug problems occurring at the outpatient clinic are 
‘latent error’ in the management process; in which the majority of the 
errors were caused by exogenous processes that is beyond the control of 
healthcare professionals (e.g. difficulties in obtaining medications from the 
community) or require long-term interventions (e.g. patients’ non-
adherence). Furthermore the responsibility for managing the medications 
outside the hospital is down to the patients themselves (which includes 
parent and carer). Thus, medicine management services in the community  
could be beneficial in resolving DRPs occurring in the community. 
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7.5 Implications for practice 
 
7.5.1 Clinical pharmacy practice 
Clinical pharmacy practice on the paediatric renal wards appears to be 
effective in identifying and resolving DRPs that may lead to potential harm 
in the inpatient setting but remains to be proven in the outpatient seting. 
The DRPs identified on the wards have a higher resolution rate because CPs’ 
involvement in managing medicines is integrated into the clinical team, 
coupled with simultaneous multidisciplinary care during hospitalisation, 
whereas such involvement is new at the outpatient setting. An important 
role for pharmacy practice on the wards is confirming medication histories 
on admission, as many studies have highlighted that errors are common at 
this stage (Brock and Franklin, 2007).  
Medication reconciliation could be integrated as part of the ward pharmacy 
services for renal paediatric patients and this has been recently highlighted 
for the care of adult renal patients (Pai et al., 2013; St. Peter et al., 2013). 
At the inpatient setting, the CPs have the time and opportunity for face-to-
face contact with the medical team and this is a factor associated with 
better implementation of clinical pharmacy services (Jameson and 
Vannoord, 2001). The results of the inpatient DRP study reported in Chapter 
5 of this thesis strengthen the current evidence that medication reviews 
through clinical pharmacy services in hospitalised patients lead to improved 
treatment outcomes (Graabæk and Kjeldsen, 2013; Kaboli et al., 2006).   
The RCT reported in Chapter 6 showed that pharmacy services at the 
outpatient clinic appear to have an insignificant effect in resolving the 
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problems due to the distinct nature and causes of the DRPs as well as the 
operating procedure of the standard care at the outpatient setting. 
However, an avenue that may gain benefit from pharmacy services at the 
out-patient clinics is again, medication reconciliation and programmes to 
facilitate parents/carers in managing their child’s medications.  A Cochrane 
review reported that adolescents would benefit from programmes focused 
on medicine-taking behaviour at the transition period to the adult unit 
(Haynes et al., 2008). The report suggested that the programme should be 
a continuous effort for at least 6 months. Effective medicine management in 
the community setting (e.g.  NMS, ESCAs and homecare services) could be 
a possible solution to reduce the occurrence of DRPs.  
At present in the UK and the US, clinical pharmacy services are not 
embedded into the standard care of the outpatient clinic (Brock and 
Franklin, 2007) and this circumstance would be highly similar in other 
countries. With regard to pharmacists’ interventions at the renal out-patient 
clinics aimed to improve the clinical endpoints – such as the Pharmacist-Led 
clinics for calcium-phosphate products, blood pressure control and lipid 
management – the evidence regarding their effectiveness is sparse (Stemer 
and Lemmens-Gruber, 2011; Salgado et al., 2012). It is a challenge to 
prove the effectiveness of clinical pharmacy services at the out-patient 
setting in tertiary care because of various reasons as previously described. 
Furthermore, it also involves complicated study designs and, more often 
than not, the outcomes are surrogate markers of clinical endpoint which 
may be biased and underpowered (Stemer and Lemmens-Gruber, 2011; 
Salgado et al., 2012).  
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The lack of evidence on the significant impact of pharmacists’ role in 
optimising clinical outcomes contributes to the reason why the clinical skills 
of pharmacists are unknown and under-recognised by the public, patients 
and policy makers (Royal Pharmaceutical Society, 2013a). In November 
2013 the Royal Pharmaceutical Society (RPS) Faculty initiated a recognition 
programme for specialised pharmacy practice through professional 
assessment. At present, this opportunity is open for the RPS faculty 
members practising in the UK (Royal Pharmaceutical Society, 2013b). It is 
hoped that the RPS specialist recognition for the pharmacy profession would 
widen the horizons of the pharmacy profession at all level of care and its 
success could be adapted by other countries.   
 
7.5.2 Monitoring of DRPs 
It is apparent from the current research that the number of medicines a 
patient receives during inpatient treatment is an independent risk factor for 
DRPs at the in patient setting. Even though not statistically significant, 
hospitalisation of more than four days and the higher stages of kidney 
disease could be clinically important in monitoring for DRPs. This is 
supported by the fact that patients at the late stages of CKD (stage 3B and 
above) require more medications for the management of the complications 
related to the failing kidneys, hence continuous monitoring of DRPs would 
help to prevent poor treatment outcomes.  
Children with kidney disease require lifelong treatment of complex 
pharmacotherapy. They are frequently hospitalised and medications are 
frequently altered throughout hospitalisation and at hospital discharge 
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(Warady and Chadha, 2007). In the UK, a survey among paediatric 
pharmacists found that 67% of the pharmacists reconciled medications on 
hospital admission for children; however, only 34% had a medication 
reconciliation policy in place (Huynh et al., 2013b). It is important that 
medication reconciliation is conducted at all level of care and this has been 
advocated by the NKF Guidelines for children and adolescents with kidney 
disease (Hogg et al., 2003). Medication reconciliation is an avenue to 
minimise discrepancies in the transfer of information (Rashed et al., 
2012b).  
Proper coordination for supplies of medication in the community is also 
essentially important because failure to receive medication has been 
reported as a cause of low adherence in patients with CKD (Cardone et al., 
2010). An initiative that has been taken by the ELCH Pharmacy Department 
is introducing the Drug Information Centre where parents and patients can 
seek advice on problems related to medications by telephone calls. A similar 
service (i.e. drug information centre) could be set up in the community, 
where patients spend more time.   
 
7.5.2.1 The application of electronic prescribing system in 
monitoring for DRPs 
Electronic prescribing and medicine administration system has long been 
advocated to replace paper-based system. In the present research, the use 
of ePS by CPs in screening prescriptions at one of the two study sites to 
identify potential and manifested DRPs could have contributed to the types 
of DRPs reported in this thesis.  
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The hospital that uses ePS at the inpatient setting in the current research 
were seen to successfully prevented allergy reactions. This supports the 
benefit of ePS in improving the interception of potentially harmful 
prescribing errors (Caldwell and Power, 2012). In the conventional paper-
based documentation, the screening of medication charts could only be 
conducted whenever the CPs visit the wards. The availability of ePS enables 
the CPs to review patients’ medication lists remotely from the wards and 
support clinical pharmacy activities.  
Nevertheless, pharmacists’ role to ensure patient safety would be more 
challenging in hospitals that use ePS  (Sanghera et al., 2006) because of 
the high possibility of information errors which include prescribing errors. 
The occurrence of prescribing errors in the use of ePS include: wrong drug 
being ordered by the prescribers because the lacked of detailed information 
concerning the choices of products available at the dispensary, failure to 
renew or stop a treatment leading to underuse or overuse of medicines and 
delay in charting immediate orders which may affect the schedule of drug 
administration (Koppel et al., 2005).   
 
7.5.3 Interventions to solve DRPs 
There is no cure for kidney disease. Children with kidney disease are a 
group of patients who require lifelong treatment and complex drug therapy. 
Surveillance for the prevention and resolution of problems in the use of 
medicines in children with CKD should be a continuous effort at all levels of 
care (Hogg et al., 2003). The nature of the disease progression and the 
required treatment expose these children to DRPs even though when 
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dosage adjustment recommendations are carefully followed (Verbeeck and 
Musuamba, 2009). The interventions to solve DRPs at the inpatient setting 
and the outpatient clinics should be approached with different strategies 
according to their characteristics.  
In the inpatient setting, a majority of DRPs are largely contributed by 
prescribing errors. Prescribing errors have been reported to be preventable 
(Conroy and Carrol, 2009; Dean et al., 2010; Ghaleb et al., 2010) thus, 
having continuous awareness programmes on medication safety in 
paediatrics remains essential in practice (Conroy and Carrol, 2009; Rashed 
et al., 2012b).  
At the outpatient clinics, services focused on changing patients’ of cognitive 
behaviour towards medications and/or specific clinical outcomes as well as 
empowering patients’ involvement in managing their medications have been 
proven to show benefits in the long term for patients with kidney disease 
(Cardone et al., 2010; So et al., 2011; Stemer and Lemmens-Gruber, 
2011). The challenges to achieve such interventions are to formulate an 
indicator that is measurable and providing human as well as financial 
resources for the service. The DRP classifications and the DRP screening 
tool used in the present research could also be integrated into the 
physician’s practice.  
Interventions to identify and solve DRPs should be a shared responsibility of 
all healthcare providers. Mason and Bakus (2010) suggested eight 
structured process that can be adapted by all healthcare providers in 
identifying and resolving DRPs: 
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1. Obtaining an accurate medication list that truly reflects what the 
patient is taking. 
2. Evaluating whether each medication is necessary or whether any 
other medication is required. 
3. Determining whether each medication is the preferred one for its 
indication. 
4. Assessing that the dosages and regimen are correct. 
5. Reviewing the medications list for interactions or adverse effects. 
6. Ensuring that proper monitoring takes place. 
7. Assessing adherence and causes of non-adherence and 
8. Resolving any discrepancies between the actual list and the one in 
the medical records.  
For the paediatric population, the researcher suggests an addition of 
another two points to the process: 
9. Facilitate parents/carers in the monitoring, prevention and resolution 
of DRPs and  
10. Empower children (age appropriate) and especially adolescent with 
motivation to be confident to take charge of their medications.  
 
7.6 Strengths and limitations 
The strengths and limitations of each study in this thesis have been stated 
at the end of Chapter 5 and Chapter 6. In this section, the focus is on the 
overall research.  
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The strength of this Ph.D. research lies in the use of multiple methods to 
investigate the characteristics of DRPs in children with kidney disease 
during hospitalisation as well as at the renal outpatient clinics. In addition, 
this thesis also included the first randomised control trial to explore CP-led 
intervention in resolving DRPs among children attending the renal 
outpatient clinics. Even though the trial showed no significant difference in 
the resolution of DRPs in participants who received intervention, the 
epidemiology data from this research contributed new knowledge to clinical 
pharmacy practice. This research included two paediatric hospitals in 
London, and therefore the results are not necessarily generalised to other 
settings. However, as the two largest UK paediatric renal centres, it could 
be hypothesised that their care already reduces the DRPs, and other centres 
may well have increased rates. 
The DRP classification system used in this study was adapted from the PCNE 
classification version 6.2 and hence the data interpreted in this research 
may generate some differences in the groups into which the DRPs are 
classified when using different versions of the PCNE classification  
The DRP severity assessment tool used in this research was initially 
developed to evaluate the severity of administration errors; however, it was 
the most appropriate tool to be used in the present research. In using this 
tool, the degree of agreement amongst the judges in scoring the severity 
levels of DRPs identified in the inpatient setting was higher compared to the 
outpatient clinics (ICC coefficient: inpatient 0.69 versus outpatient: 0.48).  
The lower number ICC coeficient at the outpatient clinic could be due to the 
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smaller number of DRPs compared to the inpatient setting (64 versus 203 
DRPs); however, this was not further evaluated in the present research.  
 
7.7 Suggestions for future research 
The epidemiology data of DRPs presented in this thesis form a foundation 
for future medication safety research in children with kidney disease.  
 The adapted version of the PCNE DRP classification developed in this 
research can be used to characterise DRPs in future research 
involving paediatrics and adults. The operational definition of this 
adapted version could be useful in minimising bias in data 
interpretation and would enable comparison of data.  
 
 Currently, no validated tools have been introduced for the 
assessment of DRP severity. Future research in testing the methods 
for evaluating DRPs would be very beneficial.  
 
 This research has shown medication discrepancies as a contributory 
factor for DRPs in patients with kidney disease. Very little work has 
been done in this area and it would be interesting to investigate the 
effect of medication reconciliation as a strategy to minimise DRPs at 
all levels of care for children with kidney disease.  
 
 As health technology is becoming more relevant in today’s healthcare 
system, many studies have been done to study the reliability of the 
eMR in identifying medication safety signals at the primary care level. 
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Patients with kidney disease are frequently seen at the clinics and 
frequently admitted due to complications and/or further clinical 
investigations. It would be interesting to investigate the degree of 
discrepancies of information in the eMR and the paper-based medical 
charts in identifying medication safety signals at the tertiary care 
setting.  
 
 The thesis also revealed that problems of sub-optimal drug effects 
and drug administration problems identified at the renal outpatient 
clinics were contributed by patient’s poor understanding of treatment 
and difficulties in getting supply of refill prescriptions at the 
community level. Further research is required to investigate whether 
these problems were latent factors resulting in medicine-related visits 
to the emergency department or hospitalisation. It would also be 
important to formulate a comprehensive intervention framework to 
measure the positive effect of a medicine management programme in 
the community. Experience from this research would highly suggest 
the need for proper financial and human resources in order to 
formulate a comprehensive intervention model at the outpatient 
setting.  
 
 The consumption of financial and human resources as well as the 
healthcare professionals’ time required in identifying and resolving 
DRPs were not part of this research objective. Future research could 
include the economic impact of managing DRPs for children with 
kidney disease.     
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7.8 Research contributions 
What is already known on this topic? 
 Drug-related problems may lead to significant drug-related morbidity 
and mortality  
 There is a lack of epidemiology data on DRPs in children with kidney 
disease at the tertiary care  
What this research adds? 
 Epidemiology data on the characteristics (incidence, risk factors, 
severity, types, contributory factors and resolutions rate) of DRPs  
 Strategies to identify, prevent and solve DRPs  
 Potential tools that could be used for the identification and 
classification of DRPs in clinicians’ practice  
 Strategies to improve the conduct of observational and interventional 
research in pharmacy practice  
in children with kidney disease at the inpatient and outpatient setting. 
 
7.9 Conclusion  
This research has successfully filled in the gap in the knowledge of DRPs in 
nephrology paediatric patients. This thesis compiles the epidemiological 
data on DRPs in children with kidney disease that was investigated using 
with mixed methodological approaches and a standard definition as well as 
  
260 
 
classification system for DRPs. This thesis also investigated the impact of CP 
interventions  at the renal outpatient clinic. The DRPs in children with 
kidney disease are different to those in adults but share similar 
characteristics with the general paediatric population. DRPs in children with 
kidney disease at inpatient level differ to those seen in renal outpatient 
clinics. Therefore, strategic approaches should be tailored to meet 
requirements of different hospital settings.   
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Appendix 1  Overview of the classification system  for drug-related problems from 1990 to 2010 
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Strand classification 
(Strand et al., 1990) 
Drug-related problem 
This is the first DRP classification that 
became the foundation of new 
classifications.  
Y 
An event or 
circumstance involving 
drug therapy that 
actually or potentially 
interferes with the 
patient’s experiencing 
an optimum outcome 
of medical care 
8 N N N N Y 
American Society of 
Hospital Pharmacists 
(ASHP) guideline, 1996  
Medication-related problem  
This system was part of a published 
guideline for a standardised 
Y 
An event or 
circumstance involving 
13 N I N N Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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) 
 
(ASHP, 1996)  
 
pharmaceutical care. Prior to this, in 
1993 ASHP adapted the classification 
derived by Strand et al., 1990.   
 
medication therapy 
that actually or 
potentially interferes 
with an optimum 
outcome for a specific 
patient 
 
Westerlund classification, 
1996 
 
(cited in van Mil et al., 
2004) 
Drug-related problem 
This system included intervention 
classification and manual for its use. It 
was developed as part of a Ph.D thesis 
and was first used in 1996. This 
system underwent minor amendments 
prior to incorporation into nationwide 
Swedish pharmacy software. 
 
Y 
A drug-related 
problem is a 
circumstance related 
to patient’s use of a 
drug, that actually or 
potentially prevents 
the patient from 
gaining the intended 
benefit of the drug 
 
13 N I Y Y Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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 p
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c
e
) 
Problems-Assessment- 
Solutions (PAS) System 
(van Mil and Thromp, 
1997)  
No specific term for DRP was 
introduced 
This classification system was originally 
developed to document patients’ 
questions on their drug therapy, not to 
classify all DRPs.  
 
N 5 Y Y Y Y N 
Cipolle et al., 1998  
 
(cited in Fernandez-
Llimos et al., 2004, pg 
3957) 
Drug therapy problem  
Drug-related problems in this system 
did not include potential problems and 
thus can only be employed when an 
event has already been experienced by 
the patient. Used in many community 
pharmacies in the US to evaluate 
pharmacists’ activities in their daily 
provision of pharmaceutical care.  
Y 
Any desirable event 
experienced by the 
patient that involves 
or is suspected to 
involve drug therapy 
and that actually or 
potentially interferes 
with desired patient 
outcomes 
 
7 N N N Y Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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e
) 
Granada classification  
1st consensus 1998 
2nd consensus 2002 
3rd consensus 2007 
 
(Granada Consensus 
Committee, 2002; 
Granada Consensus 
Committee, 2007) 
 
 
 
Drug therapy problem and later 
changed to Negative health 
outcome associated with 
medications  
 
 
  
Y 
Health problem that 
are considered as 
negative clinical 
outcomes, resulting 
from 
pharmacotherapy, 
that for different 
reasons, either do not 
achieve therapeutic 
objectives, or produce 
undesirable effect 
6 N I N N Y 
PCNE classification, 1999  
 
 
Medicine-related problem and later 
changed to Drug-related problem 
This system was developed in 1999 by 
pharmacy practice researchers during 
a working conference of the 
Pharmaceutical Care Network Europe 
Y 
A drug related 
problem is an event or 
circumstance involving 
drug therapy that 
actually or potentially 
6 Y Y N Y Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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 p
ra
c
ti
c
e
) 
(PCNE) in an effort to develop a 
standardised classification system that 
is suitable and comparable for 
international studies. This was the first 
classification scheme that introduced a 
hierarchical structured system with a 
clear definition of DRP. It comprised 
separate codes for problems, causes 
and interventions. In the 2nd version, 
The word ‘medicine’ was changed to 
‘drug’.  The latest version is 6.2 
introduced in 2010.  
 
interferes with desired 
health outcomes 
The ABC of DRPs, 2000 
 
(Meyboom et al., 2000) 
Drug-related problem 
Problems were separated from dose-
unrelated problems and appropriate 
use from inappropriate use. This 
classification system was created for 
N 3 N I N N N 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
N
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b
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r 
o
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m
a
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c
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g
o
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e
s
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b
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u
s
a
b
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 i
n
 p
ra
c
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c
e
) 
use in the World Health Organisation 
(WHO) and focuses on side effects and 
adverse reaction.   
 
Krska classification, 2001 
 
(Krska, et al., 2001)  
Pharmaceutical care issue 
This classification system was 
developed during a drug-use 
evaluation research involving 332 
patients. 
Y 
Pharmaceutical care 
issue is an element of 
a pharmaceutical care 
need which is 
addressed by the 
pharmacist 
 
13 N N N I Y 
Mackie classification, 
2002  
 
(cited in van Mil et al., 
2004)  
Clinical drug-related problem 
Adapted from a classification system 
introduced by Cipolle et al., (1998). 
This classification system was 
generated based on the authors’ 
research on a random sample of 50 
Y 
A clinical drug-related 
problem is considered 
to exist when a 
patient experiences or 
is likely to experience 
13 N N N N Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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) 
patients with one or more DRP. either a disease or 
symptom having an 
actual or suspected 
relationship with drug 
therapy 
Problem-Intervention 
Documentation (PI-DOC), 
2002 
 
(Schaefer, 2002)  
 
Drug-related problem 
Hierarchical system for problem-
intervention documentation developed 
in Germany with emphasis on the user-
friendliness in community pharmacy 
practice. The first study that used PI-
Doc classification was published in 
1995. Implemented in most German 
pharmacy-software systems. Also used 
in a study in Denmark with a slightly 
modified format. Subcategories 
indicate the causes of DRP.  
 
N 6 Y I N Y Y 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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c
e
) 
National Coordinating 
Council for Medication 
Error Reporting (NCC-
MERP) Taxonomy of 
Medication Errors, 2003 
 
(NCC-MERP, 2003) 
 
 
Drug-related problem 
 
Definition of DRP in this system is 
process-oriented and focuses on 
injectable administration of drug in 
non-ambulatory settings. The error 
section includes errors (potential DRPs) 
that do not become relevant for the 
patient.  This is a hierarchal 
classification that separated the 
problems from the causes but does not 
provide clear intervention taxonomy.  
 
Y 
Any preventable event 
that may cause or 
lead to inappropriate 
medication use or 
patient harm while the 
medication is in 
control of the health 
care professional, 
patient or consumer 
 
14 N I N Y Y 
Health Base Foundation 
Subjective Evaluation 
Plan (SHB-SEP), 2003 
 
(cited in van Mil et al., 
No specific term for DRP was 
introduced 
Developed by the Health Base 
Foundation in Netherland for use in 
pharmacy software. Based upon 
N 
 
10 Y Y N Y N 
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   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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) 
2004) medical SOEP 
(Subjective/Objective/Evaluation/Plan). 
The S and O codes have been 
combined into one problem 
description. This system is still in use 
but each updated version is not 
sequentially numbered to facilitate 
differentiation from previous versions.  
Gordon classification, 
2005 
 
(Gordon et. al., 2005)  
Medication-related problems  
A tool to identify medicine related 
problems from patients’ perspective at 
the community settings.  
 
Y 
Any problem 
experienced by a 
patient that may 
impact on their ability 
to manage or take 
their medicines 
effectively 
9 N N Y N Y 
AbuRuz classification, 
2006 
Treatment-related problems 
 
Y 
An event or 
6 Y Y Y Y Y 
APPENDICES 
 
293 
 
   *DRP classification criteria 
Classification system 
Term for drug-related problem (or 
other similar terms) 
Is this classification 
system based on clear 
definition for drug-
related problem (or 
other similar terms)? 
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) 
  
(AbuRuz et al., 2006)  
 
This classification system was 
developed as a tool for use in teaching, 
practicing and researching 
pharmaceutical care and to improve 
identification, resolution and 
prevention of treatment-related 
problems in Jordan.  
circumstances 
involving patient 
treatment that 
actually or potentially 
interferes with an 
optimum outcome for 
a specific patient 
I = cause integrated in the problem description; Y = yes; N = no  
*DRP Classification criteria as suggested by van Mil et al., 2004 
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Appendix 2  List of search terms and literature search strategy 
Search terms for 
‘Drug related problem’ 
 A
N
D
 
Search terms for 
‘Paediatric’  
A
N
D
 
Search terms for  
‘Chronic kidney disease’ 
"adherence"  
 
“adverse drug event(s)"  
 
"adverse drug reaction(s) reporting 
systems” 
 
"compliance"  
 
"drug toxicity" 
 
"drug eruptions" 
 
"non-adherence"  
 
"noncompliance"  
 
"non-compliance"  
 
"drug related problem(s)"  
 
OR 
 
OR 
 
OR 
 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
 "adolescent(s)"  
 
"adolescence" 
 
"child"   
 
"children"  
 
"juvenile"  
 
"neonatology" 
 
"Pediatric nursing"  
 
"paediatric(s)" 
 
"pediatric(s)"  
 
"teenager(s)"  
 
"preschool"  
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 "acute kidney 
disease"  
 
"acute renal disease"  
 
"acute kidney failure" 
 
"acute renal failure"  
 
"chronic kidney 
failure"  
 
"chronic renal 
disease"  
 
"chronic renal failure" 
 
"dialysis" 
 
"end stage kidney 
disease"  
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 APPENDICES 
 
295 
 
Search terms for 
‘Drug related problem’ 
 A
N
D
 
Search terms for 
‘Paediatric’  
A
N
D
 
Search terms for  
‘Chronic kidney disease’ 
"drug-related problem(s)"  
 
"drug therapy problem(s)"  
 
"drug-therapy problem(s)" 
  
"medication error(s)" 
 
"medication therapy management"  
 
"medicine related problem(s)"  
 
"medicine-related problem(s)"  
 
"pharmaceutical care" 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
 
 
 
 
 
 
 
 
 
"preschool child"  
 
"preschool 
children"  
 
"youth(s)"  
 
 
OR 
 
OR 
 
OR 
 
OR 
 
 
"end-stage kidney 
disease"  
 
"end stage renal 
failure"  
 
"end-stage renal 
failure"  
 
"end stage kidney 
failure" 
  
"end-stage kidney 
failure"  
 
"haemodialysis"  
 
"hemodialysis" 
 
"kidney disease"  
 
"kidney failure, 
chronic" 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
 
OR 
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Search terms for 
‘Drug related problem’ 
 A
N
D
 
Search terms for 
‘Paediatric’  
A
N
D
 
Search terms for  
‘Chronic kidney disease’ 
   
"kidney diseases"  
 
"kidney failure"  
 
"nephrology"  
 
"renal failure"  
 
"renal disease" 
  
"peritoneal dialysis"  
 
 
OR 
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Appendix 3  Visual analogue scale for DRP severity assessment 
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Appendix 6  Descriptions of DRPs identified in feasibility study (I) (n=13) 
Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
1 Co-Amoxiclav tablet 
Patient A has acute kidney impairment 
due to acute tubular necrosis. Upon 
discharge, kidney function shows 
improvement. The dosage regimen to 
take away for Co-amoxiclav not 
adjusted to the current kidney profile. 
Pharmacist suggested the BD interval 
be increased to TDS.  
Treatment 
effectiveness 
(Potential) Drug 
effect not 
optimal 
Dose selection 
Dose too low 
Dosage regimen 
not frequent 
enough 
Drug level 
Changed dosage 
Totally solved 
2 Hydralazine 25mg tablet 
Patient B has severe hypertension due 
to vascular disease and will undergo 
vascular surgery on day 3 of 
admission. Blood pressure is stable on 
4 types of antihypertensives: Atenolol 
50mg OD, Clonidine 25ug OD, 
Doxazosin 3mg OD (increased from 
2mg), Hydrazaline 9.4mg BD and 
Treatment 
effectiveness 
(Potential) 
Wrong effect of 
drug 
Drug selection 
Too many drugs 
for indication 
Drug level 
Drug stopped 
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
Amlodipine 5mg OD.  Pharmacist 
suggests to review antihypertensives 
pre-operatively to prevent drug-
induced intra-op hypotension. Atenolol 
50mg is withheld on the night before 
surgery.  
3 Atenolol 25mg tablet 
Patient B has severe hypertension due 
to vascular disease and will undergo 
vascular surgery on day 3 of 
admission. Blood pressure is stable on 
4 types of antihypertensives; Atenolol 
50mg OD, Clonidine 25ug OD, 
Doxazosin 3mg OD (increased from 
2mg), Hydrazaline 9.4mg BD and 
Amlodipine 5mg OD.  Pharmacist 
suggests to review antihypertensives 
pre-operatively to prevent drug-
induced intra-op hypotension. 
Clonidine 25ug is withheld on the night 
Treatment 
effectiveness 
(Potential) 
Wrong effect of 
drug 
Drug selection 
Too many drugs 
for indication 
Drug level 
Drug stopped 
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
before surgery. 
4 Doxazosin 4mg tablet 
Patient B has severe hypertension due 
to vascular disease and will undergo 
vascular surgery on day 3 of 
admission. Blood pressure is stable on 
4 types of antihypertensives: Atenolol 
50mg OD, Clonidine 25ug OD, 
Doxazosin 3mg OD (increased from 
2mg), Hydrazaline 9.4mg BD and 
Amlodipine 5mg OD.  Pharmacist 
suggests to review antihypertensives 
pre-operatively to prevent drug-
induced intra-op hypotension. 
Doxazosin 3mg is withheld on the 
night before surgery. 
Treatment 
effectiveness 
(Potential) 
Wrong effect of 
drug 
Drug selection 
Too many drugs 
for indication 
Drug level 
Drug stopped 
Totally solved 
5 Clonidine 25 µg tablet Treatment Drug selection Drug level Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
Patient B has severe hypertension due 
to vascular disease and will undergo 
vascular surgery on day 3 of 
admission. Blood pressure is stable on 
4 types of antihypertensives: Atenolol 
50mg OD, Clonidine 25ug OD, 
Doxazosin 3mg OD (increased from 
2mg), Hydrazaline 9.4mg BD and 
Amlodipine 5mg OD.  Pharmacist 
suggests to review antihypertensives 
pre-operatively to prevent drug-
induced intra-op hypotension. 
Hydrazaline 9.4mg is withheld on the 
night before surgery. 
effectiveness 
(Potential) 
Wrong effect of 
drug 
Too many drugs 
for indication 
Drug stopped 
6 Methylprednisolone sodium succinate 
500mg injection 
Patient C is supposed to be on a three-
day course of injections of 
Methylprednisolone 600mg OD for the 
treatment of glomerulonephritis. 
Prescription for injection 
Adverse reaction 
(Potential) Toxic 
adverse event 
Treatment 
duration 
Treatment 
duration too long 
Drug use process 
Drug over-
Drug level 
Changed 
instruction for 
use  
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
Methylprednisolone 600mg OD has 
missing information on treatment 
duration. Pharmacist notifies 
prescriber and suggest adding 
treatment duration to prevent 
prolonged treatment. 
administered 
Logistics 
Prescribing error 
(treatment 
duration not 
mentioned) 
7 Sevelemer 2.4mg sachet 
Patient D is admitted for tenkoff 
catheter insertion. He is on 
maintenance dose of Sevalemer 
600mg TDS. On admission Sevalemer 
is ordered as 2.4g three times daily. 
Pharmacist notifies prescriber of the 
dosing error and suggests correction 
as follows:  Sevalemer 600mg (Take 1 
blue scoop of Sevalemer 2.4g) three 
times daily. 
Adverse reaction 
(Potential) Toxic 
adverse event 
Dose selection 
Drug dose too 
high 
Logistics 
Prescribing error 
(wrong dose) 
Drug level 
Dosage changed 
Changed 
instruction for 
use 
Totally solved 
8 Darbopoetin alpha injection Treatment cost Dose selection Drug level Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
Patient D is admitted for tenkoff 
catheter insertion. He is on 
maintenance dose of Darbopoetin 
alpha once a week at every alternate 
week. Darbopoetin alpha is prescribed 
for continuation on admission; 
however, there was no clear 
information on his exact dose and 
dosing schedule. The pharmacist 
checked with carer who keeps a drug 
diary and confirms the dose of 2000 
units to be given every alternate week 
on Thursdays starting in the coming 
week instead of the present week. 
(Potential) more 
than necessary 
Dosage regimen 
too frequent 
 
Drug use process 
Drug over-
administered 
Logistics 
Prescribing error 
(treatment 
duration not 
mentioned) 
Dosage changed 
Patient level 
Talked to family 
member 
(mother) to 
obtain drug 
history 
 
9 Dailyvit tablet 
Patient E is on Dailyvit tablet OD. 
During this current admission, Dailyvit 
is temporarily out of stock. Pharmacist 
informs prescriber and suggests 
Ketovite as an alternative. 
Treatment 
effectiveness 
(Potential) 
Untreated 
indication 
Drug use process 
Patient gets drug 
at wrong time 
(delayed 
administration 
time because 
prescribed drug 
Drug level 
Dosage changed 
 
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
(or its 
alternative) is 
not available 
Logistics 
Prescribed drug 
not available 
10 Dailyvit tablet 
Patient F is on Dailyvit tablet OD. 
During this current admission, Dailyvit 
is temporarily out of stock. Pharmacist 
informed prescriber and suggested 
Ketovite as alternative.  
 
 
Treatment 
effectiveness 
(Potential) 
Untreated 
indication 
Drug use process 
Patient gets drug 
at wrong time 
(delayed 
administration 
time because 
prescribed drug 
(or its 
alternative) is 
not available 
Logistics 
Prescribed drug 
Drug level 
Dosage changed 
 
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
not available 
11 Total parenteral nutrition  
Patient G is on total parenteral 
nutrition (TPN). At almost 12 noon, 
the new TPN formulation is not yet 
finalised, pending the latest blood test 
result (request for TPN must reach the 
lab before 12 noon for compounding). 
Pharmacist reminds the prescriber to 
put up a TPN request, then suggests 
the most optimal formulation in a 
short discussion and passes the TPN 
order form to the lab for 
compounding.  
Treatment 
effectiveness 
(Potential) 
Untreated 
indication 
Logistics 
Prescribed drug 
not available 
Drug level 
Formulation 
changed 
Totally solved 
12 Total parenteral nutrition  
Patient H is on total parenteral 
nutrition (TPN). The clinical team 
decides to increase calorie content of 
TPN once G has started haemodialysis. 
On the actual day, no changes are 
Treatment 
effectiveness 
(Potential) 
Untreated 
indication 
Dose selection 
Drug dose too 
low 
Drug level 
Changed 
formulation 
Totally solved 
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Case 
number 
Drug 
Description of drug-related problem 
Problem type 
Main & sub -
categories 
Possible causes 
by sub-
categories 
Level of actions Outcome for 
actions 
made to the formulation. Pharmacist 
notifies prescriber and suggests new 
formulation.  
13 Ranitidine syrup is ready to be 
dispensed. The pharmacist notices that 
it is not supposed to be prescribed for 
the patient and prevents it from being 
dispensed.  
 
Treatment 
effectiveness 
(Potential) 
Untreated 
indication 
Drug selection 
No indication for 
drug 
Logistics 
Dispensing error  
 
Other level 
Pharmacy level  
Totally solved 
OD – Once daily                                         
BD – Twice daily                                              
TDS – Three times daily 
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Appendix 7  Operational definition for the adapted PCNE DRP classification version 6.2 
Main Category: Types of 
DRPs 
Codes Sub-categories Operational definition 
Drug effect 
 
P1  There is a (potential or manifested) problem with the 
(lack of) effect of the pharmacotherapy. 
P1.1 No effect of treatment/therapy 
failure 
There is neither improvement nor worsening of 
patient’s symptoms.  
P1.2 
 
Sub-optimal drug effect 
 
There is improvement in patient’s symptoms but not 
to the intended target.  
P1.3 
 
Wrong effect of drug treatment 
 
NA 
P1.4 Untreated indication There is a symptom (or an anticipated symptom) 
requiring drug therapy that is not treated 
Adverse drug events P2  Patient suffers, or will suffer, from an adverse drug 
event 
P2.1 
 
 
Non-allergic adverse reaction 
 
An unintended pharmacological effect from an adverse 
drug event not suspected as allergic reaction (or toxic 
effect) commonly known to be related to the 
prescribed drug at doses normally used for the 
intended indication (e.g. side effects, intolerable 
intended pharmacological effect, e.g. hypotension 
from the use of an antihypertensive agent) 
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Main Category: Types of 
DRPs 
Codes Sub-categories Operational definition 
P2.2 
 
Allergic drug reaction  An unintended pharmacological effect from an adverse 
drug event suspected as an allergy reaction or 
toxicity; commonly known to be related to the 
prescribed drug at doses normally used for the 
intended indication (e.g. rash and Penicillin). 
P2.3 Toxic adverse reaction An unintended pharmacological effect related to the 
drug at doses higher than maximum dose normally 
used for the intended indication or adverse effect 
cause by accumulated doses. 
Treatment costs 
 
P3  The drug treatment is more expensive than necessary 
P3.1 Drug treatment more costly 
than necessary 
There is an alternative drug that is cheaper but not 
being used 
P3.2 Unnecessary drug treatment The drug that is newly (or previously) prescribed is 
not required (or no longer required) 
Other P4  Other causes not specified above 
P4.1 
 
Patient dissatisfied with 
therapy despite optimal clinical 
and economic treatment 
outcomes 
* 
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Main Category: Types of 
DRPs 
Codes Sub-categories Operational definition 
 P4.2 Drug administration 
problems 
Difficulties in administering the appropriate drug at 
the correct doses to the intended patient (e.g. 
Paracetamol suppository 540mg was prescribed but 
the preparation available at the dispensary is 240mg 
suppository; incomplete instructions for drug 
administration; any circumstance that hinders drug 
administration)  
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
Drug selection 
 
C1  The cause of the DRP is related to the selection of 
drug 
 C1.1 
 
Inappropriate drug (including 
contra-indication) 
 
The wrong drug is selected or the selected drug is 
contraindicated for the patient. 
Wrong drug is, for example, a patient who is supposed 
to be on antibiotic A, but is administered antibiotic B. 
Contraindicated drug use is, for example, a patient 
received a drug to which s/he had previously 
experienced an allergy reaction 
 C1.2 Inappropriate combination of 
drugs 
 
The selected drug interacts (or has the potential to 
interact) with another drug(s), food or device  
 
 C1.3 
 
Inappropriate duplication of 
therapeutic group or active 
ingredient 
More than one drug of the same therapeutic group or 
active ingredient is used concurrently 
 C1.4 
 
Indication for drug treatment 
not noticed 
The drug that is indicated to treat a symptom is not 
used because the existence of the symptom is not 
noticed 
 C1.5 
 
Too many drugs prescribed for 
an indication 
 
More than the necessary drugs are used for treating 
the same symptom(s) 
 
 C1.6 
 
More cost-effective drug 
available 
 
An alternative drug that is cheaper and as effective 
(or more effective) is not used 
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
 C1.7 
 
Synergistic/preventive drug 
required and not given 
 
A drug that is required to enhance the existing 
treatment (synergistic effect) or to prevent the 
development of another symptom is not used 
 C1.8 New indication for drug 
treatment presented 
The drug has a new indication that requires change of 
dosing regimen (e.g. steroid maintenance dose in post 
transplantation and pulse doses in acute rejection) 
Drug form C2  Inappropriate drug form 
C2.1 Inappropriate drug form Inappropriate drug form and/or formulation 
Dose selection C3  The cause of the DRP is related to the selection of the 
dosage schedule 
C3.1 
 
Drug dose too low 
 
Dose is insufficient to achieve the therapeutic 
outcome 
C3.2 
 
Drug dose too high 
 
Dose is more than necessary to achieve the 
therapeutic outcome 
C3.3 
 
Dosage regimen not frequent 
enough 
 
Dosing frequency is insufficient to achieve the 
therapeutic outcome 
C3.4 
 
Dosage regimen too frequent 
 
Dosing frequency is more than necessary to achieve 
the therapeutic outcome 
C3.5 
 
No therapeutic drug 
monitoring 
 
Serum level for drug with narrow therapeutic index 
not monitored 
C3.6 
 
Pharmacokinetic problem 
requiring dose adjustment 
Changes in renal function requiring dose adjustment  
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
C3.7 
 
 
Deterioration/Improvement of 
disease state requiring dose 
adjustment 
 
Changes to disease state requiring dose adjustment 
C3.8 Dose difficult to measure Prescribed dose is difficult to measure 
Treatment duration C4  The cause of the DRP is related to the duration of 
therapy 
C4.1 
 
Treatment duration too short 
 
Treatment duration is shorter than necessary 
C4.2 Treatment duration too long Treatment duration is longer than necessary 
Medication errors 
 
C5  Mishaps or accidents during any stage of drug 
handling, prescribing, transcribing, dispensing 
and administering 
C5.1 
 
Inappropriate timing of 
administration and/or dosing 
intervals 
 
Error in the process of drug administration  
C5.2 
 
Drug underused/under-
administered  
 
Error in the process of drug administration 
C5.3 
 
Drug overused/over-
administered  
 
Error in the process of drug administration 
C5.4 Drug not taken/administered Error in the process of drug administration 
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
 at all 
 
C5.5 
 
Wrong drug 
taken/administered 
 
Error in the process of drug administration 
C5.6 
 
Drug abused (unregulated 
overuse) 
 
* 
C5.7 
 
 
Patient unable to use 
drug/drug form as directed 
 
Moved to category Patient factor (C7.5) 
C5.8a 
 
Prescribing error in 
decision making 
 
Error in deciding for treatment 
C5.8b Prescribing error in 
prescription writing  
Error in writing prescription 
C5.9 Dispensing error Error in dispensing the prescribed drug 
C5.10 Dilution error Error in the process of diluting a drug to its prescribed 
concentration  
Drug supply C6.1 
 
Prescribed drug not available 
 
Prescribed drug not available for use 
 
Patient factor C7  The cause of the DRP can be related to the personality 
or behaviour of the patient. 
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
C7.1 
 
Patient forgot to use/take drug 
 
* 
C7.2 
 
Patient used unnecessary drug 
 
* 
C7.3 
 
Patient took food that interacts 
with the prescribed drug(s) 
 
* 
C7.4 Patient stored drug 
inappropriately 
* 
C7.5 Patient refused to take the 
drug 
* 
C7.6 Patient unable to use the drug * 
Others C8  Other causes not specified above 
C8.1 Poor medication 
reconciliation 
 
Discrepancies between patient’s own drugs with the 
ones prescribed on admission. 
Discrepancies between drugs planned to take home 
and the ones on Discharge Prescriptions  
C8.2 
 
Unwanted side effects 
 
Known undesirable effect of a drug other than the 
intended therapeutic effects 
C8.3 Inappropriate drug 
administration site/route 
Wrong site and/or route for the prescribed drug 
 
Main Category: Intervention Codes Sub-categories Operational definition 
I0: No intervention I0 No intervention No intervention 
I1: At prescriber level I1.1 Prescriber informed only Note: In this research, pharmacist encounters with 
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
I1.2 
I1.3 
 
I1.4 
 
I1.5 
Prescriber asked for 
information 
Intervention proposed, 
approved by prescriber 
Intervention proposed, not 
approved by prescriber 
Intervention proposed, 
outcome unknown 
the prescriber were seen as a process that precedes 
an intervention rather than a type of intervention (see 
discussion) 
I3: At drug level I2.1 
 
Drug changed to… 
 
Changes to the selection of drug 
I2.2 
 
Dosage changed to… 
 
Changes to the prescribed dose  
I2.3 
 
Drug form/formulation 
changed to… 
 
Changes to the types of drug formulation 
I2.4 Instructions for use changed 
to… 
 
Changes to the instruction on using the drug (e.g. 
drug dilution).  
I2.5 Drug stopped 
 
The prescribed drug was stopped  
I2.6 New drug started A new drug prescribed  
I2.7 Dosing frequency changed 
to… 
Changes to the dosing frequency  
 I2.8 Route/site of administration Changes to the route or site of administration 
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Main Category: Contributory 
factors for DRPs 
Codes Sub-categories Operational definition 
changed to… 
 I2.9 Treatment duration changed 
to… 
Changes to the number of days in the treatment 
 I2.10 Request for serum drug level * 
I3: At patient/carer level I3.1 
 
Patient (medication) 
counselling 
 
Counselling on drug treatment  
I3.2 
 
Written information provided 
only 
 
* 
I3.3 
 
Referred patient to prescriber  The solution of the DRP requires referral to prescriber 
for further action  
I3.4 
 
Family members spoken to Discussion with family members/carer to solve 
problems 
I4: Interventions of other 
levels 
I4.1 
I4.2 
Other intervention (specify) 
Side effect reported to 
authorities 
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Main Category:   
Outcome of the 
interventions 
Codes Sub-categories Sub-categories 
O0: Not known O0.0 Outcome intervention not 
known 
Outcome intervention not known 
O1: Solved O1.0 Problem totally solved Problem is solved not requiring further interventions 
O2: Partially solved O2.0 Problem partially solved The problem is temporarily solved and requires further 
intervention 
O3: Not solved O3.1 Problem not solved, lack of 
cooperation from patient 
 
* 
 
 O3.2 
 
Problem not solved, lack of 
cooperation from prescriber 
 
* 
 
 O3.3 
 
Problem not solved, 
intervention not effective 
 
* 
 
 O3.4 No need or possibility to solve 
problem 
* 
The new category/sub-category introduced or modified are in bold 
Operational definition that were not adapted from the original classification are in italics 
*Self-explanatory  
NA – Not applicable because the CPs were not comfortable in using the term  
Potential DRPs: Drug problems identified before the problem occurred/patient experienced harm 
Manifested DRPs: Drug problems identified after the problem had occurred/patient experienced harm 
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Appendix 8  Drug-related problem registration form (DRP-Rf)
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Appendix 9  Study information leaflet for healthcare providers (Inpatient) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACY RESEARH PROJECT IN PAEDIATRIC NEPHROLOGY UNITS AT  
GREAT ORMOND STREET HOSPITAL AND EVELINA CHILDREN’S HOSPITAL 
For circulation to healthcare providers 
 
 Who do I speak to if  I have further enquiries, 
suggestions or complaints? 
For enquiries and suggestions, please contact the 
researcher, Ms Nor Ibrahim, by phone on  
020 7874 1531 or by email on 
norkasihan.ibrahim@live.pharmacy.ac.uk 
 
If you have any complaints about the way in which this 
study is being or has been conducted, please discuss 
them with Ms Nor Ibrahim in the first instance. If the 
problems are not resolved, or you wish to comment in 
any other way, you may contact:-  
 
Professor Ian C.K Wong, Director  
The Centre for Paediatric Pharmacy Research (CPPR) 
The School of Pharmacy, University of London 
Tel: 020 7874 1530 extension 1535 
Email: ian.wong@pharmacy.ac.uk 
 
Dr Yogini Jani, Chief Investigator 
The Centre for Paediatric Pharmacy Research (CPPR) 
The School of Pharmacy, University of London 
Tel: 084515555 extension 5000/73509 
Email:  yogini.jani@pharmacy.ac.uk  
 
Patient Advice and Liaison Service (PALS): 
1) Great Ormond Street Hospital for Children 
Tel: 020 7829 7862  
2) St Thomas' Hospital 
Tel: 020 7188 7188 
 
Why is it  important to understand the nature of DRP in 
children with CKD?  
The incidence of CKD in children has steadily increased and 
it is known to be one of the most common chronic illnesses 
in childhood. It demands lifelong health care and future solid 
organ transplantation. The management of drug therapy for 
patients with kidney disease is specialised and complex puts 
this group of children at risk of DRPs. Examples of DRPs are 
adverse drug reactions, inadequate or toxic drug effect, 
therapy failure, increased cost of healthcare and patients’ 
poor adherent to treatment. Each of these may contribute to 
the progression CKD. 
 
How wil l this study affect my dai ly work? 
Your work is unlikely to be affected. 
 
 How will i t be conducted? 
Throughout this study, a pharmacy PhD student will collect 
information about DRPs by observing ward pharmacists 
perform their daily ward rounds. The PhD pharmacy student 
will suggest intervention only in the situation that a DRP with 
the possibility of harming the patient is not otherwise 
identified. The presence of the researcher will be as discrete 
as possible so as not to interfere with the work of the ward 
pharmacist and other ward staff. 
What is a DRP? 
A drug-related problem (DRP) is also known as a 
medicine-related problem or medication-related 
problem. By definition, a DRP is “An event or 
circumstance involving drug therapy that actually or 
potentially interferes with desired health outcomes”.  
 
 
What is the aim of the study? 
The global challenge in nephrology is to shift the 
emphasis of treating kidney disease from providing 
more kidney replacement therapy to early detection 
and prevention of progressive chronic kidney 
disease (CKD). Pharmaceutical care has an 
important role to play in achieving this target. It is 
crucial to investigate the DRP component to 
complement the impact of medical intervention. 
Studies of DRPs in CKD so far have only been 
performed in adults and little is known of their 
epidemiology in children. Hence, the aim of this 
study is to investigate the epidemiology of DRPs in 
paediatric patients with CKD. 
 
How long is the study period?  
This study will be conducted from 1st September 
2011 to 30th September 2012. 
 
 
 
Drug Related Problems (DRP) 
in paediatric patients with chronic kidney disease 
Leaflet for circulation to healthcare providers   V1.1/11072011 
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Appendix 10  Study invitation: Cover letter 
 APPENDICES 
 
330 
 
Appendix 11  Study Information Leaflet for parents 
 
Information about the research – for parent (carer)/ Protocol V2-02112012/ 12/LO/0709 
 
 
Page 1 of 4 
 
 
 
Medicine-related Problems in Children with Chronic Kidney Disease 
An Invitation 
We would like to invite you and your child to take part in our study. 
 
Before you decide we would like you to understand why the study is being done and what it would involve for you 
and your child.  We would suggest this should take about 5 minutes. 
 
Part 1 tells you the purpose of this study and what will happen if you and your child take part. Part 2 gives you more 
detailed information about the conduct of the study. 
 
Two weeks after the postage of this study material, we will phone you to see if you have received the postage and 
whether you are interested in taking part. 
 
Talk to others about the study if you wish.  A member of our team will go through the information sheet with you at 
the clinic and answer any questions you have.  You  can  tell  us   your  de ci sion  du ring  your  child’s  ne x t  re nal  clinic  
appointment.  Please ask us if there is anything that is not clear. 
 
PART 1 – This section provides information on the purpose of the study and what will happen to you and your 
child as study participants. 
 
What is the purpose of our study? 
Our study is to answer two questions – (1)  ‘What  types of problems related to the use of medicines are faced by 
children with chronic kidney disease (CKD) and does having a medication review (MR) programme by clinical 
pharmacist  at  the  renal  clinic  helps  in  resolving  the  problems?’ and (2) ‘Does MR programme help in achieving a 
better blood pressure control in children with chronic kidney disease who  ha s  be en  di agnosed  hypertension?’   
 
Similar studies conducted in the adult group have shown that patients in CKD are more likely to have problems with 
their medications.  Efforts  to  manage  these  problems  have  shown  positive  effects  to  patient’s  treatment  outcome.  
Such information is not available for children. Currently, we are assuming children shares similar problems and 
solutions; this assumption may not be valid. 
 
What  does  the  term  ‘medicine-related  problems’  in  the  title  mean?   
A medicine-related problem (MRP) is an event or circumstance involving medication therapy that actually or 
potentially interferes with desired health outcomes. Medicine-related problem includes adverse reactions, allergy, 
medication error and undesired experience caused by medicines such as side effects, drug-drug or drug-food 
interaction, unpalatable taste or formulation, administration problem and difficulties in obtaining supplies to name a 
few. 
 
What does the  term  ‘chronic  kidney  disease’  and  ‘medication  review’  mean  in the title? 
Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as normal. A person 
with CKD may or may not yet be on dialysis, and this includes those who have undergone kidney transplantation. 
Medication Review  is  a  holistic  review  of  patient’s  medication  with  patient’s  underlying  condition.  This  activity  is  
focused on identifying actual and potential problems related to the use of medicines that  may  compromise  patient’s  
treatment outcome.   
 
Why have you and your child been invited? 
You and your child are invited into this study because your child has been prescribed with medicines for the kidneys. 
As medicines for children with CKD are sometimes complex, we would like to know if your child is having problems in 
taking them as prescribed.  
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Information about the research – for parent (carer)/ Protocol V2-02112012/ 12/LO/0709 
 
 
Page 2 of 4 
 
Do you and your child have to take part? 
It is up to you and your child to decide. We will call you two weeks after posting this study material to ask whether 
you are interested to participate. If you do, we will go through this information sheet at the clinic when you come for 
the next renal clinic appointment. When you have decided to participate, we will ask you to sign a consent form. We 
will also seek agreement (assent) from your child. You and your child are free to withdraw at any time, without 
giving a reason. This would not affect the standard of care your child receives. 
 
What will happen to me and my child if I take part? 
When you  have  given  a  signed  consent,  the  researcher  will  screen  through  your  child’s  medical  notes  to  identify  any  
medicine-related problems. Participants will then be assigned into two groups – the pharmaceutical care group and 
the standard care group. To make sure the groups are the same to start with, each patient is put into a group by 
chance (randomly). There is a 50% chance for you to be assigned in either of the groups. 
 
If you fall in to the pharmaceutical care group, you and your child will receive pharmaceutical care service whilst 
waiting to see the doctor. This service is a 20-minute session with the clinical pharmacist. During this session, the 
clinical pharmacist will review the medication and ask questions to determine: 
 
•  An  ac c urate  list of your child’s long term medications 
•  How  your  c
h
i ld  is  ge t ting  on with the medications and whether there is   
 any problem in taking them as prescribed.  
 
The pharmacist will then summarise the problems your child may have in regards to medications and provide 
appropriate recommendations to the doctor on a note that will be placed in the medical file. The doctor will then 
discuss the matter with you to decide if there is a need for changes to your child's current medications or other 
possible resolution (when required). Other than meeting the clinical pharmacist, you are not expected to do 
anything  extra  ap a rt  from  the  usual  ro utine  during  your  ch i ld’s  re nal  cl inic  ap p ointments. 
If you fall in to the standard care group, you will follow the normal clinic routine. No new intervention will be 
introduced to the usual routine during your child’s  renal clinic appointments.  
 
We will measure and compare the types and numbers of medicine-related problems that may have the potential to 
compromise  patient’s  treatment  in both groups. If your child has a diagnosis of hypertension, we will trace the blood 
pressure level from the medical notes four weeks afterward.  Your child is not required to come for any extra visit to 
the hospital for this purpose.  
 
Please refer to the flow chart at the end of this sheet to gain a better understanding about the process of this 
research. 
 
How much time will this involve? 
The  whole  process  will  take  place  during  your  child’s  renal  clinic  appointment day. The session with the clinical 
pharmacist is approximately 20 minutes.  
 
What will my child and I need to do? 
You are not expected to do anything more than what is required from your normal routine at the renal clinic. If you 
are assigned to the pharmaceutical care group, you may need to facilitate your child to answer questions about 
his/her medicines during the session with the clinical pharmacist.  
 
What are the possible benefits and risks of taking part?  
We do not see any risk involved with taking part in this research.  We cannot promise the study will help your child 
but the information we get from this study will help improve the medicine management of children with chronic 
kidney disease. We would also like to use the results of this study to improve pharmacy services for renal patients at 
the outpatient setting. All information will be kept confidential and only those related to medications are recorded.  
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Information about the research – for parent (carer)/ Protocol V2-02112012/ 12/LO/0709 
 
 
Page 4 of 4 
 
Research flowchart 
 
 
 
 
 
Study information materials will be posted 3 weeks before your next 
clinic appointment 
Two weeks later, we will make a phone call to see if you have 
received the postage and whether you are interested in taking part 
When  you  come  to  re gister  your  child’s  re nal  clinic  ap pointment,  the  
research team will ask about your decision to participate in the study. 
If you decide to take part, you will have to sign the consent form 
The  researcher  will  screen  through  your  ch i ld’s  medical  notes  to  
identify any medication related problems.  You will then be randomly 
assigned to either the Standard Care or the Pharmaceutical Care 
group 
STANDARD CARE group PHARMACEUTICAL CARE group 
The  pharmacist  will  re view  your  child’s  current  
medicines and discuss about problems your child 
may have in taking them as prescribed (this may 
take approximately 20 minutes and will take 
place while you are waiting to see the doctor) 
The pharmacist will then summarise relevant 
information on a note that will be delivered to 
your doctor. The doctor will discuss the matter 
with you to decide if there is a need for changes 
to the medicines or other possible solution  
 
The researcher will evaluate the resolution of the identified problems from documentation in the medical 
notes                          
4 weeks later 
If your child has been diagnosed high blood pressure, we will trace blood pressure level from the medical 
notes. Your child does not have to come for any extra visit to the hospital apart from the scheduled renal 
clinic appointments. 
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Appendix 12  Study Information Leaflet for children aged 16 to 
18 years 
 
Information about the research – for children aged 16 to 18/ Protocol V2-02112012/ 12/LO/0709 
 
 
Page 1 of 4 
 
 
 
Medicine-related Problems in Children with Chronic Kidney Disease  
An Invitation 
We would like to invite you to take part in our study. 
Before you decide we would like you to understand why the study is being done and what it would involve 
for you. We would suggest this should take about 5 minutes.  Part 1 tells you the purpose of this study and 
what will happen to you if you take part. Part 2 gives you more detailed information about the conduct of 
the study. 
Two weeks after the postage of this study material, the researcher will phone you to see if you have 
received the postage and whether you are interested in taking part. Talk to your family, friends, doctor or 
nurses about the study if you wish. You can tell us your decision during your next renal clinic appointment. 
Ask us if there is anything that is not clear.  A member of our team will go through the information during 
your next renal clinic appointment. 
 
PART 1 – This section provides information on the purpose of the study and what will happen to you as study 
participants. 
 
What is the purpose of our study? 
Our study is to answer two questions – (1)  ‘What  types of problems related to the use of medicines are faced by 
children with chronic kidney disease and does having a medication review programme by clinical pharmacist at the 
renal  clinic  helps  in  resolving  the  problems?’  and  (2)  ‘Does  MR  programme  help  in  achieving a better blood pressure 
control  in  children  with  ch r onic  ki dney  di sease  who  ha s  be
e
n   di agnosed  hy p ertension?’   
 
Similar studies conducted in the adult group have shown that patients in CKD are more likely to have problems with 
their  medications.  Efforts  to  manage  these  problems  have  shown  positive  effects  to  patient’s  treatment  outcome.  
Such information is not available for children. Currently, we are assuming children shares similar problems and 
solutions; this assumption may not be valid. 
 
What  does  the  term  ‘medicine-related  problems’  in  the  title  mean?   
A medicine-related problem (MRP) is an event or circumstance involving medication therapy that interferes with 
desired health outcomes. Medicine-related problem includes adverse reactions, allergy, medication error and 
undesired experience caused medicines such as side effects, drug-drug or dug-food interaction, unpalatable taste or 
formulation, administration problem and difficulties in obtaining supplies to name a few. 
 
What  does  the  term  ‘chronic  kidney  disease’  and  ‘medication  review’  mean  in  the  title? 
Chronic kidney disease is a long-term condition where the kidneys do not work as well as normal. A person with CKD 
may or may not yet be on dialysis, and this includes those who have undergone kidney transplantation. Medication 
Review is  a  holistic  review  of  patient’s  medication  with  patient’s  underlying  condition.  This  activity  is  focused  on  
identifying actual and potential problems related to the use of medicines that  may  compromise  patient’s  treatment  
outcome. 
 
Why have you been invited? 
You are invited into this study because you are taking medicines for the kidneys.  As medicines prescribed for 
children with CKD are sometimes complex, we would like to know if you are facing any difficulties in taking them as 
prescribed.  
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Do you have to take part? 
No. It is up to you to decide. We will describe the study and go through this information sheet when you come for 
your next renal clinic. If you agree to take part, we will then ask you to sign a consent form.  You are free to 
withdraw at any time, without giving a reason. This would not affect the standard of care you receive. 
 
What will happen to me if I take part? 
When you have given a signed consent, the researcher will screen through your medical notes to identify any 
medicine-related problems. Participants will then be assigned into two groups – the pharmaceutical care group and 
the standard care group. To make sure the groups are the same to start with, each patient is put into a group by 
chance (randomly). There is a 50% chance for you to be assigned in either of the groups. 
 
If you fall in to the pharmaceutical care group, you will receive pharmaceutical care service whilst waiting to see the 
doctor. This service is a 20-minute session with the clinical pharmacist. During this session, the clinical pharmacist 
will review the medication and ask questions to determine: 
 
•  An  ac c urate  list of your long term medications 
•  How  you are getting on with the medications and whether there is  any problem in taking them as prescribed.  
 
The pharmacist will then summarise the problems you may have in regards to medications and provide appropriate 
recommendations to the doctor on a note that will be placed in the medical file. The doctor will then discuss the 
matter with you to decide if there is a need for changes to your current medications or other possible resolution 
(when required). Other than meeting the clinical pharmacist, you are not expected to do anything extra apart from 
the usual routine during your renal clinic appointments. 
If you fall in to the standard care group, you will follow the normal clinic routine. No new intervention will be 
introduced to the usual routine during your renal clinic appointments.  
 
We will measure and compare the types and numbers of medicine-related problems that may have the potential to 
compromise  patient’s  treatment  in  both  groups.  If  you  have  been  diagnosed  hypertension,  we  will  trace  the  blood  
pressure level from the medical notes four weeks afterward.  You are not required to come for any extra visit to the 
hospital for this purpose.  
 
Please refer to the flow chart at the end of this sheet to gain a better understanding about the process of this 
research. 
 
How much time will this involve? 
The whole process will take place during your renal clinic appointment day.  The session with the clinical pharmacist 
is approximately 20 minutes. 
 
What will I need to do? 
You are not expected to do anything more than what is required from your normal routine at the renal clinic. If you 
are assigned to the intervention group, you will need to answer questions about how you are getting on with your 
medicines during  
the session with the clinical pharmacist.  
 
What are the possible benefits and risks of taking part?  
We do not see any risk involved with taking part in this research.  We cannot promise the study will help you but the 
information we get from this study will help improve the medicine management of children with chronic kidney 
disease. We would also like to use the results of this study to improve pharmacy services for renal patients at the 
outpatient setting. All information will be kept confidential and only those related to medications are recorded. 
Please refer to the flow chart at the end of this sheet to gain a better understanding about the process of this 
research. 
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Research flowchart 
 
 
 
 
 
 
 
Study information materials will be posted 3 weeks before your next 
clinic appointment 
Two weeks later, we will make a phone call to see if you have 
received the postage and whether you are interested in taking part 
When you come to register your renal clinic appointment, the 
research team will ask about your decision to participate in the study. 
If you decide to take part, you will have to sign the consent form 
The researcher will screen through your medical notes to identify any 
medication related problems.  You will then be randomly assigned to 
either the Standard Care or the Pharmaceutical Care group 
STANDARD CARE group PHARMACEUTICAL CARE group 
The pharmacist will review your current 
medicines and discuss about problems you 
may have in taking them as prescribed (this 
may take approximately 20 minutes and will 
take place while you are waiting to see the 
doctor) 
The pharmacist will then summarise relevant 
information on a note that will be delivered to 
your doctor. The doctor will discuss the matter 
with you to decide if there is a need for 
changes to the medicines or other possible 
solution 
The researcher will evaluate the resolution of the identified problems from documentation in the medical 
notes                         
 4 weeks later 
If you are diagnosed high blood pressure, we will trace your blood pressure level from the medical notes. 
You do not have to come for any extra visit to the hospital apart from your scheduled renal clinic 
appointments. 
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An Invitation 
We are asking if you would take part in a research project to understand what problems children who attend the 
renal clinic may have with their medicines.   
Before  you  de cide  if  you  want  to  jo in  in,  it’s  important  to  un derstand  why  the  re search  is  being  do ne  an d   what  it  will  
involve for you.  We will phone your mom and dad in two weeks time to see if you have received this reading 
material and whether you are interested in taking part. So please consider this leaflet carefully.  
Talk about it with your family, friends, doctor or nurse if you want to.  
 
PART 1 – This section should help to give you first thoughts about the project. 
Why are we doing this research? 
When children have health conditions that affect their kidneys, the doctor usually prescribes them medicines. 
Sometimes children may have problems with these medicines. We would like to know what problem these children 
have with their medicines and how pharmacists can help with these. If these children have high blood pressure, we 
would like to know how pharmacists can help to improve blood pressure levels.  
 
What does the research title means?  
A medicine-related problem refers to any undesired effect caused by medicines.  This includes for example allergic 
reaction, unwanted side effects and unpalatable taste. Chronic kidney disease is a condition where the kidneys do 
not work as well as normal. 
 
Why have I been invited to take part? 
You are invited into this study because you are taking medicines for your kidneys. There are approximately 1000 
children with kidney disease in the UK and this is the earliest study to look into problems these children have in 
taking the prescribed medicines.  
 
Do I have to take part? 
No. It is up to you. We will phone your parent (or carer) to see if you have received this material and whether you 
are interested in taking part. If you do, we will answer any questions you have about this study in your next renal 
clinic appointment. If you are still happy to participate, your mom and dad will have to sign the agreement form. You 
will be given a copy of this information sheet and your signed form to keep. You are free to stop taking part at any 
time during the research without giving a reason. If you decide to stop, this will not affect the care you receive.  
What will happen to me if I take part? 
First, you will be assigned to one of two groups. Then, the researcher will read your medical notes.  If you are in 
Group A, you will follow the usual routine during your renal clinic appointments.  
If your name falls in Group B we will invite you, parent(s) for a 20-minute session to meet a clinical pharmacist; this 
will be whilst you are waiting to see the doctor. The clinical pharmacist will review your medical notes and ask you 
several questions to find out if you have any problems with your medicines. The clinical pharmacists will note down 
the problems you may have with your medicines. Later on, the doctor will discuss with you, mom and dad on the 
best solution for the problems you have with your medicines. Other than meeting the clinical pharmacist, you are 
not expected to do anything extra from the usual routine during your renal clinic appointments. 
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Who do I speak to if I have further enquiries, suggestions or complaints?  
If you have any enquiries, suggestions or complaints about the way in which this study is being or has been 
conducted please contact the research team: 
 
 
Mrs Nor Ibrahim Researcher  
E: norkasihan.ibrahim.11@ucl.pharmacy.ac.uk 
 020 7874 1531  
 
Dr Yogini Jani  Chief Investigator 
E: y.jani@ucl.ac.uk 
 020 3456 7890 ext 7350 
Mr Stephen Tomlin Principal Investigator 
stephen.tomlin@gstt.nhs.uk  
 020 7188 9202 
 
If you are still not happy and wish to comment in any other 
way,  
you may contact:- 
 
Patient Advice and Liaison Service (PALS) St Thomas' Hospital 
  
Tel: 020 7188 8801/03 
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Research flowchart 
 
 
 
 
 
 
 
Study information materials will be posted 3 weeks before your next 
clinic appointment 
Two weeks later, we will make a phone call to see if you have 
received the postage and whether you are interested in taking part 
When you come to register your renal clinic appointment, the 
research team will ask about your decision to participate in the study. 
If you decide to take part, you will have to sign the consent form 
The researcher will screen through your medical notes to identify any 
medication related problems.  You will then be randomly assigned to 
either the Standard Care or the Pharmaceutical Care group 
Group A Group B 
The pharmacist will review your current 
medicines and discuss about problems you 
may have in taking them as prescribed (this 
may take approximately 20 minutes and will 
take place while you are waiting to see the 
doctor) 
The pharmacist will then summarise relevant 
information on a note that will be delivered to 
your doctor. The doctor will discuss the matter 
with you to decide if there is a need for 
changes to the medicines or other possible 
solution 
The researcher will evaluate the resolution of the identified problems from documentation in the medical 
notes                         
 4 weeks later 
If you are diagnosed high blood pressure, we will trace your blood pressure level from the medical notes. 
You do not have to come for any extra visit to the hospital apart from your scheduled renal clinic 
appointments. 
 
 
 
 
 
 APPENDICES 
 
342 
 
Appendix 14   Study Information Leaflet for children aged 
6 to 10 years 
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  When you come to the clinic, you see your doctor    
                        and nurse. The pharmacist also wants to see you. 
 
 
 
 
Pharmacist  takes care of your  
medicine. The pharmacist would  
like to talk to your mum and dad  
about your medicine.  
 
 
The pharmacist will work with your doctor 
to help solve the problems that make you 
unhappy with your medicine.  
 
 
 
 
If you like to take part, your mum and dad will have to give their 
consent. We will not share this information to anyone except for 
your doctor, nurse and the research team. 
 
 
Hi! I am your 
pharmacist. Can I help 
with your medicines? 
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Appendix 15  Study Information Leaflet for children aged 5 and 
below 
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Appendix 16  Informed consent form 
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Appendix 17  Assent form 
  
Inform'Consent'Form/'DRP'in'Children'with'CKD/Protocol'V2:02112012/'12/LO/0709'
'
'
When%completed,%1%copy%for%patient;%1%copy%for%researcher%site%office;%1%(original%copy)%to%be%kept%in%medical%note%
%
'
!
 
Centre Number:  
Study Number:  
Patient Identification Number for this study:  
 
 
ASSENT FORM  
 
Title of Project: MEDICINE-RELATED PROBLEMS IN CHILDREN WITH CHRONIC KIDNEY DISEASE 
 
 
Your name ___________________________  Date ______________  
 
The pharmacist who explained this project to you needs to sign too:  
 
Pharmacist Name ______________________    Sign ______    Date ____  
 
 
 
  
 
'
Child (or if unable, parent on their behalf) /young person to tick all  
they agree with:- 
 
 
Have you read (or had read to you) about this project?   
 
 
Has somebody else explained this project to you?  
 
 
Do you understand what this project is about?  
 
 
Have you asked all the questions you want?  
 
 
Have you had your questions answered in a way you understand?  
 
 
Do you understand it’s OK to stop taking part at any time?  
 
 
Are you happy to take part?  
 
 
If any answers are ‘no’ or you don’t want to take part, don’t sign 
your name!  
 
 
If you do want to take part, you can write your name below  
 
 
'
YES NO 
'
'
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Appendix 18  Medication review form (Pages 1-3) 
  
Medication Review Form/ DRP in Children with CKD/Protocol V2-02112012/ 12/LO/0709               ID: 
 
1 
 
 
 
 
 
 
Centre Number:  
Study Number:  
 
 
Patient Identification 
Number for this study:  
 
 
Birth date  
Gender Boy / Girl 
Day of medication review Mon / Tue / Wed / Thur / Fri 
Date of medication review  
Pharmacist 1 / 2 / 3 
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Medication Review Form/ DRP in Children with CKD/Protocol V2-02112012/ 12/LO/0709               ID: 
 
3 
 
A.  
Drug name and regimen 
B.  
Type of drug problem 
 
C.  D.  
What causes the drug 
problem? 
Refer Table 2 for causes of 
DRPs. If the cause(s) is not 
listed, describe it here. 
E.  
What is the recommendation to 
solve this problem? If a solution 
is not possible/not required, 
please explain the reasons. 
(M)Manifested  (P)Potential  
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Appendix 19 Screening tool for DRP by Gordon et al. (2005) – 4 
pages 
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Appendix 20 Pharmacist Note 
  
 APPENDICES 
 
354 
 
Appendix 21  Patient interview form (Pages 1-6) 
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Appendix 22 Study information leaflet for healthcare providers (Outpatient) 
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Appendix 23  List of drugs associated with DRPs by the first 
level of the WHO ATC Classification system (N=203) 
WHO – ATC code Counts  
(A) ALIMENTARY TRACT AND METABOLISM (n=52) 
 Alfacalcidol 4 
Bisacodyl 1 
Calcihew D3 Forte 4 
Calcium acetate anhydrous 1 
Calcium carbonate 5 
Calcium lactate 
Glycopyrronium bromide  
1 
1 
Lactulose 1 
Macrogol, combinations  1 
Magnesium glycerophospate 1 
Nystatin 16 
Omeprazole 4 
Ranitidine 11 
  
(B) BLOOD AND BLOOD FORMING ORGANS (n=27)   
Acetylsalicylic acid  7 
Darbopoetin alfa 4 
Erythropoetin  5 
Human albumin 1 
Iron and multivitamins  1 
Magnesium glycerophosphate 1 
Sodium bicarbonate 2 
Sodium chloride 2 
Sodium feredetate  3 
Sodium phosphate 1 
Tranexamic acid  1 
  
(C) CARDIOVASCULAR SYSTEM (n=10)   
Clonidine 1 
Doxazosin 1 
Enalapril 1 
Furosemide 2 
Midodrine 1 
Nifedipine 2 
Prazosin 1 
Spironolactone 1 
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WHO – ATC code Counts  
(D) DERMATOLOGICALS (n=4)   
Fusidic acid 1 
Gentamicin 1 
Mupirocin 1 
Zinc product 1 
  
(G) GENITO URINARY SYSTEM AND SEX HORMONES    
Oxybutynin 2 
  
(H) SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX 
HORMONES AND INSULINS (n=15)   
Hydrocortisone 1 
Levothyroxine sodium 1 
Methylprednisolone 4 
Octreotide 1 
Prednisolone 8 
  
(J) ANTIINFECTIVES FOR SYSTEMIC USE (n=49)   
Amikacin 2 
Amoxicillin 2 
Amoxicillin and enzyme inhibitor  3 
Cefotaxime 1 
Ceftazidime 4 
Ceftriaxone 1 
Ciprofloxacin 6 
Dapsone 2 
Diphtheria-Hemophilus influenzae B-pertussis-poliomyelitis-
tetanus vaccine 
1 
Flucloxacillin 1 
Fluconazole 3 
Ganciclovir 1 
Gentamicin 1 
Linezolid 1 
Meningococcal polysaccharide groups A, C, Y and W135 
vaccine 
2 
Metronidazole 1 
Penicillin V 1 
Piperacillin and enzyme inhibitor  3 
Sulfamethoxazole and trimethoprim 2 
Teicoplanin 1 
Trimethoprim 5 
Valganciclovir 2 
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WHO – ATC code Counts  
Vancomycin hydrochloride 2 
Varicella vacine (live) 1 
  
(L) ANTINEOPLASTIC AND IMMUNOMODULATING 
AGENTS (n=11)   
Azathioprine 1 
BCG Vaccine 2 
Cyclophosphamide 1 
Mycophenolic acid 2 
Tacrolimus 5 
  
(M) MUSCULO-SKELETAL SYSTEM (n=1)   
Pamidronic acid 1 
  
(N) NERVOUS SYSTEM (n=23)   
Codeine 1 
Levetiracetam 1 
Morphine 6 
Paracetamol 15 
  
(P) ANTIPARASITIC PRODUCTS, INSECTICIDES AND 
REPELLENTS (n=1)   
Levamisole 1 
  
(R) RESPIRATORY SYSTEM (n=7)   
Calcium lactate gluconate 1 
Cetrizine 1 
Chlorpheniramine 1 
Cyclizine 2 
Fluticasone 2 
  
(S) SENSORY ORGANS (n=1)   
Dexamethasone and antiinfectives  1 
  
(V) VARIOUS   
Polystyrene sulfonate  1 
  
 
 APPENDICES 
 
364 
 
Appendix 24  Description of DRP cases and severity score (Inpatient) 
DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
1 2Y 2M 11.75 251 Tx The desired concentration for Tacrolimus in a post renal transplant 
patient was between 8  and 10mg/L but this increased to 12mg/L 
possibly caused by its interaction with Fluconazole. 
3.3 
2 7M 6D not 
available 
not 
available 
NDT Sodium chloride 8mmols three times a day was increased to 
9mmols three times a day in the past 7 days. However, mother 
was not aware of the dosage change and continued to administer 
8mmols three times a day. 
2.1 
3 1Y 8M 9.1 401 HD A Codeine suspension was prescribed 'as and when required' but 
no maximum dose frequency was stated. 
3.7 
4 4Y 7M 16.9 35 NDT A patient developed unexplained fever; possibly caused by 
Levimasole which was prescribed for the past 6 months for the 
management of nephrotic syndrome. Influenza-like syndrome are 
among the common symptoms of prolonged treatment with 
Levimasole [CRP 5mg/L; WBC 7x10^9/L/L; blood culture showed 
no growth of any microorganisms] 
2.2 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
5 3Y 3M 13 415 Tx The patient was regularly taking Omeprazole 10mg once a day but 
was prescribed twice a day in hospital. 
2 
6 12Y 8M 53.2 629 PD Oxybutynin 5mg was prescribed once a day. However, the 
recommended dosage frequency for the patient's age should have 
been twice a day. 
1.9 
7 9M 14D 5.5 321 NDT The patient was taking Calcium carbonate 1000mg nightly and 
250mg four times a day with snacks. However, the hospital had 
prescribed only 1000mg to be taken once a day. There were no 
plans to change the dosage regimen. [PO4 2.22mmol/L] 
 
3.5 
8 10M 16D 6.35 340 NDT The patient regularly took SYTRON® 27.5mg twice a day but was 
prescribed three times a day on the ward. There were no plans to 
change the dosage regimen. [Hb 11.3g/dL; Transferrin saturation 
33.5%] 
1.5 
9 1Y 2M 7.09 19 NDT Liquid Sodium bicarbonate was prescribed but the prescription 
could not be fulfilled because the preparation was not available 
due to manufacturing problems. 
1.7 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
10 44 DAYS 1.8 370 HD IV Ranitidine 3.75mg (equivalent to 2mg/kg) three times a day 
was prescribed. The appropriate dose for the patient's age and 
renal function should have been in the range of 1 to 2mg (which is 
0.5-1mg/kg) three times a day. 
3.4 
11 10M 16D 6.35 340 NDT The patient's urine culture showed a strain resistant to 
Trimethoprim and therefore treatment with Trimethoprim should 
have been stopped. 
3.9 
12 2Y 2M 11.75 251 Tx At 14 days post renal transplant, it transpired that the patient did 
not take Prednisolone for 5 days as it was suspended during IV 
Methylprednisolone therapy for graft rejection treatment and not 
restarted. 
6 
13 2Y 6M 14.7 672 PD IV Ciprofloxacin 5mg/kg twice a day was prescribed, however the 
correct dose should have been 10-15mg/kg once a day as per the 
protocol.  [PD fluid culture: Pseudomonas sensitive to 
Ciprofloxacin] 
4.1 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
14 3Y 1M 15 689 Tx Paracetamol 240mg four times a day was prescribed for post 
operative pain and febrile. However, the dosing frequency should 
have been amended to 'when required' because the patient was 
afebrile and no longer in persistent pain. 
1.3 
15 1Y 7M 13.4 80 Tx Poorly dissolved Omeprazole enteric-coated granules may have 
caused clogging of the nasogastric tube. Treatment should have 
been changed to Lansoprazole orodispersible tablets, which are 
more soluble. 
4.5 
16 14Y 2M 37.7 1187 PD The patient had a history of being allergic to Penicillin but this was 
not documented on the patient's medication chart. 
6.2 
17 9Y 3M 24.35 408 HD 55mg of an oral iron supplement taken once a day should have 
been changed to administration by injection as the patient's 
dialysis modality had been changed from PD to HD. The patient is 
susceptible for iron deficiency anaemia due to parental non-
compliant. [Hb 8.2g/dL; Transferrin saturation 26%]. 
3 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
18 11Y 15D 3.8 185 PD IV Paracetamol 60mg every (which equates to a dose of 15mg/kg) 
6 hours as and when required was prescribed. However, the 
recommended dosage regimen for the patient's weight was 
7.5mg/kg/dose every 4 to 6 hours. 
4.6 
19 12Y 2M 23.95 98 Tx The patient was taking 37.5mg of Aspirin twice a week but was 
prescribed 37.5mg once a day in hospital. However, there were no 
plans to change the dosing frequency. 
2.0 
20 2Y 6M 14.7 672 PD IV Amikacin 150mg once a day was prescribed and patient 
received 2 doses without drug level monitoring. The Amikacin 
trough level requested by the pharmacist on the third day before 
the next dose was 31mg/L. 
5.1 
21 8Y 9M 21 1124 PD 2500 units of Epoetin beta initially prescribed to be taken twice a 
week was increased to three times a week. The treatment should 
have been switched to 10mcg of Darbopoetin alfa  once a week as 
it is more cost-effective for children over 20kg in weight. 
1.3 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
22 9Y 3M 45 518 Tx A patient had constipation possibly caused by IV Morphine which 
was prescribed for the past 10 days for post-operative pain. The 
condition did not noticeably improve with a combination of 
Lactulose and Doccusate Sodium treatment. A third agent (e.g. 
MOVICOL®) should have been prescribed to promote a synergistic 
effect. 
2.9 
23 4Y 7D 16.9 35 NDT After IV Cyclizine administration, the patient developed a whole 
body rash and complained of  'heart started to race' and dizziness. 
The aforementioned symptoms developed 
immediately after the administration of IV Cyclizine.  It was noted 
that the patient had a history of allergic reactions to Cyclizine in 
previous hospital admissions but this had not been documented on 
the patient's medication chart. 
7 
24 9M 10D 6.42 53 NDT IV Ranitidine 10mg twice a day was prescribed on the discharge 
prescription. However, the dosage form should have been stated 
tablets instead. 
1.9 
25 10Y 7M 25.25 46 PD The patient was taking one tablet of Calcichew (calcium carbonate) 
three times a day but had been prescribed one tablet of Calcihew 
D3 Forte (calcium carbonate-vitamin D3 combination) three times 
a day.  There were no plans to change the treatment; and the 
recommended dosage frequency for Calcichew D3 Forte is once a 
1.7 
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DRP 
No 
Patient's details Drug-related problems Severity Score£ 
Age Weight 
(kg) 
Cr 
(µmol/L) 
RRT 
day. [Ca 1.71mmol/L; PO4 1.92mmol/L; Alb <20g/dL] [Each 
Calcichew D3 Forte tablet contains 500mg of Calcium carbonate 
and 10mcg of  vitamin D3] [Each Calcihew tablet contains 500mg 
of Calcium carbonate]. 
 
26 1Y 11M 11.28 229 PD The patient's dialysis was temporarily suspended after the removal 
of the haemodialysis access. The dosage regimen for IV 
Ceftazidime 120mg every 24 hours, which was previously 
prescribed while the patient was on dialysis, should have been 
changed to every 48 hours. 
4 
27 7Y 4M 19 295 PD Intraperitoneal Ciprofloxacin was prescribed on the discharge 
prescription. The treatment duration was stated as '28 days' but 
should have been '10 days'. 
3.6 
28 1Y 9M 11.9 53 NDT Alfacalcidol was suspended during a clinic assessment due to the 
patient's low level of parathyroid hormone but was continued when 
the patient was in hospital. There were no recent PTH levels 
measured and no notes detailing when the treatment should be 
restarted. [PTH level taken 2 weeks prior to hospital admission was 
27ng/L]. 
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29 1Y 10M 12 218 PD The patient was prescribed Chlorpheniramine 'as and when 
required' for the management of purpuric rash. However, a regular 
dose of three times a day should have been prescribed as the 
patient was constantly itching [Urea 24.6mmol/L]. 
2.3 
30 13 3.6 415 Tx IV Ceftazidime for the prevention of surgical site infection was not 
prescribed on the pre-operation prescription. 
4.7 
31 17Y 10M 38.75 553 HD Dapsone 75mg once a day was prescribed for the preceding 6 
months for PCP prophylaxis post renal transplant but may have 
resulted in worsening anaemia. The patient also had cardiac and 
pulmonary disease; two risk factors that are suscpetible to 
Dapsone induced haemolytic anaemia [Cr 553µmol/L; Hb 6.5g/dL]. 
 
5.5 
32 2Y 9M 13.9 613 HD IV Paracetamol 210mg (0.21ml) four times a day was prescribed. 
The dose should have been rounded to down to 200mg (0.2ml) for 
ease of administration. 
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33 9M 10D 6.42 53 NDT Oral Ranitidine 10mg twice a day was changed to IV Ranitidine 
10mg twice a day. However, the appropriate dosage regimen for 
IV Ranitidine should have been 6mg three times a day.  The 
recommended IV Ranitidine dosage frequency for the patient's age 
and renal function was 1mg/kg three times a day. 
2.1 
34 5M 8D 7.3 218 PD IV Piperacillin/Tazobactam was prescribed for the wrong patient. 4.5 
35 12Y 6M 41 232 Tx Neutropenia was possibly caused by Mycophenolate Mofetil which 
was prescribed for the last 6 months [WBC 3.2 x10^9/L; MMF 
level 0.3 mg/L]. 
3.1 
36 8Y 9M 21 1124 HD The patient completed treatment with broad spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been stopped as 
per the protocol. 
1.2 
37 9Y 6M 24 279 Tx Co-Trimoxazole for the treatment of PCP and urinary tract infection 
prophylaxis post transplant was not prescribed. The patient was at 
day 3 post transplant. All patients should have received PCP 
prophylaxis post transplant as per the protocol. 
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38 9Y 1M 28 585 Tx Paracetamol 540mg four times a day was prescribed. However, the 
dosage should have been determined by taking into account the 
rounded to nearest measureable dose for ease of administration. 
Paracetamol tablets are available is in strengths of 500mg and 
1000mg. 
0.9 
39 2Y 23.75 25 NDT Methylprednisolone for IV Rituximab premedication was prescribed 
as daily dose but should have been a 'stat' dose and not continued. 
4.1 
40 2Y 11M 15.1 127 Tx IV Amikacin 150mg once a day was prescribed but level 
monitoring was not ordered. The daily drug level should have been 
monitored for the first three days in order to prevent toxicity. 
4.3 
41 11Y 15D 3.8 185 PD Morphine suspension 0.243ml (4.87mg) four times a day was 
prescribed. However, the dose should have been rounded down to 
0.24ml (4.8mg) for ease of administration. The recommended 
dose for the patient's age was from 5 to 10mg. 
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42 14Y 2M 37.7 1187 PD Calcium carbonate 1.5g was prescribed three times a day. 
However, this did not prove to be a sufficient dose in order to 
control serum phosphate levels because the patient snacked 
between main meals. The dosage should have been amended to 
take into account snacking between main meals. [PO4 2.7 mmol/L; 
CorCa 1.58mmol/L; PTH 959 ng/L] 
3.3 
43 9M 10D 6.42 53 NDT IV Co-Amoxiclav was prescribed for a urinary tract infection but 
the dose was not stated. 
2.6 
44 6Y 14.7 218 NDT Bisacodyl 1.6mg once a day was prescribed. However, the 
recommended dose based on the patient's body weight and age 
should have been 3.3mg once a day. 
1.8 
45 1M 30D 3.8 35 NDT 5mg of IV Furosemide was administered after an albumin infusion. 
However, within the same hour as the IV Furosemide was 
administered, the patient had already received 4mg of Furosemide 
in tablet form. This resulted in the patient having a systolic blood 
pressure of 60mmHg. The recommended Furosemide dose for the 
patient's age is 2 to 8mg which equates to 0.5 to 2mg/kg divided 
into 2 to 3 doses a day. 
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46 11M 15D 3.8 185 PD IV Fluconazole was prescribed for a fungal infection. Nystatin 
which had previously been prescribed for candidiasis prophylaxis 
while the patient was on broad spectrum antibiotics should have 
been stopped. 
2.5 
47 2Y 6M 14.7 672 PD Ranitidine 1.66ml (25mg) twice a day was prescribed but should 
have been rounded up to 2.0ml (30mg) in order to simplify 
administration. The recommended Ranitidine dose for the patient's 
age and renal function is 1-2mg/kg twice a day. 
0.1 
48 4M 24D 3.2 47 NDT A ‘stat’ dose of 3mg IV Furosemide for administration at 0600hrs 
was prescribed twice. 
3.8 
49 12Y 8M 53.2 629 PD The patient was taking two tablets of Calcichew (calcium 
carbonate) three times a day but had been prescribed two tablets 
of Calcihew D3 Forte three times a day (calcium carbonate-vitamin 
D3 combination). The patient was already taking Alfacalcidol.  
There were no plans to change the treatment; and the 
recommended dosage regimen for Calcichew D3 Forte is one tablet 
once a day. [Ca 2.47mmol/L; PO4 2.0mmol/L] [Each Calcihew D3 
Forte  tablet contains 1250mg of Calcium carbonate and 10 mcg of  
vitamin D3] [Each Calcihew tablet contains 500mg of Calcium 
carbonate] 
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50 10M 23.3 633 NDT Morphine suspension 4.54ml (9.08mg) four times a day was 
prescribed; however, the dose should have been rounded down to 
4.5ml (9.0mg) for ease of administration. 
0.4 
51 8Y 9M 21 1124 NDT Calcium polystyrene sulfonate 20g once a day was prescribed for 
the management of hyperkalaemia. The prescribed dose should 
have been divided into 3 to 4 doses adjusted against the serum 
potassium level of 5mmol/L in order to avoid severe potassium 
depletion. 
4.5 
52 8Y 9M 21 1124 PD Intraperitoneal Ciprofloxacin was prescribed for PD peritonitis but 
the treatment duration was not stated. 
2.7 
53 11M 15D 3.8 185 PD Fluconazole 25mg once a day was prescribed for fungal infection 
prophylaxis. The correct dose based on the patient's age and 
dialysis modality should have been a 25mg-loading dose and a 
subsequent dose of 12.5mg once a day. 
3.4 
54 7Y 5M 27.8 480 Tx Valganciclovir 500mg once a day was prescribed for the treatment 
of cytomegalovirus prophylaxis. The correct dose based on the 
patient's body surface area and renal function should have been 
90mg once a day. 
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55 6Y 7M 23.2 53 NDT Doxazosin 2mg once a day was prescribed for the past 7 days but 
did not prove effective in improving systolic blood pressure. The 
dose should have been increased. [The patient's SBP was in the 
range of 130-140mmHg; the target range was 111-123mmHg]. 
 
2.7 
56 8M 19D 3.2 540 NDT Ranitidine 0.5ml (7.5mg) three times a day was prescribed but the 
patient was administered 5ml (75mg) three times a day. The 
recommended dose for the patient is in the range of 3.2 to 6.4mg 
(equivalent to 1-2mg/kg) three times a day. 
5.7 
57 11M 15D 3.8 185 PD Oxybutynin 12.5mg twice a day was prescribed. However, the 
correct dosage regimen should have been 0.5mg once a day. [The 
recommended Oxybutynin dose for children less than 2 years old is 
0.1-0.2mg/kg/day; the maximum dose is 1.25mg three times a 
day]. 
6.1 
58 9Y 3M 24.35 408 HD IV Ciprofloxacin 5mg/kg twice a day was prescribed. However, the 
correct dose should have been 10 to 15mg/kg once a day as per 
the protocol. [PD fluid culture: E. coli sensitive to Ciprofloxacin]. 
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59 9Y 1M 28 585 Tx Morphine suspension 6.46mg (0.32ml) 'as and when required' was 
prescribed. However, the dose should have been rounded down to 
6mg (0.3ml) for ease of administration. The recommended dose 
for the patient's age was from 5 to 10mg. 
0.4 
60 1Y 3M 7.7 229 PD Mupirocin 2% ointment was prescribed for topical application 
around the gastrostomy site. The correct preparation should have 
been Mupirocin intransal ointment because Mupirocin 2% ointment 
contains polyethylene glycol (macrogol) which is not compatible 
with plastic tubing. 
3.2 
61 11M 15D 3.8 185 PD Fluconazole was not prescribed post nephrostomy tube insertion 
but should have been prescribed for candidiasis prophylaxis as per 
the protocol. 
3.6 
62 11M 15D 3.8 185 PD Trimethoprim 8mg was prescribed to be taken nightly. However, 
the aforementioned was a duplicate prescription as the patient was 
already taking 8mg of Trimethoprim twice a day. 
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63 8Y 9M 21 1124 NDT Live attenuated vaccines were administered in the same week as 
the Tuberculin test takes place. The Tuberculin test should have 
taken place four weeks later as it suppresses the effect of 
vaccination. 
3.5 
64 44 DAYS 1.8 370 HD IV Linezolid 20mg (equivalent to 11mg/kg) three times a day was 
prescribed. The recommended dose for the patient's age was 
18mg (equivalent to 10mg/kg) three times a day. [Cr 370µmol/L; 
TBil <2µmol/L; ALP 106 IU/L; ALT 13 IU/L]. 
 
1.5 
65 3Y 1M 15 689 Tx Co-Trimoxazole (a combination of Trimethoprim and 
sulphamethoxazole) was prescribed for post renal transplant 
prophylactic treatment of PCP. Trimethoprim that was already 
prescribed for prophylactic treatment of recurrent urinary tract 
infection should have been stopped. 
1.9 
66 6Y 10M 27.15 64 Tx The patient was 6 months post transplant. Nystatin for candidiasis 
prophylaxis should have been stopped as per the protocol. 
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67 11Y 8M 63.5 53 NDT The patient received Prednisolone 60mg once a day for the 
management of nephrotic syndrome but steroid-induced gastritis 
prophylaxis treatment was not prescribed for. 
3.1 
68 45.7 10.08 184 NDT Liquid Ciprofloxacin was prescribed on the discharge prescription 
but the patient would have preferred 'tablet' form. 
1.9 
69 15Y 7M 20 933 HD The patient's weight was 20kg but was misread as 30kg. This error 
resulted in 600mg of Paracetamol being prescribed four times a 
day. The correct dose should have been 400mg four times a day. 
5.7 
70 12Y 10M 116.2 174 NDT Hydrocortisone 100mg premedication for IV Rituximab infusion 
was prescribed in tablet form. The prescription should have been 
prescribed for an injection form. Patient was never exposed to 
Rituximab. [Rituximab infusion-related side effects are frequently 
reported primarily during the first infusion]. 
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71 3Y 2M 15.2 25 Tx The patient was taking Aspirin 15mg once a day but was 
prescribed 7.5mg once a day in the hospital. However, there was 
no documentation to suggest a change in dose. 
1.8 
72 1Y 10M 12 218 PD The patient was prescribed Paracetamol 'as and when required' for 
pain due to purpuric rash. However, regular doses of Paracetamol 
should have been prescribed as the patient was in constant pain. 
3.2 
73 1M 30D 3.8 35 NDT Spironolactone prescribed for the previous 4 days for the 
management of congenital nephrotic syndrome may have been the 
cause of hypernatremia. At this point, Spironolactone should have 
been suspended. [Na baseline was 137mmol/L, Na four days after 
Spironolactone was 132mmol/L]. 
3.7 
74 8Y 6M 22.5 500 HD The patient was taking 1.5g of calcium carbonate three times a 
day but the hospital prescribed 1.5g to be taken three times a 
week. No plans to change the dosing frequency were documented. 
[Ca 1.34mmol/L; PO4 1.8mmol/L;  Alb 42g/L]. 
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75 9Y 3M 28.5 56 Tx A patient at 5 weeks post transplant missed 1 day of steroid 
treatment because Prednisolone was not restarted after IV 
Methylprednisolone pulse doses for the treatment of graft 
rejection. 
2.7 
76 9Y 1M 28 585 Tx Methylprednisolone 45mg twice a day was prescribed on day 1 
post renal transplant.  However the dose should have been 22mg 
twice a day as per the protocol. The recommended Prednisolone 
dose day 1 to day 3 post-op is 60mg/m2/day in two separate 
doses [BSA 0.75m2]. 
 
3.3 
77 4Y 11M 20.35 169 NDT A PAMIDRONATE® infusion of 15mg every 24 hours for the 
treatment of hypocalcaemia was prescribed but the termination 
date was not stated. The recommended dosage regimen should 
have been for infusions over 2 to 4 days based on the daily serum 
calcium level in order to avoid severe hypocalcaemia.  [Ca 
2.3mmol/L] 
4.4 
78 6Y 7M 23.2 53 NDT IV Clonidine that was prescribed for the past 5 weeks for the 
management of resistant hypertension was stopped abruptly. 
Clonidine should have been withdrawn gradually in order to avoid 
hypertensive crisis. 
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79 2Y 3M 9.6 169 Tx Post-op Prednisolone 52.2mg was prescribed after a renal 
transplant. The total daily dose of Prednisolone 7 days post-op 
should have been adjusted from 52.2mg to 50mg as per the 
protocol. 
0.7 
80 9M 10D 6.42 53 NDT Sodium chloride 1mmol twice a day was prescribed on the 
discharge prescription. However, the correct dose should be 
11mmol twice a day. 
4.5 
81 3Y 1M 15 689 Tx IV Fluconazole was prescribed for a fungal infection. Nystatin 
which was previously prescribed for candidiasis prophylaxis while 
the patient was taking broad spectrum antibiotics should have 
been stopped. 
0.5 
82 1Y 8M 9.1 194 PD Paracetamol 5.62ml (135mg) four times a day was prescribed. 
However, the dose should have been rounded down to 5.7ml 
(134.4mg) for ease of administration. The recommended dose for 
the patient's age was 120 to 240mg every 4 to 6 hours as and 
when necessary. 
0.6 
83 1Y 8M 9.1 194 PD 135mg of Paracetamol was prescribed 'as and when required' but 
the maximum dosage frequency was not stated. 
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84 15Y 6M 40.9 871 PD The patient was reluctant to comply to taking MOVICOL®, 
Doccusate Sodium and Lactulose which had been prescribed in the 
past 8 days for the management of impacted faecal matter. 
However, when the patient did take the treatment this resulted in 
positive bowel movement and output and therefore the ongoing 
treatment should have been simplified as per the protocol. 
2.8 
85 7Y 5M 27.8 41 Tx Valganciclovir 400mg once a day was prescribed for the treatment 
of cytomegalovirus prophylaxis. The dose should have been 
optimised to 500mg as the patient's renal function had improved. 
[Previous Cr 120µmol/L; Current Cr 41µmol/L]. 
3.6 
86 1Y 10M 12 218 PD IV Ceftriaxone 960mg once a day was prescribed. However, the 
recommended dosage regimen for the patient's age and renal 
function should have been approximately 500mg once a day. 
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87 14Y 8M 35.3 63 Tx Ranitidine 140mg twice a day was prescribed. However, the 
recommended dose for the patient's age and renal function should 
have been 150mg twice a day. 
0.4 
88 14Y 9M 53.7 661 NDT The patient was taking two tablets of Calcichew (calcium 
carbonate) three times a day but had been prescribed two tablets 
of Calcihew D3 Forte (calcium carbonate-vitamin D3 combination) 
three times a day. The patient was already taking Alfacalcidol. 
There were no plans to change the treatment; and the 
recommended dosage regimen for Calcichew D3 Forte is one tablet 
once a day. [Ca 2.54mmol/L; PO4 2.14mmol/L] [Each Calcihew D3 
Forte tablet contains 1250mg of Calcium carbonate and 10 mcg of  
vitamin D3] [Each Calcihew tablet contains 500mg of Calcium 
carbonate]. 
 
3.4 
89 6Y 7M 23.2 53 NDT Glycopyrronium 1mg once a day did not effectively improve 
hypersalivation; the dosage regimen should have been optimised 
to 1 to 2mg three to four times a day. 
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90 3Y 1M 15 689 Tx Tacrolimus induction therapy was prescribed 30 minutes prior to 
the living donor renal transplantation the day of the operation. 
However, Tacrolimus should have been administered one hour 
prior to the operation as per the protocol. 
0.9 
91 17Y 4M 45.2 445 Tx During a clinic visit, Darbopoetin alfa was increased from 40 to 
80mcg to be taken once a week. One week later, the dose was 
again increased from 80mcg to 100mg to be taken once a week in 
hospital. However, the patient did not receive the previously 
prescribed doses (40mcg and 80 mcg once a week). [Hb 7.9 g/dL]. 
2.9 
92 5M 5D 2.23 23 NDT Sudocream was prescribed as 'Pseudocream'. 0.2 
93 12Y 32 393 Tx At day 7 post transplant the patient was prescribed Prednisolone of 
which 35mg was to be taken in the morning and 25mg at night. 
However, the correct doses for weaning the patient off medication 
should have been 30mg in the morning and 25mg at night. 
1.8 
94 9Y 1M 28 585 Tx Flucloxacillin empirical therapy for PD exit site infection that was 
prescribed before the patient's renal transplant should have been 
stopped, as the patient was 5 days post transplant and the PD 
catheter had been removed. 
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95 2Y 2M 11.75 251 Tx IV Fluconazole was prescribed for a fungal infection. Nystatin 
which was previously prescribed for candidiasis prophylaxis while 
the patient was taking broad spectrum antibiotics should have 
been stopped. 
0.3 
96 6Y 7M 23.2 53 NDT IV Octreotide prescribed for the past 14 days for the management 
of gastrointestinal bleeding was abruptly stopped. It should have 
been withdrawn gradually by halving the infusion rate every 6 to 
12 hours. 
3.6 
97 9M 9.3 252 PD Intraperitoneal Vancomycin was prescribed on the discharge 
prescription. The treatment duration was stated '28 days' but 
should be '11 days'. 
4.2 
98 12Y 2M 23.95 98 Tx Tacrolimus was prescribed a post transplant patient but the brand 
name was not stated. The dispensary kept 3 different brands of 
Tacrolimus. The patient was on regular doses of Tacrolimus 
(PROGRAF®). 
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99 6Y 7M 23.2 53 NDT Ranitidine 3.33ml (50mg) twice a day was prescribed and rounded 
down to 3.0ml (45mg) in order to simplify administration. The 
recommended Ranitidine dose for the patient's age and renal 
function is in the range of 46 to 93mg (equivalent to 2-4mg/kg) 
twice a day. 
0.4 
100 7 22.4 96 Tx Alfacalcidol 0.25mcg once a day was prescribed '0.25mo' once a 
day in hospital. 
2.8 
101 9Y 3M 3.12 518 Tx A post renal transplant patient was prescribed 30mg of 
Prednisolone to be taken in the morning and 30mg at night. The 
night dose was abruptly reduced from 30mg to 15mg within 24 
hours when it should have been reduced by 5mg per day for 3 
days in accordance with the protocol. 
 
1.7 
102 13 3.6 415 Tx Nifedipine MR tablets were prescribed but patient could not 
swallow tablets or capsules. The prescription should have been 
changed to liquid Nifedipine. 
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103 17Y 10M 38.75 553 HD A patient experienced suicidal thoughts possibly caused by 
Levetiracetam 1250mg twice a day, which was prescribed for the 
previous 3 months. The maximum recommended dose for patient's 
age, weight and renal function is approximately 400mg twice a 
day. [Suicide, suicide attempt, suicidal ideation and behaviour 
have been reported in patients treated with anti-epileptic agents 
including Levetiracetam]. 
7 
104 9Y 6M 24 279 Tx 1000mg of Tranexamic acid was required to be applied to the 
haemodialysis exit site in order to prevent local haemorrhaging 
during dialysis. However an IV route of administration was 
prescribed. 
4.6 
105 11M 15D 8.9 415 PD A second dose of Meningococcal vaccine that should have been 
scheduled to be administered three weeks after the first dose as 
per the trial protocol was not referred to in the treatment plan. 
3.3 
106 17Y 10M 38.75 553 HD Dapsone treatment for PCP prophylaxis continued 7 months post 
transplant but should have been stopped at 6 months post 
transplant as per the protocol. 
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107 9M 9.3 252 PD Nystatin was prescribed on the discharge prescription. The 
treatment duration was stated as '28 days’ but should have been 
'11 days'. 
0.9 
108 9Y 10M 23.3 633 NDT The patient was taking 6 tablets of  Calcichew (calcium carbonate) 
three times a day; but had been prescribed  6 tablets of Calcihew 
D3 Forte three times a day in hospital. There were no plans to 
change the treatment; and the recommended dosage regimen for 
Calcichew D3 Forte is one tablet once a day.  [Ca 2.36mmo/l, PTH 
62.3ng/L] [Each Calcihew D3 Forte  tablet contains 1250mg of 
Calcium carbonate and 10 mcg of  vitamin D3] [Each Calcihew 
tablet contains 500mg of Calcium carbonate] 
 
4.7 
109 8Y 9M 21 1124 NDT Calcium carbonate 2000mg four times a day was prescribed for the 
past 7 days but did not effectively control serum phosphate levels 
despite diet restrictions. The treatment should have been switched 
to Calcium acetate  [Ca 1.29mmol/L; PO4 3.13mmol/L; PTH 
168ng/L]. 
2.4 
110 15Y 7M 20 933 HD A loading dose of 6mg IV Morphine was prescribed when a dose of 
4mg (the correct dose) should have been prescribed. [The 
recommended loading dose for the patient's age was 0.1-
0.2mg/kg]. 
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111 1Y 7M 13.4 80 Tx The patient had PTH level at the higher end of normal range and 
hypocalcaemia and should have been treated with vitamin D 
supplements [PTH 58ng/L; Ca 2.02; Alb 24 g/dL;  CorCa 
2.44mmol/l] 
2.7 
112 15Y 7M 20 933 HD The patient's weight was 20kg but was misread as 30kg. This error 
resulted in 30mg of Cyclizine being prescribed three times a day. 
The correct dose should have been in the range of 10 to 20mg 
three times a day. 
4.1 
113 1M 27D 3.6 65 NDT Co-Amoxiclav was prescribed on the patient's discharge 
prescription. The dosing frequency was stated as 'three times a 
day' but should have been 'once a day' based on the patient's age. 
3.6 
114 12Y 5M 91 641 HD The patient was taking 37.5mg of Aspirin on dialysis days but was 
prescribed three times a day in hospital. However, there were no 
plans to change the dosing frequency. 
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115 10.9 6.12 19 NDT The patient had a history of being allergic to Penicillin but this was 
not documented on the patient's medication chart. 
5.5 
116 15Y 10M 61.95 762 NDT IV Gentamicin was prescribed for the management of septicaemia 
but serum drug level was not monitored. This resulted in acute 
kidney injury. The patient had also received iodine radiocontrast 
which may worsen kidney injury. [Cr baseline not available; Cr on 
presentation 762µmol/L]. 
7.4 
117 13 3.6 415 Tx The patient's Omeprazole dose was increased from 10mg once a 
day to 20mg once a day while the patient was on high dose steroid 
treatment. The dose should have been changed back to 10mg once 
a day after the steroid treatment had been completed. 
2.2 
118 12Y 2M 23.95 105 Tx Epoetin beta 2500units once a day was prescribed. However, the 
recommended dosage frequency is twice a week. [Hb 9.0 g/dL] 
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119 9M 10D 6.42 53 NDT IV Co-Amoxiclav was prescribed for a urinary tract infection but 
duplicated treatment as the patient was already taking oral 
Amoxicillin. The oral antibiotic treatment should have been 
stopped before the IV antibiotic commenced. 
1.9 
120 6M  3D 29.8 42 Tx IV Cefotaxime was prescribed but the treatment duration was not 
stated. 
2 
121 5M 19D 8 279 NDT IV Piperacillin/Tazobactam 570mg (equivalent to 71mg/kg) twice a 
day was prescribed. However, the correct dose based on the 
patient's renal function should have been 730mg (equivalent to 
90mg/kg) twice a day. 
2.9 
122 7Y 5M 27.8 283 Tx Prednisolone was prescribed at Day 0 post renal transplant but the 
dose was not stated. 
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123 14Y 9M 49.7 320 Tx Nifedipine capsule 10mg twice a day was prescribed. However, the 
dosing frequency should have been three times a day. [The 
manufacturer' s dosing frequency for Nifedipine preparations are 
as follows:  three times a day for capsules, twice a day for 
modified release tablets and once a day for slow release tablets]. 
2.2 
124 7Y 4M 19 295 PD A 50mcg in 5ml preparation of Levothyroxine was prescribed on 
the discharge prescription. However, the appropriate preparation 
should have been 25mcg in 5ml because there was problem in 
obtaining supply for the 50mcg in 5ml preparation during that 
period. 
1.3 
125 3Y 1M 15 689 Tx Aspirin was prescribed on the discharge prescription. The 
instruction for GP to continue the prescription after the patient has 
completed 14 days treatment was stated as 'yes' but should have 
been 'no'. 
3.7 
126 2Y 9M 13.9 613 HD Ranitidine 75mg (equivalent to 5.4mg/kg) twice a day was 
prescribed. The appropriate dose for the patient's age and renal 
function should have been in the range of 14 to 28mg (equivalent 
to 0.5-1mg/kg) twice a day. 
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127 5M 19D 8 239 NDT Paracetamol 120mg  'as and when required' was prescribed but 
the maximum dose frequency was not stated. 
3.6 
128 2Y 3M 9.6 169 Tx Aspirin 10mg once a day was prescribed on the discharge 
prescription but the dispensary produced a label stating that 25mg 
was to be taken once a day. 
4.4 
129 3Y 1M 12 220 PD Paracetamol 180mg four times a day was previously prescribed for 
pyrexia but should have been stopped because the patient was no 
longer presenting with pyrexia. 
 
2.8 
130 1Y 2M 7.09 19 NDT The patient was prescribed a phosphate supplement on the 
discharge prescription. The dose stated was '2.8mmols three times 
a day' but should have been '4mmols three times a day'. 
3 
131 7Y 5M 27.8 283 Tx The patient was prescribed IV Ceftazidime 1.4g twice a day but the 
correct dosage frequency based on the patient's renal function 
should have been once a day. 
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132 12Y 5M 91 641 HD Repeated serum magnesium level was below the normal range. 
Magnesium supplements should therefore have been prescribed. 
[Mg 0.59mmol/L] 
2.0 
133 32D 4.1 21 NDT A 50mcg stat dose of Prazosin was prescribed but 500mcg was 
administered. The recommended dose for children is 10-
15mcg/kg/dose. 
5.5 
134 8Y 9M 21 1124 NDT The Varicella vaccination for a renal transplant candidate was not 
scheduled as part of the pre-transplant treatment plan. 
3.4 
135 2Y 2M 2.88 36 NDT Maxitrol eye ointment preparation that was intended for topical 
application at the gastrotomy site was prescribed for 
administration on both eyes. 
3.7 
136 3Y 1M 15 689 Tx Methylprednisolone induction therapy was prescribed 30 minutes 
prior to the living donor renal transplantation on the day of the 
operation. However, Methylprednisolone should have been 
administered one hour prior to the operation as per the protocol. 
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137 7Y 4M 19 295 PD Intraperitoneal Vancomycin was prescribed on the discharge 
prescription. The treatment duration was stated as '28 days' but 
should have been '10 days'. 
3.6 
138 3Y 1M 15 689 Tx Paracetamol was prescribed on the discharge prescription. The 
treatment duration was stated as '28 days'  but should have been 
'11 days';  and the instruction for GP to continue prescribing was 
stated as 'yes' but should have been 'no'. 
2.6 
139 9Y 1M 28 585 Tx Fusidic acid cream empirical treatment for PD exit site infection 
should have been stopped as the patient was no longer on dialysis. 
1.9 
140 9Y 9M 26.4 1027 Tx Azathioprine was administered 8 hours pre-transplant but should 
have been administered post transplant as per the transplant 
protocol. 
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141 1M 30D 3.8 35 NDT 20% Human albumin was mixed with IV Furosemide. However, the 
manufacturer's compatibility report does not recommend Human 
albumin to be mixed with other medicinal products except the 
recommended diluent (e.g. 5% glucose or 0.9% sodium chloride). 
2.8 
142 1M 30D 3.8 35 NDT Enalapril that is indicated for the management of congenital 
nephrotic syndrome was prescribed without a test dose. A test 
dose with a short acting ACE-inhibitor (e.g. Captopril 50mcg/kg) is 
recommended to prevent severe hypotension in neonates. 
3.8 
143 11Y 8M 63.5 53 NDT Penicillin 250mg four times a day was prescribed for the treatment 
of prophylaxis against gram positive infection in 
glomerulonephritis. However, the correct frequency for 
prophylactic treatment should have been twice a day. 
2.9 
144 16Y 11M 62 178 Tx IV Piperacillin/Tazobactam was changed to Co-Amoxiclav tablets 
but both antibiotics were prescribed on the discharge prescription. 
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145 14Y 2M 37.7 1187 PD The patient was prescribed Calcium (SANDOCAL®) but the dose 
not stated. This resulted in the patient receiving 1000mg tablets 
instead of the usual prescription of 400mg tablets three times a 
day. 
4.3 
146 1M 30D 3.8 35 NDT The patient has been hospitalised on a long-term basis for 
congenital nephrotic syndrome. A Diphtheria vaccination is a 
requirement at 2 months of age but appears to have been 
overlooked as it was not in the treatment plan. 
3.4 
147 16Y 11M 62 178 Tx Injections of Metronidazole were prescribed on the discharge 
prescription but oral Metronidazole should have been prescribed 
instead. 
2.4 
148 11M 15D 3.8 185 PD The haemoglobin concentration achieved was 13g/dL as a result of 
the patient receiving Epoetin beta treatment. The Epoetin dose at 
the time was not reviewed. 
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149 4Y 1M 16.8 893 PD Teicoplanin 160mg twice a day was prescribed. However, the 
correct dosing regimen based on the patient's renal function 
should have been 55mg once a day hours for 3 days and 
subsequently 30mg once a day maintenance dose. 
3.8 
150 8Y 7M 21 1124 PD The BCG vaccination for a renal transplant candidate was not 
scheduled as part of the pre-transplant treatment plan. 
4 
151 15Y 1M 51.8 280 NDT IV Cyclophosphamide 750mg once a month was prescribed for the 
management of systemic lupus erythematous. However, only half 
of the total dose was administered because the patient developed 
acute chronic renal failure. The remaining dose, which was 
supposed to be given in 2 weeks, was not documented in the 
treatment plan. [Cr 280µmol/L; BSA: 1.5m2]. 
3.6 
152 15Y 7M 20.7 933 HD The patient was taking SERETIDE® accuhaler (combination of 
Fluticasone and Salmeterol) but was prescribed FLIXOTIDE® 
accuhaler (Fluticasone monotherapy) in hospital. There were, 
however, no plans to change the combination treatment. 
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153 1Y 8M 9.1 401 HD Midrodrine 1.25g once a day was prescribed but did not effectively 
prevent intradialysis hypotension. The dose should have been 
optimised to 2.5mg as per the protocol. 
4.2 
154 2Y 11M 14.7 114 Tx Prednisolone pulse doses for the management of graft rejection 
were prescribed 'stat' without an accompanying continuation 
schedule. The Prednisolone pulse doses should have been 
prescribed for at least 3 days as per the protocol. 
4.2 
155 11Y 15D 33.15 67 Tx Ganciclovir 80mg twice a day was prescribed but this dose should 
have been increased to 160mg twice a day based on the renal 
status of the patient at the time. [Previous GFR 30ml/min/1.7m3; 
Current GFR 80ml/min/1.7m3]. 
5 
156 9Y 9M 26.4 1027 Tx Methylprednisolone, which was supposed to be administered post 
renal transplant, was not prescribed. It should have been 
prescribed as per the protocol. 
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157 8Y 9M 21 1124 HD The patient was on treatment with broad spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per the protocol. 
3.6 
158 3Y 4M 15 38 NDT Paracetamol 250mg 'as and when required' was prescribed but the 
maximum dose frequency was not stated. 
3.6 
159 11Y 9M 9.48 264 Tx Darbopoetin alfa treatment was increased from 20mcg to 40 mcg 
once a week. The correct dose based on the patient's weight 
should have been 30mcg once a week. [Hb 10.9g/dL] [The 
recommended Darbopoetin alfa dose is 1mcg/kg] 
1.8 
160 11M 15D 3.8 185 PD Trimethoprim 14mg twice a day was prescribed. However, the 
recommended dose for the patient's age, weight and renal function 
should have been approximately 8mg twice a day. 
2.8 
161 12Y 6M 41 232 Tx A post renal transplant patient experienced diarrhoea possibly 
caused by combination of high Tacrolimus level. The patient was 
also prescribed Mycophenolate mofetil 750mg twice a day. 
[Patient's Tacrolimus level was 20mg/L]. 
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162 8Y 9M 21 1124 PD SYTRON® 5ml (27.5mg iron) once a day prescribed in the past 14 
days did not effectively improve haemoglobin levels. The dose 
should have been optimised to approximately 15ml (80mg) divided 
into 2 to 3 doses as recommended for the patient's age. [Hb 
7.1g/dL; Transferrin saturation 20%] [Other relevant medicine was 
Epoetin beta 2000 units twice a week]. 
3.4 
163 17Y 10M 38.75 553 HD Epoetin beta was prescribed as a daily dose but should have been 
prescribed three times a week for a patient on haemodialysis. 
4 
164 1Y 11M 11.28 229 HD IV Ceftazidime 230mg three times a day was prescribed. However, 
the recommended dose based on the patient's renal function was 
approximately 120mg once a day. 
5 
165 4Y 2M 16.6 55 NDT Calcium carbonate, which was prescribed for hyperphosphatemia 
during the oliguric phase of acute kidney injury, was no longer 
required and should have been stopped. [Levels during kidney 
injury was PO4 level 2.5mmol/L;  Cr 297µmol/L] [Levels after AKI 
episode was PO4 1.7mmol/L; Cr 55µmol/L]. 
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166 14Y 8M 35.3 63 PD Co-trimoxazole 425mg was prescribed once a day for the 
treatment of urinary tract infection prophylaxis but was rounded 
up to 480mg for ease of administration (one tablet is 480mg). 
However, the recommended dose for the patient's weight was 
420mg (equivalent to 12mg/kg) once a day. 
1 
167 8Y 9M 21 1124 PD Patient's serum phosphate levels gradually increased from 
1.12mmol/L to 1.68mmol/L within 3 days. However, phosphate 
binder treatment that was previously suspended not restarted. 
2.6 
168 11M 15D 3.8 185 PD Trimethoprim 8mg twice a day was prescribed for prophylactic 
treatment of post micturating cystourethrogram (MCUG). However, 
the correct frequency for prophylactic treatment should have been 
once a day. 
1.3 
169 5M 5D 2.23 23 NDT Omeprazole 6mg was prescribed once a day for administration via 
a nasogastric tube. However, the dose should have been 5mg for 
ease of administration. [Tablet Omeprazole is available in 10mg 
and 20mg strengths]. 
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170 3Y 1M 15 689 Tx Prednisolone 32mg once a day was prescribed post-op renal 
transplant. The total dose should have been divided into two 
separate doses of 16mg twice a day as per the protocol. 
1.7 
171 9M 14D 5.5 321 NDT The patient was taking '1000 units' of Epoetin beta once a week 
but the hospital had prescribed '2 units' once a week. 
4 
172 1Y 8M 9.2 394 PD Gentamicin cream for the treatment of PD exit site infection 
prophylaxis was prescribed for the previous 6 weeks. However, the 
treatment should have been stopped after 4 weeks as per the 
protocol. [PD fluid culture was negative] 
2.3 
173 11Y 15D 3.8 185 PD Paracetamol suppository 540mg was prescribed as and when 
required. However, the preparation available at the dispensary is 
240mg suppository. 
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174 12Y 9M 65.2 96 Tx Mother forgot to serve two doses of Tacrolimus. Patient was at 1.5 
months post transplant. [Cr baseline is approximately 70-
80µmol/L; Cr on presentation 96µmol/L; Tacrolimus level on 
presentation 5mg/L; Tacrolimus target range 8-10mg/L] 
4.5 
175 7Y 5M 27.8 283 Tx Omeprazole 10mg once a day was prescribed for the prevention of 
gastritis during treatment with high a dose steroid. However, the 
correct dose should have been 20mg once a day. 
2 
176 3Y 3M 13 415 Tx The patient was prescribed Ranitidine for steroid induced gastritis 
prophylaxis but was already taking Omeprazole. 
1.6 
177 8Y 9M 21 1124 PD IV Morphine 2.1mg three times a day was prescribed. The dose 
should have been rounded down to 2.0mg for ease of preparation. 
0.4 
178 15Y 6M 40.9 871 PD The patient was diagnosed with eosinophilic peritonitis and 
therefore should have been prescribed an antihistamine. 
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179 1Y 8M 9.2 394 PD Tablet Ciprofloxacin 90mg once a day was prescribed for the 
previous 6 weeks for urinary tract infection prophylaxis but should 
have been stopped as the urine culture test was giving negative 
results. 
 
1.9 
180 14Y 9M 53.7 658 PD Darbopoetin alfa for renal anaemia was prescribed as a 'stat' dose. 
However, the recommended dose frequency is once a week. 
2.4 
181 15Y 6M 42 40 NDT The patient was regularly taking 500mg of Mycophenolate Mofetil 
twice a day for the treatment of lupus nephritis. However, the 
patient was prescribed 500mg of Mycophenolate Mofetil once a day 
in the hospital. There was no plan to change the dosage regimen. 
5.4 
182 8Y 9M 21 1124 PD Darbopoetin alfa for administration on dialysis days was not 
prescribed on the discharge prescription. 
2.5 
183 13Y 10M 60.9 715 HD A Furosemide infusion of 20mg/hour was prescribed. However, the 
patient was already receiving a regular dose of 100mg Furosemide 
tablets twice a day.  The oral Furosemide should have been 
suspended and only restarted depending on the patient's response 
to the infusion. 
4.1 
184 16Y 11M 62 178 Tx The patient was regularly taking Alfacalcidol 1mcg once a day but 
was prescribed 0.1mcg in hospital. 
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185 14Y 9M 49.7 320 Tx Tacrolimus was prescribed a post transplant patient but the brand 
name was not stated. The dispensary kept 3 different brands of 
Tacrolimus. The patient was on regular doses of Tacrolimus 
(PROGRAF®). 
3.3 
186 12Y 9M 65.2 96 Tx Paracetamol 1000mg as and when required was prescribed but the 
maximum dose frequency was not stated. 
3.7 
187 1M 44D 1.95 233 NDT Acute renal failure was possibly caused by IV Amikacin prescribed 
for 5 days in total for the management of septicaemia at the local 
hospital. However, the drug level was not monitored. 
6.6 
188 3Y 1M 15 689 Tx Fluconazole was prescribed on the discharge prescription. The 
instruction for GP to continue after the treatment completed was 
stated as 'yes' but should have been 'no'. 
3.5 
189 12Y 8M 53.2 629 PD IV Paracetamol 1000mg as and when required was prescribed for 
post catheter insertion pain. However, the maximum dosage 
frequency was not stated. The patient was also taking 1000mg 
tablets of Paracetamol every 6 hours. 
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190 2Y 9M 9.7 499 PD Patient was taking DIALYVITE® one tablet a day but had not been 
prescribed in hospital. There was no documentation to suggest 
that DIALYVITE® had been intentionally omitted. 
1.3 
191 15Y 7M 20.7 933 HD Ranitidine 1.33ml (20mg) twice a day was prescribed but should 
have been rounded up to 1.4ml (21mg) in order to simplify 
administration. The recommended Ranitidine dose for the patient's 
age and renal function is 1-2mg/kg twice a day. 
0.2 
192 9M 14D 9.3 252 PD Paracetamol was prescribed on the discharge prescription. The 
treatment duration was stated as '28 days’ but should have been 
'11 days'. 
2.8 
193 2Y 10M 9.6  Tx The patient completed treatment with broad spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been stopped as 
per the protocol.  
2.4 
194 8Y 7M 22.5  HD The patient completed treatment with broad spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been stopped as 
per the protocol.  
2.3 
195 4M 13D 7.3  PD The patient completed treatment with broad spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been stopped as 
per the protocol.  
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196 1Y8M 9.2  PD Aspirin was prescribed on the discharge prescription. The 
instruction for GP to continue the prescription after the patient has 
completed 14 days treatment was stated as 'yes' but should have 
been 'no'. 
 
1.2 
197 2D   NDT The patient was taking SERETIDE® accuhaler (combination of 
Fluticasone and Salmeterol) but was prescribed FLIXOTIDE® 
accuhaler (Fluticasone monotherapy) in hospital. There were, 
however, no plans to change the combination treatment. 
 
1.2 
198 1D 1.8  HD The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol.  
1.9 
199 5Y11M 13.8  NDT The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol.  
1.9 
200 17Y4M 45.2  Tx The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol.  
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201 4Y1M 16.8  PD The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol.  
1.9 
202 5M 8.0  NDT The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol.  
1.9 
203 2Y2M 11.8 Tx  The patient was being treated with broad-spectrum antibiotics; 
Nystatin for candidiasis prophylaxis should have been prescribed 
as per protocol. 
1.9 
§ Severity score: Minor (0-<3), Moderate (3-<7), Severe (7-10) 
(HD) Haemodialysis, (PD) Peritoneal dialysis, (Tx) Post transplant, (NDT) Not on HD, PD or Tx 
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Appendix 25 Description of DRP cases and severity score (Outpatient) 
DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
1 14Y 
5M 
53.8 171.9 SAH Doxazosin 1mg daily is prescribed in combination with Atenolol 
50mg daily for hypertension; but patient stopped taking 
Doxazosin for the previous 6 months because of feeling dizzy and 
tired when taking in combination with Atenolol [BP 138/52mmHg] 
4.8 
2 19Y 
6M 
70.6 181.7 SSNS Mycophenolate Mofetil is prescribed but patient is unsatisfied with 
treatment because of inadequate information on its side effects. 3.9 
3 3Y 2M 14.5 96.3 STG5 One Alpha Calcidol 0.25mcg a day is prescribed for the prevention 
of hyperparathyroidism, but patient has problems in obtaining 
supply from the community. [PTH 566 (previous level 93 ng/l); 
CorCa 2.41mmol/l)]  
3.9 
4 4Y     STG3A Magnesium Glycerophosphate is prescribed but patient is 
dissatisfied because the tablets are too big, chalky and taste 
awful. 
3.6 
5 10Y 
6M 
48.4 142.4 HSPN Patient complains of acne; this could be caused by long-term 
treatment with Prednisolone 60mg daily, prescribed for Henoch 
Schönlein purpura nephritis. 
3.2 
6 13Y 61.4 146.7 SRNS Mycophenolic acid is prescribed for steroid-resistant nephrotic 
syndrome but patient has problems in taking the medicines as GP 
surgery refuses to supply. 
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7 7Y 5M 22 116 STG4 Patient struggles to take Sytron at home because dislikes the 
taste [Ferritin 65ug/L, Hb 11.5g/dl] 2.1 
8 17Y 
6M 
36.4 142.3 STG5 Patient is on a transplant workout requiring Pneumococcal 
vaccine; but an updated vaccination record requested from the GP 
surgery has not been obtained for over 5 months. 
2.9 
9 14Y 
5M 
    1Y PTx A patient at 6 months post transplant has Tacrolimus toxicity as 
shown from a renal biopsy [Tacrolimus level 8ng/l (target level is 
6-7ng/L), Serum creatinine 121umol/L (baseline 87umol/L)] 4.5 
10 8Y 8M     9Y  PTx A patient who has been hyponatremic for the last 6 months 
refuses to have sodium supplement dose increased [Na 
130mmol/l, Sodium Chloride dose 1200mg three times a day (12 
tablets/day)] 
4.8 
11 2Y 9.9 80.7 NC One Alpha Calcidol has been prescribed for the past 8 months, but 
patient has been supplied with vitamin D3 from the community.  3.9 
12 14Y 
9M 
    MCNS Myfortic 540mg twice a day is prescribed, but patient is unable to 
obtain refill as the community pharmacy is unable to get supply. 4.7 
13 3Y 2M 13.5   STG 5 Sodium Bicarbonate 10mmol three times daily is prescribed, but 
patient has problems in obtaining supply from the community 
[HCO3 21mmol/l]. 
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14 11Y 39.5 143 SSNS The family wants the patient to take alternative medicines to 
complement the prescribed treatment; but patient is dissatisfied 
with having to take alternative medicine together with prescribed 
medicines.  
2.4 
15 7Y 5M 23 120 STG4 Patient struggles to get sufficient supply of Ferrous Sulphate from 
the community whenever going away on extended periods of 
holiday. 
2.3 
16 7Y 4M     9Y PTx Neutropenia was possibly caused by Azathioprine 75mg daily 
which was prescribed for the last 6 months [Neutrophil 0.8 
x10^9]. 
4.9 
17 11Y 
2M 
35.8 140 CRF Melatonin liquid is prescribed but patient has problem in obtaining 
extra supply of Melatonin from the community whenever going 
away on extended periods of holiday. 
2.8 
18 3Y 6M     1Y PTx Mycophenolate Mofetil liquid 0.85mg twice a day is prescribed but 
patient has problem in obtaining extra supply from the 
community. 
5 
19 7Y 5M  23 120 STG4 Patient struggles to get sufficient supply of Sodium Bicarbonate 
from the community whenever going away on extended periods of 
holiday. 
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20 11Y 39.5 143 SSNS Patient complains of gastrointestinal upset; which is possibly 
caused by combination of Prednisolone and Mycophenolic Mofetil. 
Ranitidine for the prevention of steroid-induced gastritis is 
prescribed at alternate day dosing instead of twice daily as per 
family request in order to take alternative medicines. [The 
recommended dosing frequency for oral Ranitidine is twice a day]. 
4.3 
21 8Y 5M 65.3 138.4 STG3B Metformin for weight loss is prescribed at full dose at community; 
the dose should have been reduced by 25% of normal dose based 
on patient's renal function to prevent lactic acidosis [GFR 40, BMI 
36.6].  
5.2 
22 7Y 5M 23 120 STG4 Sodium Bicarbonate 3 tablets three times a day is prescribed but 
patient sometimes forgets to take the lunchtime dose if out and 
about. 
3.4 
23 7Y 5M 23 120 STG4 Patient finds it difficult to swallow Ferrous Sulphate because of the 
large tablet size. 
 
3 
24 9Y 9M 18.1 114 STG 3B Lisinopril liquid is prescribed at 2.5mg daily; but patient has 
problems obtaining sufficient supply from the community. 
 
3.5 
25 3Y 6M 17.3 96.9 1Y PTx Patient has difficulty in taking Mycophenonate Mofetil because of 
problems with nasogastric tube reinsertion which is relied on for 
medication. 
5.3 
 APPENDICES 
 
416 
 
DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
26 10Y 
8M 
41 136 SDNS Prednisolone is prescribed at 35mg daily for 6 days and to be 
continued with 10mg alternate days during nephrotic relapse; but 
patient misunderstood and took 4 days of 35mg and continued 
with 10mg alternate days. [Albumin 39g/l, Scr 66 (baseline 45-
50umol/l)] 
4.7 
27 6Y     SDNS Prednisolone 10mg alternate days is prescribed and patient is 
instructed to increase the dose to 60mg daily during relapses of 
nephrotic syndrome.  However, patient has difficulties in obtaining 
adequate supply from the community during relapse. 
5.2 
28 6Y 7M 21 106 PGN Patient developed facial stigmata due to chronic use of steroid. 
4.6 
29 15Y 
9M 
169 51 STG4 Forceval is prescribed at a dose of 1 tablet daily, but patient does 
not comply with treatment. 
 
2.2 
30 3Y 2M 13.3 93.2 STG5 One Alpha Calcidol liquid dose prescribed from the hospital is 
0.25ml (0.5mcg) once a day, but patient receives 0.25mcg 
capsules from the GP.  
3.7 
31 7Y 5M 23 120 STG4 Patient struggles to get sufficient supply of Folic Acid from the 
community whenever going away on extended periods of holiday. 2.2 
32 3Y 6M     1Y PTx One Alpha Calcidol is prescribed but patient has problems in 
ordering and obtaining adequate supply from the community. 3.1 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
33 11Y 
5M 
    9Y PTx Tacrolimus is prescribed for post kidney transplant but the 
prescription is not repeated by GP surgery. 
 
5.4 
34 17Y 
6M 
36.4 142.3 STG5 Patient is on a transplant workout requiring vaccination for 
Meningitis; but an updated vaccination record requested from the 
GP surgery has not been obtained for over 5 months. 3.1 
35 3Y 5M 17.3 96.9 1Y PTx Patient has difficulty in taking Prednisolone because of problems 
with nasogastric tube reinsertion which is relied on for medication. 4.9 
36 15Y 
9M 
169 51 STG4 Sodium Bicarbonate 1g twice a day but patient is not compliant 
with treatment. 
 
4.3 
37 11Y 
11M 
    SDNS Patient is prescribed Cyclosporine for focal segmental 
glomerulosclerosis; but had not been attending clinic since the 
dose was adjusted 8 months ago.  
 
5.3 
38 3Y 6M 17.3 96.9 1Y PTx Patient has difficulty in taking One Alpha Calcidol because of 
problems with nasogastric tube reinsertion which is relied on for 
medication. 
 
3.8 
39 16Y 
8M 
48.5 156.3 5Y PTx Tacrolimus 1.5mg twice daily is prescribed but patient takes 
2.5mg twice daily. 5.7 
40 3Y 2M     SSNS Prednisolone 40mg daily is prescribed for 4 weeks in a weaning 
schedule following nephrotic relapse; but patient stops taking 
Prednisolone after 2 weeks.  
4.7 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
41 11Y 
2M 
43.4 128.8 7Y PTx The 12 hours' trough Tacrolimus level taken in clinic is 1ng/l. The 
patient is unsure of current medications. [Target level is 4ng/l, Scr 
stable 79umol/l]  
 
5.3 
42 5Y 8M 15.6 93.6 STG4 Patient has problems in taking Sodium Bicarbonate consistently at 
home because of inadequate supply from the community. 3.6 
43 5Y 
11M 
16.6 103.3 STG5 Sodium Bicarbonate 15mmol three times a day is prescribed but 
patient has problem in obtaining supply from the community. 3.4 
44 2Y 
11M 
11 78 STG4 Calcium Carbonate liquid 360mg three times daily is prescribed 
but patient has problem in obtaining supply from the community. 3.5 
45 16Y 
8M 
48.5 156.3 5Y PTx One Alpha Calcidol was increased from 0.25 to 0.3mcg four weeks 
ago, but patient still takes 0.25mcg because preparation is only 
available in 0.25mcg, 0.5mcg and 1mcg capsules. 3 
46 3Y 13.5   STG 5 Sodium Chloride 15mmol daily is prescribed, but patient has 
problems in obtaining supply from the community. [Chloride 
102mmol/l] 
 
3.6 
47 7Y 
11M 
23 120 STG4 Cephalexin liquid is prescribed for urinary tract infection 
prophylaxis. Patient struggles to get sufficient supply of 
Cephalexin liquid from the community whenever going away on 
extended periods of holiday. 
3.4 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
48 5Y 7M 16.6 103.3 STG5 Dialyvite Multivitamin is prescribed but patient has problem in 
obtaining supply from the community. 
 
2.7 
49 19Y 
6M 
70.6 181.7 SSNS Patient is unsatisfied with steroid treatment because of inadequate 
information on its side effects. 
 
3.2 
50 15Y 
10M 
49.4 159 3Y PTx Patient complains of diarrhoea when started taking Ferrous 
Fumarate in the past 1 week. 
 
3 
51 15Y 
9M 
169 51 STG4 Bisacodyl 1 tablet daily is prescribed but patient is not compliant 
with treatment 
 
2.6 
52 3Y 9M 12.9 94 9Y PTx Sodium Bicarbonate 4mmol three times a day is prescribed, but 
patient has difficulty in obtaining extra supply from the community 
whenever going away on extended periods of holiday. 2.7 
53 18Y 
9M 
136 175.3 SAH Increased level of alanine transaminase, possibly induced by long-
term use of Fluoxetine. 
 
4.5 
54 4Y 6M     1Y PTx Prednisolone 5mg every other day is prescribed but patient has a 
problem in obtaining supply from the community. 4.8 
55 16Y 
7M 
    GFR40 Patient refuses to take Magnesium Glycerophosphate because 
dislikes the taste. 4.1 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
56 14Y 
6M 
    MCNS Adcal D3 caplets are prescribed 2 daily; but patient is not 
compliant in taking them because tablets too large to swallow and 
dislikes the taste. [Adcal D3 is a calcium and vitamin D 
supplement] 
3.9 
57 17Y 44.2   SRNS A  nephrotic patient is responsive to Cyclosporine and alternate 
day Prednisolone therapy but non-compliant with dosing schedule. 
This could possibly contribute to the ongoing proteinuria [Urine 
protein 3+, Alb 36g/L, Cyclosporine trough 66ug/L]. 
4.9 
58 17Y 
6M 
36.4 142.3 STG5 Patient is on a transplant workout requiring vaccination for 
Hepatitis B; but an updated vaccination record requested from the 
GP surgery has not been obtained for over 5 months. 4.2 
59 15Y 
2M 
51.5 162 3Y PTx Patient buys Spatone iron supplement over the counter, which is 
quite expensive; other cheaper alternatives could be obtained on 
prescription. 
 
1 
60 9Y 2M 25.7 127.6 PKD Patient experienced mood swing and sleep disturbance possibly 
due to side effects of Prednisolone. 
 
3 
61 11Y      1Y PTx Risperidone is prescribed for the management of aggressive 
behaviour but patient refuses to take it. 
 
3.6 
62 3Y 9M 12.4 90 STG3A Antibiotic prophylaxis for urinary tract infection is prescribed but 
patient refuses to take it. 3.5 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
63 4Y 6M     1Y PTx Tacrolimus is prescribed in post renal transplant but patient has 
problems in obtaining correct prescriptions and adequate supply 
from the community. 
 
5 
64 16Y 
10M 
81 176 STG4 Vitamin D3 is prescribed for the management of 
hyperparathyroidism, but patient is not compliant with treatment 
[PTH 97 (previous level 63ng/l)]. 
 
4.2 
65 4Y 6M 17.3 96.9 1Y PTx Patient has difficulty in taking Sodium Bicarbonate because of 
problems with nasogastric tube reinsertion which is relied on for 
medication. 
 
3.7 
66 10Y 
8M 
28 127 1Y PTx Tricitrate 30ml four times a day is increased to 31ml for 
hypokalemic symptoms; but patient does not receive the new 
dose from the community and still experiences symptoms.  3.7 
67 15Y 
9M 
169 51 STG4 Enalapril is prescribed at 2.5mg daily but patient is unsure of 
medications and not complying with treatment.  4.2 
68 16Y 
5M 
65.9 158.7 SRNS Patient complains of feeling tired and weak all the time; could 
possibly be caused by long-term side effect of Cyclosporine; the 
patient is also taking Prednisolone alternate days. 4 
69 15Y 
9M 
169 51 STG4 Trimethoprim 50mg daily is prescribed for recurrent urinary tract 
infection; but patient is unsure of medications and not complying 
with treatment.  
3.1 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
70 5Y 
11M 
16   STG5 Sodium Bicarbonate tablet 1g three times a day is prescribed in 
combination with Sodium Bicarbonate liquid 15mmol three times a 
day; but patient only takes the liquid formulation because having 
problems in obtaining supply of the tablets from the community 
[HCO3 18mmol/l]. 
 
3.1 
71 4Y 6M     1Y PTx Sodium Bicarbonate is prescribed but patient has a problem in 
obtaining supply from the community. 
 
3.5 
72 16Y 
5M 
44.2   SRNS A  nephrotic patient is responsive to Cyclosporin and alternate day 
Prednisolone therapy but non-compliant with dosing schedule. This 
could possibly contribute to the ongoing proteinuria [Urine protein 
3+, Alb 36g/L, Cyclosporin trough 66ug/L]. 
5.8 
73 15Y 
7M 
45 163 STG3B Forceval capsule is prescribed but patient has difficulty in 
obtaining supply from the community due to national supply 
problem. 
 
2.4 
74 16Y 
5M 
36.4 142.3 STG5 Patient is on a transplant workout requiring Varicella vaccination; 
but an updated vaccination record requested from the GP surgery 
has not been obtained for over 5 months. 3.4 
75 11Y 
5M 
    9Y PTx Mycophenolate mofetil is prescribed for post kidney transplant but 
prescription not repeated by GP surgery. 5.9 
76 11Y 
9M 
    9Y PTx Itraconazole is prescribed for a post kidney transplant patient but 
prescription not repeated by GP surgery. 5.4 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
77 13Y 
5M 
104.8   4Y PTx Patient complains of acne; this could be caused by long-term 
treatment with Prednisolone. 
 
3.6 
78 5Y 7M 17.8 103.5 STG 3B Patient is dependent on nasogastric tube and experienced 
difficulty in taking Sodium Chloride 5mmol (1ml) three time a day 
orally. 
2.9 
79 4Y 6M 17.3 96.9 1Y PTx Patient has difficulty in taking Tacrolimus because of problems 
with nasogastric tube reinsertion which is relied on for medication. 5.1 
80 10Y 
1M 
35.4 134.8 SDNS Unable to take post-12 hours Tacrolimus level because patient 
missed previous night’s dose.  4.5 
81 5Y 9M 18 99 2Y PTx Tacrolimus is prescribed but patient had problems in ordering and 
obtaining adequate supply from the community. 5.5 
82 11Y 
5M 
    9Y PTx Prednisolone 7.5mg alternate days is prescribed for post kidney 
transplant but prescription not repeated from the community. 5.7 
83 9Y 9M 18.1 114 STG 3B Sodium Bicarbonate 5mmol three times a day is prescribed but 
patient takes it twice a day as the midday dose is missed. 3.3 
84 5Y 7M 17.8 103.5 STG 3B Patient is dependent on nasogastric tube and experienced 
difficulty in taking Sodium Bicarbonate 20mmol twice a day orally. 3.7 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
85 13Y 61.4 146.7 SRNS Patient complains of being forgetful, feeling tired and sometimes 
'grumpy', possibly due to side effects of Prednisolone. 3.7 
86 1Y 5M 11 78 NS PKD Sodium Bicarbonate 6mmol three times a day is prescribed but 
patient has a problem in obtaining supply from the community. 4.1 
87 4Y 6M 13.5   STG 5 Calcium carbonate 300mg three times daily is prescribed for the 
prevention of hyperphosphatemia, but patient has problems in 
obtaining supply from GP and local chemist. [PO4 1.3mmol/l] 3.5 
88 9Y 9M 18.1 114 STG 3B Patient complains of constipation after taking Sytron and thus 
stopped taking it at home.   
 
3 
89 3Y 6M 17.3 96.9 1Y PTx Treatment for Attention Deficiency Hyperactivity Disorder (ADHD) 
should have been started 3 months ago; but this is delayed as the 
Community Paediatrician is unsure of potential interaction 
between the newly prescribed medication for ADHD and 
immunosuppressants that patient is currently taking. 
3.6 
90 5Y 7M 17.8 103.5 STG 3B Patient is dependent on nasogastric tube and experienced 
difficulty in taking Sytron 10mls once a day orally. 2.1 
91 15Y 
9M 
169 51 STG4 One Alpha Calcidol is prescribed at 0.75mcg a day, but patient is 
not compliant. This could possibly contribute to elevated 
parathyroid hormone [PTH level 163ng/l (previous level 103 
ng/l)]. 
4.7 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
92 8Y 8M     SDNS A patient missed two doses of Tacrolimus prior to clinic 
appointment. Tacrolimus was switched from Mycophenolic acid 2 
months ago due to frequent nephrotic relapse.  
 
4.1 
93 13Y 
6M 
35.8 147.3 STG3 Lisinopril 5mg daily is prescribed but patient is not compliant with 
treatment. 
 
4.1 
94 13Y 
9M 
35.8 147.3 STG3 Nitrofurantoin 50mg daily is prescribed but patient is not 
compliant with treatment. 
 
3.1 
95 17Y 
6M 
37 142.3 STG5 Patient ran out of medication supply and missed 7 days of Sodium 
Bicarbonate 1.5g three times daily [HCO 19mmol/l]. 5.3 
96 2Y 1M 9.6 78 STG4 Sodium Chloride 2.5mmol four times a day is prescribed; but 
patient takes half the dose for two days due to difficulties in 
obtaining supply from the community. 
 
4.6 
97 18Y 136 175.3 SAH Increased alanine transaminase, possibly caused by long-term use 
of Fluoxetine. 
 
5.3 
98 17Y 
6M 
36.4 142.3 STG5 Patient is on a transplant workout requiring HIB vaccination; but 
an updated vaccination record requested from the GP surgery has 
not been obtained for over 5 months. 3.5 
99 8Y 8M     SDNS Patient is Cushingnoid; this could possibly caused by prolonged 
high dose steroid. 4.4 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
100 3Y 2M     SSNS Levamisole is restarted as steroid sparing agent following 
nephrotic relapse for 4 weeks; but patient takes the medicine only 
for the first 2 weeks [Urine protein 2+]. 
 
4.9 
101 7Y 3M 19   STG4 Patient developed widespread erythemateous uticaria rash over 
whole body which started a few days after taking Amoxicillin for 
upper respiratory tract infection. 
 
5.4 
102 18Y 70.6 181.7 SSNS Clonidine is prescribed for the management of hypertension; but 
patient is unsatisfied with treatment because of inadequate 
information on its side effects. 
 
4.3 
103 17Y 
8M 
65.9 158.7 SRNS Patient complains of feeling tired and weak all the time; this could 
possibly caused by long-term side effect of Prednisolone. The 
patient is also taking Cyclosporin. 
 
4.4 
104 15Y 
9M 
169 51 STG4 Unsure of medications and not complying with taking Calcium 
Carbonate during meal times. 
 
4.6 
105 15Y 
9M 
169 51 STG4 Ferrous Fumarate 400mg once a day is prescribed but patient is 
not compliant.  
 
3.3 
106 5Y 7M 18 105 CRF Itraconazole is prescribed for gene therapy, but patient is unable 
to finish the treatment because could not tolerate the side effects 
- vomiting and diarrhoea. 
4.7 
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DRP 
No 
Patient's details* 
Drug-related problems  Average 
Score * 
Age** 
Weight 
(kg) 
Height 
(cm) 
Kidney 
disease*** 
107 7Y 3M 27.7 122.7 SDNS Patient experiences abdominal pain possibly caused by the 
combination of Prednisolone 15mg alternate days and 
Mycophenolate Mofetil 750mg twice a day; but prophylaxis for 
steriod-induced gastritis is not prescribed.  
 
5.3 
108 11Y 39.5 143 SSNS Acne on face possibly related to Prednisolone. 3.7 
109 13Y 
2M 
59.3 158.2 SLE Mycophenolate Mofetil is prescribed but patient has problem in 
obtaining regular supply from the community due to different pack 
sizes, which are available in either 50 or 100 tablets per pack.  3.4 
110 5Y 8M 15.6 93.6 STG4 Patient is taking Losartan liquid 10mg daily but received 
prescription for Losartan tablets from the community. 2.7 
*Average Score in severity:  Minor (0 - <3), Moderate (3 - <7), Severe (7-10) 
(HSP) Henoch Schönlein Purpura, (SAH) Systemic arterial hypertension, (SDNS) Steriod dependant nephrotic syndrome, (SLE) 
Systemic lupus erythematous, (SRNS) Steroid resistant nephrotic syndrome, (SSNS) Steroid sensitive nephrotic syndrome, 
(STG) CKD Stage, (PTx) Post transplant 
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Appendix 26 List of drugs associated with baseline DRPs by the 
first level (N=64) 
WHO – ATC code Counts  
n (%) 
 
(A) ALIMENTARY TRACT AND METABOLISM 12 (18.8) 
Alfacalcidol 5 
Bisacodyl 1 
Calcium carbonate 3 
Forceval (Multivitamins) 1 
Metformin 1 
Trictrate 1 
  
(B) BLOOD AND BLOOD FORMING ORGANS 15 (23.4) 
Ferrous fumarate 1 
Ferrous sulphate 1 
Magnesium glycerophosphate 1 
Sodium bicarbonate 6 
Sodium chloride 4 
Sodium feredetate  2 
  
(C) CARDIOVASCULAR SYSTEM 2 (3.1) 
Enalapril 1 
Lisinopril 1 
  
(H) SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX 
HORMONES AND INSULINS 10 (15.6)  
Prednisolone 10 
  
(J) ANTIINFECTIVES FOR SYSTEMIC USE 11 (17.2) 
Amoxicillin 2 
Haemophilus influenzae type B vaccine 1 
Hepatitis B vaccines 1 
Itraconazole 1 
Meningococcal polysaccharide groups A, C, Y and W135 
vaccine 
1 
Nitrofurantoin 1 
Pneumococcal vaccine 2 
Trimethoprim 1 
Varicella vacine  1 
  
(L) ANTINEOPLASTIC AND IMMUNOMODULATING 
AGENTS 10 (15.6) 
Azathioprine 1 
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WHO – ATC code Counts  
n (%) 
 
Ciclosporin 2 
Mycophenolic acid 2 
Tacrolimus 5 
  
(N) NERVOUS SYSTEM 3 (4.7) 
Dexamefetamine 1 
Fluoxetine 1 
Risperidone 1 
  
(P) ANTIPARASITIC PRODUCTS, INSECTICIDES AND 
REPELLENTS 1 (1.6) 
Levamisole 1 
*Data are count or percentage (%)  
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Appendix 27 Comparison of DRP data in children with kidney diease to other other populations  
Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
Setting and study 
design 
Observational 
study in the 
paediatric renal 
wards of two 
children’s teaching 
hospitals  
RCT at the 
paediatric renal 
clinic of a 
children’s 
teaching hospital  
Observational study 
in the general 
medical wards, NICU 
and PICU of two 
children’s teaching 
hospitals  
Review of articles 
from 1990-2010  
Observational 
study in a renal 
unit of a teaching 
hospital  
Country UK UK UK and Saudi Arabia US India 
Sample size 127 unique 
patients (from a 
total of 166 
admissions) 
100 patients 333 unique patients 
(from a total of 732 
patients) 
48 articles 308 patients 
Number of DRPs 
identified & method 
of identification 
203 DRPs from 
prescription chart 
review by 
pharmacists 
64 DRPs from 
eMR (active 
problems n=31) 
478 DRPs from 
prescription chart 
review by 
pharmacists 
NA 327 from 
pharmacists’ 
documentation 
Study duration 10 months 8 months 3 months NA 9 months 
DRP definition  Adapted from the 
PCNE  
Adapted from the 
PCNE  
Adapted from the 
PCNE  
Adapted Hepler and 
Strand (1990) 
Adapted Hepler 
and Strand (1990) 
DRP classification Adapted from the 
PCNE classification 
version 6.2 
Adapted from the 
PCNE 
classification 
Adapted from the 
PCNE classification 
version 5.0 
Adapted from the 
Hepler and Strand 
classification  
Adapted from the 
Hepler and Strand 
classification 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
version 6.2 (1990) (1990) 
Incidence of DRPs 
(95% CI) 
 
51.9% (43.2-60.6) 
of patients 
18% (11.3-26.7) 
of patients with 
newly identified 
DRPs  
 
 
UK and Ssaudi 
Arabia data: 
45.2% (41.5-48.8) 
UK data:  
39.4% (34.4-44.6) 
All studies reported 
that all patients 
have at least one 
DRP  
All patients 
Predominant types 
of DRPs 
 Sub-optimal drug 
effect (21.7%) 
 Toxic adverse 
reaction (19.2%) 
 Unnecessary drug 
treatment 
(20.2%) 
 
eMR review: 
 Sub-optimal 
drug effect 
(39.1%) 
 Drug 
administration 
problems 
(29.7%) 
 Non-allergic drug 
reaction (17.2%) 
 
Patient interview: 
 Drug 
administration 
problems 
 Dose too low or 
dosing interval too 
long (31.6%) 
 Dose too high or 
dosing interval too 
short (19.2%) 
 Non-allergic drug 
reaction (10.7%) 
 
 Indication without 
therapy  
 Inappropriate 
laboratory 
monitoring 
 
 Overdose (19.3%) 
 Adverse drug 
reactions (19.0%) 
 Improper dosing 
schedule (14.4) 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
(65.2%) 
 Non-allergic drug 
reaction (10.9%)  
 Patient 
dissatisfied 
because of 
inadequate drug 
information 
(10.9%) 
 
Predominant 
contributory factors  
 Prescribing errors 
 Doses too high 
 Required 
synergistic/preven
tive drug not 
prescribed 
eMR review: 
 Poor 
understanding of 
treatment plan 
and medications 
 Dependent of 
enteral feeding 
tube for drug 
administration 
 
Patient interview: 
 Difficulty in 
obtaining repeat 
 Inappropriate dose 
selection 
 Drug side effects 
 Drug 
underuse/under-
administered 
 
Not reported Not reported 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
prescriptions 
from the 
community 
 Drug side effects 
Severity of DRPs 
 
Dean and Barber 
scale (1999) 1 
 
Severe      1% 
Moderate  57% 
Mild          41% 
 
Dean and Barber 
scale (1999) 1 
 
eMR review: 
Severe        0% 
Moderate   91% 
Minor         9% 
 
Patient interview: 
Severe       0% 
Moderate   80% 
Minor        20% 
Dean and Barber 
scale (1999) 1 
 
Severe         1% 
Moderate     27% 
Minor          72% 
 
 
Not reported Alderman severity 
criteria 2 
 
Major       10% 
Moderate   16% 
Minor         74% 
 
 
Significant risk 
factors 
Number of 
medicines 
prescribed per child 
None of the risk 
factors were 
found to be 
significant 
 Number of 
medicines 
prescribed per 
child  
 Transferred from 
Several reports 
suggested the 
following factors but 
none of the articles 
reported statistical 
Risk factors not 
studied 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
another ward or 
hospital 
significance: 
 ≥3 comorbidities, 
 medications 
regimen changed 
≥4 time per year 
 On ≥5 medications 
 History of non-
adherence 
 Treatment with 
medicines with 
narrow therapeutic 
index 
 On dialysis 
DRP resolution 94% of DRPs 
resolved during 
hospitalisation 
(99% acceptance 
rate by the clinical 
team) 
No difference in 
the resolution of 
DRPs 
Not reported Not reported Not reported 
Acceptance rate by 
the clinical team 
towards 
pharmacist’s 
99% 83% Not reported Not reported 97.2% 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
recommendations 
Drugs associated 
with DRPs (by first 
level of the WHO-
ATC code) 
(J) Antiinfectives 
for Systemic Use  
 
(A) Alimentary 
Tract and 
Metabolism 
 
(B) Blood and 
Blood Forming 
Organs 
(B) Blood and 
Blood Forming 
Organs 
  
(L) Antineoplastic 
and 
Immunomodulatin
g Agents 
 
(A) Alimentary 
Tract and 
Metabolism 
 
(J) Antiinfectives for 
Systemic Use 
  
(A) Alimentary Tract 
and Metabolism 
 
(N) Nervous System 
(C) Cardiovascular 
System 
  
(J) Antiinfectives for 
Systemic Use  
 
(A) Alimentary Tract 
and Metabolism 
(C) Cardiovascular 
System 
  
(J) Antiinfectives 
for Systemic Use  
 
(A) Alimentary 
Tract and 
Metabolism 
Notes: 
Abbreviations: DRPs (drug-related problems), eMR (Electronic Medical Record), NA (Not applicable), PCNE (Pharmaceutical Care 
Network Europe) 
1 Dean and Barber (1999) severity assessment scale: 
Severe: Likely to cause death or lasting impairment, Moderate: Likely to cause adverse effects or interfere with therapeutic 
goals, Mild: Unlikely to have any adverse effects 
2 Alderman severity criteria 
Major: Interventions expected to prevent or address very serious drug-related problems, with a minimum estimated effect of 
reducing hospital stay by no less than 24 hours, Moderate: Adjustments expected to enhance effectiveness of drug therapy, 
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Study 
characteristics 
Research reported in this thesis Children without 
kidney disease 
(Rashed et al., 
2012b)  
Adult dialysis 
patients  
(Cardone et al., 
2010)  
Adult pre-dialysis 
patients  
(Castelino et al., 
2011) 
DRP study at the 
inpatient setting 
DRP study at the 
outpatient setting 
producing minor reductions in patient morbidity or treatment costs, Minor: Small adjustments and optimisations to therapy, not 
expected to significantly alter hospital stay, resource utilisation or clinical outcome 
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